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In spite of their widespread application, metallic orthopaedic prosthesis failure still occur due 
to lack of sufficient bone-bonding and the incidence of post-surgery microbial infections. The goal of 
this research was to develop multifunctional composite polymer/bioactive glass coatings as a potential 
strategy to improve surface properties of metallic implants. Using this approach, the bioactive glass 
improves osseointegration and the polymer plays a dual role: firstly to improve mechanical properties 
and secondly as a carrier for the release of therapeutics at the implantation site. Electrophoretic 
deposition (EPD) was chosen as the fabrication method, as it is a room temperature technique in which 
deposition properties can be effectively tuned and complex architectures can be coated homogenously. 
45S5 Bioglass® (BG) powder (~10 µm) and chitosan (CS); a natural polysaccharaide (85% 
deacetylated); were utilised for coating AISI 316L stainless steel substrate. In aqueous EPD of CS, the 
electrophoretic mobility and deposition rate were shown to increase with increasing pH from 2.9 to 
4.1. Aqueous EPD from BG and composite CS/BG suspensions were optimised by the Taguchi design 
of experiments approach. For BG suspensions, the pH and the electric field had the most and the least 
effects on deposition rate, respectively, and a high deposition rate of BG was attained at pH=7. For 
CS/BG suspensions, co-deposition was very sensitive to the concentration of BG due to its effect on 
suspension pH, conductivity and particles mobility. Composites with smoother surface morphology 
and more uniform distribution of BG particles in the CS matrix were obtained at lower glass 
concentrations. Structural and physical evaluations of CS and different CS/BG coatings showed that 
they were amorphous and also confirmed the formation of hydrogen-bonding between BG and CS in 
the EPD suspension. Dissolution profiles and bioactivity study of the coatings confirmed 
hydroxycarbonate apatite (HCA) formation in simulated body fluid (SBF) for composites in the higher 
range of BG loading. The bioactivity response of coatings was elucidated considering the EPD 
suspension preparation step and the role of surface charge on HCA formation. Tape-testing showed 
improvement of coating adhesion with addition of BG (for up to~ 60 wt% BG) and Vickers micro-
hardness testing revealed that the composite hardness increased with the amount of BG in the films. 
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 Two types of antibacterial agents were incorporated in the composites via EPD: nano-
particulate silver (Ag-np) and gentamicin (GS) antibiotic. For the first time, single step processing, in-
situ formation and incorporation of Ag-np during EPD of chitosan-based composite films was shown. 
The release of Ag ion and GS in SBF was measured showing an initial burst release followed by a 
reduced release rate. Although about 40% of GS was released in 5 days, less than 7% of the loaded 
silver was released within 28 days. Disk diffusion tests demonstrated inhibition of S. aureus growth up 
to 10 and 2 days for Ag-np and GS samples, respectively. A preliminary 7 day culture study of MG-63 
osteoblast like-cells on coatings indicated cellular attachment and proliferation for all coatings, except 
for Ag-np-containing films. The high amount of silver release was identified as the reason for 
cytotoxicity. Overall, the results presented in this thesis demonstrate the potential of EPD as a suitable 
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1.1. Research objectives 
Every year, medical specialists treat millions of patients world-wide by implanting biomaterial 
devices as diverse as pace makers, artificial hip joints, soft tissue and dental implants, [1]. In this 
regard, the high rate of musculoskeletal diseases and the socioeconomic consequences derived from 
the treatment of patients have resulted in the establishment and expansion of a broad research field 
focused on improving the orthopaedic implants [2, 3]. 
Metallic implants are one major group of orthopaedic devices currently in use [4]. In spite of 
their widespread applications, their failure due to various causes leads to revision surgeries. The 
reasons for failure are adjacent bone degeneration [5], detachment at the implant-tissue interface 
because of poor adhesion between them [6, 7], microbial infection [8] and release of non-compatible 
metal ions in the body [9]. One strategy to improve the surface-related biocompatibility issues of 
metallic implants is the addition of desirable material layers as functional bioactive coatings [8]. 
An important category of biomedical materials used for bone substitution and regeneration are 
“bioactive glasses (BG)”; which are based on specific silicate compositions and are capable of forming 
a biologically active phase of hydroxycarbonate apatite (HCA) on their surfaces upon contact with 
physiological fluids. HCA is similar to the mineral phase of bone and thus promotes implant bone-
bonding. Additionally, BGs dissolution products result in cellular stimulations which are beneficial to 
the generation of new tissue and to the repair of the injured bone [10]. Therefore bioactive glasses are 
attractive materials to be applied as biomedical coatings. 
Inspired by the structure of bone; which is a natural composite of a polymer phase (collagen) 
and nano-ceramic particles (nano HCA) [11]; the development of polymer/inorganic composite 
coatings for orthopaedic applications becomes essential. Such composites can have improved 
mechanical properties [12] and resolve the need for high-temperature sintering and densification of 
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ceramic-only coatings. A suitable candidate for such a composite system is “chitosan” which is a 
natural and resorbable polysaccharide obtained from the crustacean shells. Notable features of this 
biopolymer are enzymatic degradation, ability to link to and deliver growth factors and improved 
cellular adhesion [13]. On the other hand, there is a high trend in incorporating biologically active 
molecules such as proteins and growth factors in coatings to improve the interaction with bone tissue. 
However addition of such sensitive biomolecules cannot be accommodated by the high temperature 
processes which are required to prepare inorganic bioactive coatings [14]. Consequently room-
temperature processing methods for composite bioactive coatings, such as electrophoretic deposition 
(EPD), present an active field of research. EPD can be utilised to produce uniform coatings with 
controlled properties on complex-shaped and porous structures, at ambient temperature and without 
the need for expensive processing equipment [15]. 
In view of the above, there is a technological need to improve metallic implant surface 
properties by developing multifunctional bioactive polymer/inorganic composite coatings that can be 
processed at room temperature. Although extensive research has been conducted on EPD of 
bioaceramic coatings [16], there are only few studies in the literature reporting the EPD of composite 
polymer/BG coatings [17-19]. Clearly more investigations are needed to establish a robust co-
deposition fabrication technique, to modify the coating structure to impart antimicrobial as well as 
drug delivery capacity and also to evaluate the biological and mechanical features of these novel 
coatings. 
Accordingly, this thesis comprises a comprehensive research investigation focusing on the 
EPD of chitosan-based coatings combined with micron-sized bioactive glass particles (45S5 
Bioglass®) aiming at the development of a new family of resorbable bioactive composite coatings for 
metallic implants. Particular attention has been paid to the co-deposition of the polymer and BG 
particles at room temperature and for this reason EPD was chosen. The advantages of EPD in tailoring 
the deposit composition have been explored. A detailed microstructural, bioactivity and mechanical 
characterisation of the coatings has also been carried out. 
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Moreover, to address the increasing problem of bacterial infections associated with 
orthopaedic implantology, one main theme of the present research has been dedicated to develop 
antibacterial composites. The capability of EPD as a single-step deposition method for multifunctional 
composite coatings has been assessed. Two types of antibacterial agents were considered to 
demonstrate the versatility of EPD in this context: (a) silver nanoparticles; and (b) an antibiotic drug. 
Here in-situ formation and deposition of silver nanoparticles as antibacterial agent in composite 
coatings was demonstrated for the first time by using EPD. A preliminary in vitro cellular and 
antibacterial study to characterise the behaviour of these films was conducted. The results of this 
investigation can therefore contribute to a better understanding of the interaction between the 
biological environment and these novel chitosan/Bioglass® composite films intended for orthopaedic 
and bone engineering applications. 
1.2. Thesis roadmap 
This thesis starts with a broad literature review (Chapter 2) covering two main aspects: (a) a 
detailed review on bioactive (monolithic and composite) coatings with specific attention to 
multifunctional coating systems and their various fabrication techniques; and (b) the fundamentals of 
EPD adopted as the main processing technique in this study. 
Chapter 3 presents the key instrumental and characterisation methods that have been applied 
throughout this research. A detailed study of EPD of chitosan, Bioglass® and chitosan/Bioglass® 
composite films on 316L stainless steel substrate is presented in Chapter 4. Chapter 5 focuses on 
microstructural, in vitro bioactivity behaviour and mechanical characterisation of the EPD composite 
coatings developed. In Chapter 6, the capability of EPD is assessed as a mean for preparing 
multifunctional coatings and two distinct antibacterial agents; namely gentamicin and silver 
nanoparticles; have been evaluated. Results of preliminary cell culture and antibacterial studies on the 
EPD coatings are also reported in this chapter. Finally Chapter 7 summarises the findings presented 
and discussed in Chapters 4-6, providing concluding remarks and outlining the potential research 
avenues which are suggested for future work in this field. 
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2.1. Bone tissue engineering 
Increasing musculoskeletal diseases such as arthritis, osteoporosis, bone tumour, severe non-
uniform bone fractures and bone trauma due to sports and accident injuries affect hundreds of millions 
of people worldwide. In the USA alone, over 200,000 hip replacements are performed each year; a 
number which is rising steadily due to increased life expectancy [3]. In spite of the clinical 
developments, issues such as developing an implant with long-term survival or treating critical-sized 
bone defects after bone tumour resections, still represent a major challenge for the reconstructive and 
orthopaedic surgeons [20]. The socioeconomic consequences in treating these patients is a chief 
concern which requires development of new methods for bone reconstruction [21].  
Some of the available orthopaedic treatments are applying autograft, allograft or xenograft 
procedures. These involve filling the defect site with bone removed from the patient’s own body, 
another human body or non-human sources, respectively. In spite of the achieved successes, there are 
complications associated with each case. The bone autografting procedure can involve donor site 
morbidity, prolonged hospitalisation and restricted bone availability. On the other hand allografts and 
specifically xenografts have high risk of donor to recipient disease and infection transmission, 
immunogenicity and host rejection [22]. In this context, tissue engineering (TE); a bridge between life 
science and engineering; plays an important role. TE employs body’s own regenerative mechanisms 
and aims to replace, maintain, or improve human tissue function by introducing materials that promote 
tissue regeneration [23]. 
The aforementioned topic has led to production of different biomedical grade materials to be 
used in the treatment of bone diseases [12, 24]. Continuous research efforts and extensive 
investigations are conducted to produce novel bone implants and scaffolds with enhanced 
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performance, which are biologically, structurally, and mechanically more compatible with natural 
bone. 
Since an implant must fulfil different requirements to adjust to a complex system such as the 
human body, it is found that producing orthopaedic implants and scaffolds which accomplish the ideal 
criteria is not straightforward. To address the clinical requirements, bone scaffolds and implants need 
to meet a set of criteria: mechanical properties of the engineered material should match that of the host 
tissue. In the case of tissue engineering scaffolds, the scaffold should act as a template mimicking the 
structure of bone to direct tissue growth in three dimensions. In addition the surface topographies of 
implants and scaffolds should provide favourable sites for cellular attachment and further cell growth 
and proliferation. Not only tissue should be able to attach to the scaffold without formation of a 
fibrous (scar) tissue, but also the biomaterial should stimulate tissue regeneration process at the 
cellular level by gene activation. In TE, ideally the implanted scaffold should be resorbed with time in 
a controlled manner to facilitate load transfer to the forming bone. Besides its degradation products 
should be non-toxic. It is also beneficial for scaffolds and implant coatings to have the ability to 
release drugs and bioactive molecules to accelerate the healing process [25]. To investigate the proper 
biomaterials meeting these criteria, it is necessary to consider the biology and structure of bone. 
2.2. Principles of bone biology 
2.2.1. Structure of bone 
Bone is a type of hard, dense connective tissue, which, together with cartilage tissue, creates 
the skeletal system. Bone tissue has three general functions: (1) supporting body structure and the 
muscles’ locomotor activities; (2) protection of critical organs such as brain, heart and spine; and (3) 
maintaining the mineral homeostasis of the serum by releasing or absorbing of ions, mainly calcium 
and phosphate [11, 26]. 
The human adult skeletal system consists of two types of bone (Figure  2.1): cortical (compact) 
bone and cancellous (trabecular) bone. While cortical bone is dense with approximately 10% porosity, 
25 
Chapter 2: Literature Review 
the trabecular bone is 50-90% porous and has considerably lower compressive strength. The tubular 
structure of long bones (femur, tibia, etc.) consists of an external part of cortical bone and an internal 
layer of porous and spongy cancellous bone [26]. 
Human bone is a natural organic-inorganic composite. Depending on the anatomical location, 
age and general health, it consists of 50-70% bone mineral, 20-40% organic matrix, 5-10% water and 
1-5% lipids [11]. Bone mineral is mainly formed by nano-crystals of a hydrated calcium phosphate 
component, called hydroxycarbonate apatite (HCA) [27]. The chemical composition of 
hydroxycarbonate apatite is (CaX)10(PO4,HPO4,CO3)6(OH,Y)2 where X is a cation, either Mg, Na or Sr 
ion that can substitute for the calcium ions and Y is an anion (a chloride or fluoride) ion that can 
substitute for the hydroxyl group [28]. The organic matrix of bone mainly consists of type I collagen 
fibres which are synthesised by the osteoblasts and deposited in the form of preferentially oriented 
layers. There are other non-collagenous proteins in the organic matrix as well. One group of these 
proteins are growth factors and osteocalcin which are synthesised by bone-forming cells and play an 
important role in bone growth, metabolism and turnover. The other group relates to plasma-derived 
albumin and alpha2-HS-glycoprotein which facilitate matrix mineralisation [11, 26]. 
 
Figure  2.1 - Hierarchical structural organisation of bone (reproduced from Rho et.al. [29]). 
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2.2.2. Bone cell types and bone remodelling 
Bone is continuously remodelling itself through its lifetime. There are four types of cells 
involved in the remodelling process [30]: 
• Osteoblasts originate from mesenchymal stem cells and synthesise the bone matrix 
(osteoid) and provide its mineralisation. Osteoblasts are 20-30 µm. 
• Osteoclasts are large (100 µm) multinucleated cells which are responsible for removing 
bone by acid demineralisation and enzymatic dissolution of collagen [26].  
• Osteocytes are mature osteoblasts, which are buried in the bone matrix. It has been 
suggested that these are mechanosensor cells that control bone remodelling [31].  
• Bone lining cells are inactive osteoblasts which have not been buried in the bone and 
remain on the surface of the new bone. They can be reactivated by chemical or mechanical 
stimulation [32]. 
The skeleton is continuously being renewed by bone remodelling which is a process of bone 
resorption and formation. This process takes place in the microscopic cavities of the old bone. It is 
believed that adjustment to diverse mechanical loads and maintaining body’s mineral homeostasis are 
the key reasons for bone remodelling [11]. 
2.2.3. Mechanical properties of bone 
Bone is a two phase composite with hierarchical structural organisation. This hierarchy in 
which the collagen matrix and the minerals are bound in a complex system (Figure  2.1), plays an 
important role in the mechanical properties of bone [29]. Among the constituents of bone, the 
inorganic mineral, collagen protein and water are the most influential factors on bone mechanical 
behaviour [33]. Inorganic components are responsible for the compressive strength and stiffness, while 
the organic phase determines the tensile behaviour. Bone composition and hence its mechanical 
properties vary with sex, age, bone location in the body and diseases [30]. Also it has been claimed 
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that the mineral crystal sizes, shapes, location, orientation and alignment with respect to the collagen 
fibres, has a profound effect on the elastic and plastic behaviour of the calcified tissue [34]. The range 
of measured mechanical properties of bone demonstrates the influence of the aforementioned 
parameters; e.g. the compressive strength of the cortical bone is 100-230 MPa while it is in the range 
of 2-12 MPa for cancellous bone [35]. 
2.3. Orthopaedic implants 
2.3.1. Types of tissue responses to implants 
For a successful bone implantation, osseointegration should occur; i.e. formation of a direct 
functional and structural connection between the implant and its adjacent bone without any 
progressive relative movement between them [36]. Kienapfel et.al. [37] have outlined the principle 
requirements for osseointegration as follows: 
• Biomaterial biocompatibility with respect to cellular and matrix response at the interface 
•  The implant surface geometry characteristics and the implant-bone interface distances 
• Implant micro-motion and fixation mode 
Regarding their effect on living tissue, materials can be either toxic or non-toxic. 
“Biocompatible” materials which encompass non-toxic behaviour, can be categorised into almost 
bioinert, bioresorbable or bioactive. 
As no material is completely inert upon implantation, it can be said that for a nearly bioinert 
material, encapsulation of the implant occurs due to the formation of a non-adherent fibrous (scar) 
tissue around the device in the body [38] Unfavourable conditions during osseointegration such as 
premature loading and its consequent micromotion, will disrupt the formation of new tissue and leads 
to implant fibrous capsulation. This phenomenon can result in implant loosening and failure [39].  
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Resorbable materials degrade via contact with physiological fluids and are secreted by the 
kidneys. As the resorbable implant slowly degrades, it is replaced by growing tissue. Problems 
associated with these materials are lack of mechanical stability during degradation and mismatch 
between materials resorption rate and repair rate of the body [40]. 
On the other hand bioactive materials, as defined by Hench [41], stimulate a biological 
response from the body and have the ability to bond to either soft or hard tissue after implantation and 
induce the growth of new bone tissue. The interaction between the host tissue and the implanted 
device and their attachment type along with some examples are summarised in Table  2.1. 
Table  2.1 - Types of tissue attachment to biomaterials [42]. 
Type of 
implant Type of attachment Example 
Nearly inert Mechanical interlock (morphological fixation) Metals, Alumina, Zirconia, Polyethylene (PE) 
Porous Ingrowth of tissue into pores (biological fixation) Hydroxyapatite (HAp), HAp coated porous metals 
Resorbable Replacement with tissues Tricalcium phosphate, Polylactic acid (PLA) 
Bioactive Interfacial bonding with tissues (Bioactive fixation) Bioactive glasses, HAp, Bioactive glass-ceramics 
Because of the mentioned behaviour, bioactive materials are favourable candidates to improve 
osseointegration. In bone tissue engineering two classes of bioactivity are defined: class A bioactive 
materials are osteoproductive; i.e. material stimulates the growth of new bone adjacent to and away 
from the bone-implant interface due to both intracellular and extracellular factors. It encourages bone 
cell attachment, proliferation, migration and phenotypic expression and hence rapidly bonds to the 
bone. This group also bonds to soft tissue such as gum or cartilage. On the other hand class B or 
osteoconductive material bonds only to hard tissue and stimulates bone growth along the surface of the 
bioactive material, owing only to extracellular factors. The rate of bond formation is slower for this 
group [42]. 
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2.3.2. Metallic implants 
Metallic implants are one major group of orthopaedic devices currently in use mainly due to 
being non-toxic and having mechanical stability (although recent investigations show possibility of 
toxicity due to release of metallic ions [9]). These are categorised as nearly bioinert. The most 
commonly used metals in this group are AISI 316 L stainless steel, cast (F25) and wrought (F90) 
cobalt-chromium (Co-Cr) alloys and particularly Titanium alloys (e.g. Ti-6Al-4V) [4]. 
It has been shown that variation in the mechanical stresses relative to the natural situation 
would cause bone to adapt itself by remodelling its structure. Therefore a bone subjected to low 
mechanical load, will lose mass by becoming more porous or getting thinner. Human cortical bone has 
Young’s modulus of 7 to 30 GPa [35]. After implantation, as a result of significantly higher moduli 
the metallic implant will share much of the load carried previously only by bone. This phenomenon is 
known as stress shielding and will eventually result in bone resorption and weakening [43]. Among 
the above metals, Ti-6Al-4V is the most commonly used material due to lower Young’s modulus (105 
GPa compared to 200 GPa for 316L stainless steel and 230 GPa for Co-Cr alloys). Having lower 
density, being non-magnetic and higher corrosion resistance to body fluids are other characteristics 
rendering Ti-6Al-4V a favourable orthopaedic material [9]. However the great disadvantage of Ti and 
its alloys is being prone to severe wear when they are rubbed against themselves or another metal. Hip 
joint implant retrieval studies have demonstrated that compared to 316 SS and Co-Cr alloys, Ti-6Al-
4V alloy femoral heads consistently had the maximum average wear against the polymeric acetabular 
cup. Moreover higher metal concentrations were found in the tissue taken from the area around Ti 
alloy implant [44]. Furthermore, the higher shear strength of stainless steel alloys in comparison to Ti 
alloys make them more desirable for applications such as bone screws and plates [9]. 
In spite of their extensive applications, metallic implants failure due to various causes, leads to 
revision surgeries. Reasons for implant failure apart from stress shielding are: detachment at the 
implant-tissue interface because of fibrous encapsulation and poor adhesion between them [6, 7], 
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microbial infection [8], low fatigue strength and finally release of non-compatible metal ions in the 
body due to wear/corrosion [9]. 
To improve the biocompatibility of the above mentioned metallic implants in terms of surface 
modification, three strategies have been reported in the literature: 1) conversion of the existing surface 
into more desirable compositions and/or topographies; 2) removal of material from the existing 
surface to achieve specific topographies; and 3) addition of material layers providing a desirable 
function on the surface (coatings). These approaches can address complications associated with lack of 
osseointegration, microbial infections and corrosion. All of these modifications can be achieved by 
either physical or chemical techniques. Ion implantation (strategy 1), surface machining and grit 
blasting (strategy 2), plasma spraying and physical vapour deposition (strategy 3) are examples of 
physical techniques, while electrochemical oxidation (strategy 1), acidic etching (strategy 2) and 
biomimetic deposition of calcium phosphate coatings (strategy 3) are achieved by chemical techniques 
[8]. 
Strategy 3, which represents the coating of implants with specifically engineered compositions 
of biocompatible and bioactive materials, is explained in more details in the next sections with specific 
attention to bioactive glass-based coatings which will be the central theme of this investigation. 
2.4. Biomaterial coatings for orthopaedics 
2.4.1. Biomedical ceramics and glasses 
Ceramics are non-metallic, inorganic solids. This category of material share properties such as 
high hardness, insulating electrical and thermal conductivity, good thermal and corrosion resistance 
and commonly highly stiff but brittle mechanical behaviour. Depending on the microstructure, 
ceramics can be either crystalline or non-crystalline (amorphous glasses) or a mixture of these which 
are called glass-ceramics [45]. 
Many ceramics have biomedical applications. For example bioinert alumina and zirconia 
ceramics have clinical applications in total hip prosthesis, and tooth implants. Their main advantage 
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over traditional metal devices is the better wear resistance and therefore they are mainly used for 
femoral head and cup socket component of total hip implants [46, 47]. On the other hand, bioactive 
ceramics consist of calcium phosphate ceramics (e.g. hydroxyapatite), bioactive glasses and bioactive 
glass-ceramics. 
Certain compounds of calcium phosphates are of interest due to their chemical similarity with 
the mineral phase of bone. Compounds with Ca/P ratio less than 1 are not suitable for implantation due 
to a high rate of solubility [48] The most popular synthetic calcium phosphate ceramic for bone repair 
application is hydroyapatite (HAp) which has a chemical formula of Ca10(PO4)6(OH)2. HAp bonds to 
bone and is osteoconductive. Its bone bonding mechanism has been attributed to cellular activity at the 
implant surface leading to partial dissolution of Ca and P ions. These ions combined with other ions 
from body fluids form HCA microcrystals which bond to the host bone [49]. Sintered HAp (sHAp) is 
clinically used to coat metal alloys to improve osseointegration between the bone and the implant and 
to remove the need for applying bone cements [50]. If HAp is to be subjected to thermal processing, 
the Ca/P ratio gains significant importance; a slight imbalance in the stoichiometry of the material may 
lead to the formation of phases such as β-tricalcium phosphate, tetracalcium phosphate or calcium 
oxide which will adversely affect the biological responses of the material [51]. In spite of its superior 
biocompatibility, sHAp bone apposition rate is relatively slow and does not meet the criteria for an 
ideal tissue scaffold. It is also a class B bioactive material [42]. In this regard, silicate-substituted HAp 
has been demonstrated to have improved bioactivity and bone apposition rate [52]. In vivo studies by 
Porter et.al. have provided insights into the mechanisms by which silicate ions in HAp can increase 
bioactivity [53, 54]. 
Another calcium phosphate is Tricalcium phosphate (TCP) with the formula Ca3(PO4)2. It is 
biodegradable and is present in four polymorphs, the most common being TCP-α and TCP-β. To 
adjust the rate of resorption of calcium phosphate with that of tissue regrowth, the use of mixtures of 
HAp and TCP has been suggested [55]. 
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As stated previously, a distinct group of bioceramics are bioactive glasses. These are 
amorphous silicate-based materials which are classified as osteoproductive. They can bond to bone 
and stimulate new bone growth while dissolving over time. Bioglass® 45S5 (45 SiO2, 24.5 Na2O, 24.5 
CaO, 6 P2O5 in wt%) was the first bioactive glass which was shown to have the ability to bond to the 
host tissue [56]. 
Bioactive glass-ceramics are a specific group of bioactive ceramics which are crystalline 
materials produced by heating a parent bioactive glass above its crystallisation temperature. Ceravital® 
is the name for a variety of glass-ceramic materials, produced from a parent glass similar to Bioglass® 
[57]. This category of bioceramics depending on their composition is either bone-bonding or non-bone 
bonding. Their solubility level in the body can be controlled by addition of metal oxides to the 
structure; nevertheless release of metal oxides can negatively affect the cellular function and the 
development and maturation of the extracellular matrix [58] A/W (apatite/wollastonite) glass-ceramics 
are another class B bioactive material which are composed of very fine crystals of apatite and β-
wollastonite (CaSiO3) bonded by a bioactive glass interface. Bioactivity and fairly high mechanical 
strength are two major advantages of this group. The bioactivity is ascribed to the dissolution of Ca 
and Si ions and consequent formation of apatite on the implant surface [59]. 
2.4.1.1. Bioactive glass structure and bioactivity 
The backbone of the bioactive glass structure is the SiO4 tetrahedral network which displays 
short to medium-range 3D order. According to Zachariasen [60] network formers such as Si can form 
a network with bridging (BO) and non-bridging oxygens (NBO) while alkali and alkaline earth oxides 
do not have network forming capability and hence act as network modifiers by replacing BO by NBO. 
As these ions reduce the network connectivity, they can have a profound effect on the levels of 
material bioactivity [61]. The general structure of bioactive glass is displayed in Figure  2.2. 
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Figure  2.2 – Two-dimensional general structure of bioactive glass demonstrating tetrahedrons of 
SiO4 (the fourth oxygen-bond is out of the plane of the diagram) with various network modifiers 
such as sodium and calcium cations. Phosphorus can be present as orthophosphate and is 
charge-balanced by the cations (not shown) [62]. 
The bone-bonding behaviour of bioactive glasses is attributed to the formation of an active 
phase of HCA on their surfaces upon contact with physiological fluids. This phase is similar to the 
mineral phase of natural bone in terms of structure and composition and therefore it is not recognised 
by the body as a foreign object. Five stages have been proposed by Hench [63] for the occurrence of 
this HCA formation: 
stage 1: Rapid exchange of Na+ and Ca2+ with H+ or H3O+ from solution, causing hydrolysis of 
the silica groups, which creates silanols (Si-OH). This stage is usually controlled by diffusion. 
stage 2: The hydroxyl concentration of the solution increase as a result of stage 1 and this 
leads to the degradation of the silica network. Si-O-Si bond breaks and due to the continues 
formation of Si-OH at the glass solution interface, soluble silica is lost in the form of Si (OH)4. 
This stage is usually controlled by interfacial reaction. 
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stage 3: Condensation and depolymerisation of a SiO2-rich layer on the surface depleted in 
alkalis and alkaline-earth cations. 
stage 4: Migration of Ca2+ and PO43- groups to the surface through the SiO2-rich layer to form 
the surrounding fluid, forming a film rich in CaO-P2O5 on top of the silica rich layer. 
stage 5: The CaO-P2O5 film crystallizes as it incorporates OH- and CO32- onions from solution 
to form a mixed HCA layer. 
These 5 stages occurring on the material side of the interface do not need tissue presence and 
can occur in TRIS buffer solutions and simulated body fluids. But for bonding to tissue, the following 
series of stages are needed [63]: 
stage 6: Adsorption of biological moieties  
stage 7: Action of macrophages to remove the debris from the site. 
stage 8: Attachment of stem cells. 
stage 9: Differentiation of stem cells to osteoblasts. 
stage 10: Generation of matrix by osteoblasts. 
stage 11: Mineralisation of matrix. 
Bioglass® 45S5 has been shown to bond to bone more quickly compared to A/W glass-
ceramics and sHAp. In terms of resorption, Bioglass® can be rapidly resorbed compared to slowly 
resorbing A/W glass-ceramic and non-resorbable sHA [64]. 
Based on the fabrication route, bioactive glasses are divided into two groups: melt-derived and 
sol-gel derived. 
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Melt-derived bioactive glasses are produced by melting a mixture of high purity oxides of 
Si2O, Na2CO3, CaCO3 and P2O5 at a high temperature (1370 ºC). The melt is then quenched in water to 
make bioactive glass particulates. These particulates are dried and ground to the desired particle size 
range. The melt can also be poured into preheated moulds to make rods and as-cast components. 
Bioglass® 45S5 was the first bioactive glass produced via this melting process. The compositional 
range of the melt-derived bioactive glass in the ternary phase diagram of the system Si2O, Na2O and 
CaO (Figure  2.3), determines the level of its bioactivity. The most bioactive compositions (such as 
Bioglass® 45S5) are in the region S of the diagram [65]. 
 
Figure  2.3 - Compositional diagram for bone-bonding (assuming a constant 6 wt% of P2O5). 
Region S is a region of Class A bioactivity [65]. 
In contrast to the traditional melt-derived bioactive glasses, sol-gel derived ones tend to be 
more bioactive and resorb more quickly than the melt-derived glasses of equivalent compositions, as 
discussed below [66]. 
The sol-gel process is schematically illustrated in Figure  2.4. For silicate-based bioactive 
glasses, an alkoxide such as tetraethyl orthosilicate (TEOS) is used as the silicate precursor. Other 
required components apart from silica such as alkoxides or salts are added. The sol is a solution of 
silica species which can undergo polycondensation to form the silica network of Si-O-Si bonds. A gel 
forms within 3 days and after evaporating the by-products of condensation reaction the dried gel is 
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heated to remove organic by-products. Due to the type of process, there is a nanoporous network in 
these glasses, which leads to a two orders of magnitude higher specific surface area compared to melt-
derived glasses. This characteristic eases the bioresorbability due to higher dissolution rates in the 
body [45]. 
 
Figure  2.4 - Flow diagram of the process for sol-gel bioactive glass synthesis (adapted from Jones 
[67]). 
2.4.1.2. Bioactive glass coatings 
Bioactive glass has been produced as scaffolds and coatings either in monolithic or composite 
structures. One of the major constraints on a more extensive application of bioactive glass is their 
relatively poor fracture toughness [68, 69] Two solutions have been suggested to this shortcoming. 
One is to apply bioactive glass as a coating on mechanically strong materials [24] The other alternative 
is to use composites of this material, in which an organic polymer [12] or another ceramic [70] 
mechanically strengthens the bioactive glass structure. 
An investigation of the available publications is indicative of various processing techniques to 
produce bioactive glass coatings. Enamelling, plasma spraying, sol-gel, ion-beam assisted deposition, 
pulsed-laser deposition and electrophoretic deposition are the most common coating procedures 
reported. Concerning the high temperatures required for sintering these bioactive glass coatings, there 
are several key design criteria for a successful development of such coatings on an implant [71]: 
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• The firing cycle should not degrade the properties of the substrate or the glass (especially 
the bioactivity). 
• The value of the thermal expansion coefficients of the coating and the substrate should be 
close to avoid residual stress cracking of the coating. 
• The firing cycle should result in an interface with optimum adhesion between the 
bioactive glass coating and the substrate. 
Aligned with efforts to meet these criteria, it was shown that by sintering bioactive glass 
microspheres a porous texture can be developed. By this method the bioactive surface area is increased 
manifold compared to non-porous bodies [72]. Also the sintering temperature has been controlled to 
avoid its adverse effect on the bioactivity of the coatings [73]. On the other hand, compositional 
modifications to the glass structure have been applied to overcome the thermal coefficient mismatch 
between the coating and the implant [74]. Due to its relevance in the context of the present project, a 
review of the most common coating techniques is outlined in the following. 
In enamelling process, a slurry of the glass powder is prepared and then the metallic implant is 
coated by painting, spraying or dipping. After drying the coated part is heated above the glass 
softening temperature at which the inner layer of bioactive glass fuses to the metal oxide layer, 
forming a chemical-mechanical bond as the outer glass layer sinters. This process leads to formation 
of a strong bond [10, 75, 76]. Lopez-Esteban et.al. [71] have optimised the firing condition for enamel 
coatings of a family of bioactive glasses on Ti-based and Co-Cr alloys produced via dip-coating. 
Partial substitution of CaO by MgO and Na2O by K2O in the glass system has been utilised to match 
the thermal expansion of the coating to that of Ti-based alloys and hence delamination and crack 
propagation have been controlled. As non-metallic substrates, the surface of alumina-zirconia 
prosthetic implants have also been bioactivated with enamelling [77]. In another attempt, the 
compressive strength of porous HAp scaffold was improved by enamelling it with nanostructured 
bioactive glass coating [78]. In spite of being an easy and inexpensive technique, enamelling can only 
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be applied to thermally stable substrates; because the coating and the substrate are fired at the same 
temperature. Even metallic ones such as Ti alloys have been reported to suffer disadvantageous 
microstructural transformations. Moreover due to high thermal residual stresses, the film thickness 
should be controlled to avoid coating cracking [75]. 
Bioactive glasses have been deposited on metallic substrates by plasma spraying (PS) [75, 79-
83]. In this process, a gas flow (plasma spray) is injected into a chamber in which the temperature is 
raised up to 10,000-30,000 K by means of an electric arc. Powdered granular bioactive glass is pushed 
into the chamber, partially or totally melted and forcefully sprayed through a nozzle onto the surface 
of the substrate [80]. It is a flexible and completely automatisable technique and the final 
microstructure can be controlled by the spraying conditions [75]. Most importantly, as the substrate 
remains cold during deposition, it can be used on any substrates. Nevertheless it requires relatively 
expensive equipment. In vivo bone-bonding behaviour of plasma sprayed Bioglass® 45S5 on Ti-6Al-
4V alloy has been compared with that of A/W glass-ceramic and  TCP-β coatings. Detachment tests 
on the bone-implant interface has displayed a significant increase of the failure load with implantation 
time for Bioglass®[79]. Recently liquid precursor plasma spraying (LPPS) has been used to deposit 
bioactive glass ceramic on Ti substrates. A liquid precursor feedstock instead of a powder one is used 
for PS and therefore the tedious powder feedstock preparation step is eliminated [84]. Composite 
coatings of Bioglass®/HAp have also been obtained by this process [85]. PS is more suitable for HAp 
rather than bioactive glasses. Low thermal conductivity, low density and low viscosity of glass above 
its glass transition temperature (compared to crystalline materials), have been identified as main 
reasons for glass particles not flattening properly over substrate and hence forming a very defective 
and weakly bonded coating. As a result of this, a post-deposition heat treatment is usually required 
[86]. Goller et. al. [81, 82] have increased the bonding strength of Bioglass® coating on Ti substrate 
about three times by applying bond coats. Bond coating materials are used to provide a suitable 
thermal expansion match between the two layers of coating and substrate. 
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Bioactive glass coatings have also been fabricated by sol-gel process [73, 87-91]. The sol is 
prepared as described in section  2.4.1.1. The metallic substrate is dipped into the prepared sol, dried 
and thermally stabilised at temperatures in the range 600-800 °C. There are two advantages to this 
process; one is application of lower temperatures compared to other conventional methods, thus 
avoiding the reduction of bioactivity in the coating. The other is higher bioactivity due to high surface 
area and porous structure of the coating, which is inherent to sol-gel technique [92]. Fathi et.al. [73, 
87] have presented sol-gel coating of AISI 316L stainless steel substrates by micro and nano sized 
bioactive glass powders. This coating has improved the pitting corrosion resistance of stainless steel 
substrates in physiological solutions. In a similar study, sol-gel coatings containing bioactive glass and 
glass-ceramic particles in hybrid silica matrix were applied to Cr-Co-Mo, Ti-6Al-4V and AISI 316L 
surgical alloys. Long-term in vitro and in vivo tests confirmed improved corrosion resistance and 
bioactivity of these implants [93]. 
In ion beam sputtering, an ionised gas is used to sputter the bioactive glass target and build up 
a thin film of the sputtered material on the metallic substrate. Uniform and dense structured thin 
bioactive glass films have been produced by this method on Ti substrates and the adhesion strength of 
the coatings to the metal has been examined by a scratch test [94]. 
Pulsed laser deposition (PLD) consists of laser ablation of the target material, consequent 
matter-radiation interaction and the transport of the ablated material from target to the substrate [95] 
This method has several advantages over other conventional methods such as, congruent transfer of 
the target composition to the substrate, good control over final crystalline state and stoichiometry of 
the coating, high adhesion of the coating to the metallic substrate and absence of contamination and 
porosity [96]. It was found out that although the complex composition of glass is successfully 
transferred to the coating, a dramatic decrease of the concentration of Si-O Non-bonding oxygen 
groups has been observed compared to the bulk material. This effect can have a key role in the 
bioactivity of the thin films [97]. Attempts have been made to deposit bioactive glass thin films and 
multi-structures of Bioglass® with apatite on Ti substrates by PLD and the biocompatibility of these 
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coatings have been tested [96, 98-101]. A study on the influence of PLD parameters on the properties 
of bioactive glass coatings has revealed that the optimum films are obtained in vacuum and in absence 
of electrical discharge condition [95]. 
Electrophoretic deposition (EPD) involves coating a substrate by applying an electrical field to 
a suspension of charged particles. Among the outlined techniques, EPD has drawn particular interest; 
because, apart from being a low cost method, it is capable of coating 3-dimensional (3D), porous and 
complex-shaped substrates. The principles of EPD will be presented in details in section  2.5. Although 
extensive research has been conducted on EPD of HAp on different substrates [16], there is much less 
work reported on EPD of bioactive glasses. The first investigation was done by Krause et.al. [102] in 
which the aqueous EPD of Bioglass® 45S5 was investigated. A similar technique has been applied to 
cover shape memory Ni-Ti wires with a homogenous layer of Bioglass® 45S5 [103]. EPD has also 
been used to infiltrate and coat porous poly(DL-lactide) scaffolds [104]. In another study functionally 
graded bioactive glass and HAp has been electrophoretically deposited to improve the corrosion 
resistance of Ti alloy substrates [105]. As presented in Chapter 4 of this thesis, we have systematically 
investigated the effect of different EPD parameters on deposition of Bioglass® 45S5 from aqueous 
suspensions by applying design of experiment (DOE) technique [106]. 
All of the above-mentioned techniques employ a physical or chemical strategy to deposit the 
bioactive coating. There are some disadvantages related to this strategy. As organic components of the 
extracellular matrix (ECM) are increasingly recognised as key regulators of bone healing and 
mineralisation, there is a high trend in incorporating organic biomolecules in coatings. Since organic 
molecules need to be applied under physiological conditions, high temperatures associated with 
physical coating strategies present as a problem. Only the sol-gel and EPD methods have the potential 
to be performed at an ambient temperature. Furthermore, apart from EPD, physical deposition 
techniques discussed above are line-of-sight processes and can limit the effectiveness of coating 
complex, porous 3-dimensional structures [14]. 
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2.4.2. Biopolymers 
In tissue engineering it is desirable to produce matrices and scaffolds which resemble the 
ECM of the target tissue which is to be repaired [1]. This matrix provides attachment sites for cells. 
Ideally this matrix should be biocompatible; i.e. it must not elicit any inflammatory, immunogenic or 
cytotoxic response in the body of the patient. Polymeric structures are of interest in tissue engineering 
because their properties, such as resorbability rate, 3D structure and porosity configuration are 
controllable via processing parameters. Moreover, these materials can be functionalised by 
incorporating drugs, growth factors and other necessary proteins which can be locally released at a 
specific rate in the body. 
In terms of degradation in the body, there are two groups of biopolymers: resorbable and non-
resorbable. There is an increasing interest in resorbable polymers as this group can be metabolised to 
non-toxic products by biological processes and are in due course secreted via the kidneys. Degradable 
polymers are categorised as synthetic and natural. 
Poly (ethylene glycol) (PEG) or poly (ethylene oxide) (PEO) are non-degradable synthetic 
polymers with excellent hydrophilicity, solubility in a range of solvents and high solution mobility. 
Poly (vinyl alcohol) (PVA) and poly (acrylic acid) (PAA) and its derivatives such as poly (2-
hydroxyethyl methacylate) (PHEMA) are some other examples of non-resorbable polymers commonly 
used in the biomedical field. Because of the lack of resorbability, there are limitations to the 
application of these polymers in tissue engineering [107]. 
The US Food and Drug Administration (FDA) have licensed several synthetic biodegradable 
polymers to be applied in the body. The most widely used biodegradable synthetic polymers for 
biomedical applications are saturated aliphatic polyesters. These poly-α- hydroxyl acids, include 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL) and their co-polymers 
such as poly (lactic-co-glycolide) (PLGA) [108-111]. Due to their chemical composition, de-
esterification happens to these polymers, which causes degradation by hydrolysis. The oligomers and 
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monomers released are removed through natural pathways. Successful medical application of this 
group in degradable sutures, stents and wound dressings has been reported [112]. Due to 
hydrophobicity of these polymers, tissue regeneration can be problematic as a result of poor wetting 
and cellular adhesion. Plasma treatment of the polymer surface can resolve this issue, although results 
may not be permanent [12] Figure  2.5 demonstrates the chemical structure of some of the above-
mentioned polymers. 
 
Figure  2.5 - Structures of some polymers commonly used in tissue engineering. a: poly (ethylene 
glycol) (PEG), b: poly (vinyl alcohole) (PVA), c: poly (acrylic acid) (PAA), d: (2-hydroxyethyl 
methacylate) (PHEMA), e: poly (lactic acid) (PLA), f: poly (glycolic acid) (PGA) [113]. 
An imperative issue in TE is the ability of the scaffold to maintain its structural and 
mechanical integrity within a sufficient period of time prior to complete degradation, in order to allow 
for substitution and regeneration of new tissue. Bioerodable synthetic polymers are examples 
possessing this property as they go through heterogeneous degradation compared to bulk-degrading 
behaviour. This erosion process is restricted to the polymer-water interface. Poly (anhydrides), poly 
(ortho-esters) and poly (phosphazane) are of this class. Minimal toxic effects and enhanced bone in-
growth are advantages to these materials [114]. 
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Even though synthetic polymers are more versatile than natural polymers in terms of the 
tuning properties and the cost of production, they are deficient of biological signals inherent to many 
natural polymers that can promote favourable cell responses. Natural polymers are well-known for 
their similarities with extracellular matrix, good biological performance, inherent cellular interaction 
and cell or enzyme-controlled degradation [115]. Protein-origin polymers, polyhydroxyalkanoates and 
polysaccharides are three major groups of natural polymeric biomaterials. 
Protein-based polymers which have applications as biomaterials for drug or cell delivery 
systems are collagen, gelatin, silk fibroin, fibrin (fibrinogen) and other proteins such as elastin or 
soybean. Proteins are polymer structures which contain 20 distinct amino acids linked by amide or 
peptide bonds. Although these polymers mimic many features of ECM and are regarded as potential 
structures for cells to be differentiated, proliferated and delivered in, possible batch variations due to 
distinct derivation sources, is a major disadvantage. Therefore to posses perfect control over their 
functionality, proteins must be highly purified [115]. 
Collagen is the most abundant protein in the body; a fact that makes collagen one of the most 
ideal materials for tissue engineering applications. 27 types of collagen are known among which type I 
is the most important type in the structure of bone, because it can be mineralised [116]. Collagen is 
primarily derived from animal tissue and its mechanical strength and degradation properties can be 
adjusted by crosslinking [115]. Gelatin is a denatured protein achieved by acid and alkaline processing 
of collagen and as a result of this process it has lower antigenicity compared to animal source 
collagen. It has been applied to mimic tissues such as bone, cartilage and skin and is commonly used 
for its pharmaceutical and drug delivery applications [117]. Reference [115] presents a comprehensive 
review on protein-based polymers currently in use in tissue engineering. 
Polyhydroxyalkanoates (PHA) are aliphatic polyesthers produced by different microorganisms 
as part of their survival mechanism. The following polymers can be named as examples of these 
biodegradable and thermoprocessable polymers: poly (3-hydroxybutyrate) (P3HB), copolymers of 3-
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hydroxybutyrate and 3-hydroxyvalerate (PHBV) and poly (4-hydroxybutyrate) (P4HB). PHA 
polymers can be blended, surface modified or combined with other polymers, enzymes or inorganic 
materials to suit into certain applications [118]. 
Polysaccharidic polymers are another well-known group of natural polymers in the structure 
of which sugar monomers are linked together via O-glicosidic bonds that can be made to any of the 
hydroxyl groups of a monosaccharide. These materials which can be derived from microbial, vegetal 
or animal sources are non-toxic, interact with cells, present acceptable hemocompatibility and 
generally cost less than other biopolymers [119]. Chitosan, alginate, starch, hyaluronan and 
chondroitin sulphate are examples of polysaccharides studied as biomaterials. Since chitosan is the 
biopolymer chosen for this project, its properties and applications as a potential orthopaedic 
biomaterial, are discussed in detail in the following. 
2.4.2.1. Chitosan structure and properties 
Chitosan is a linear, cationic polymer consisting of β (1→4)-glucosamine and N-acetyl-D-
glucosamine and is obtained from N-deacetylation of chitin with sodium hydroxide. Chitin is naturally 
found in crustacean shells and insects’ cuticles. The molecular structure of chitin and chitosan are 
illustrated in Figure  2.6 [120]. 
 
Figure  2.6 - Molecular structure of chitin and chitosan [120]. 
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Because chitin deacetylation is almost never complete, based on the percentage of the primary 
amino groups in the molecule of chitosan, the degree of deacetylation (DDA) of the polymer varies. 
Commercial batches of chitosan have typically a DDA between 70% and 95% and molecular weight 
of 10-1000 kDa [121]. Since chitosan is a copolymer, based on its molecular weight (MW), DDA and 
sequence, its properties (e.g. the pKa) can be modified [122]. Due to the presence of amino groups, 
chitosan acts as a weak base. It dissolves in aqueous solutions at low pH as a result of protonation of 
amino groups on glucosamine and precipitates at pH higher than its pKa. For a typical chitosan with a 
DDA of 80% or less and MW of about 200kDa, pKa is ~6.3. Since its soluble-insoluble transition 
range is near neutrality, chitosan is suitable for biological applications. Moreover, the presence of 
amino and hydroxyl groups in the chitosan structure facilitates various chemical modifications of this 
polymer [115]. 
In vivo, mainly an enzyme called lysozyme hydrolyses N-acetylated residues of chitosan which 
consequently results in the polymer degradation. Apart from enzymatic degradation, aqueous 
dissolution is also playing a role in chitosan degradation; therefore prolonged degradation time has 
been observed for very low or very high DDA levels, while intermediate deacetylation levels showed 
fastest degradation rate [123, 124]. Accelerated angiogenesis (formation of new blood vessels) and 
little fibrous encapsulation for chitosan in the body have been reported [125, 126]. 
As most growth factors are linked to anionic and negatively charged molecules 
(glycosaminoglycans), chitosan; a cationic polymer; is a suitable candidate for delivery of growth 
factors due to electrostatic interaction between the two molecules [127]. Being positively charged has 
also a pivotal role in cell attachment [128]. Therefore DDA can affect cellular adhesion. This has been 
attributed to larger cationic charge density at high DDA values, better interaction with negatively 
charged cell membranes and finally improved cellular adhesion [124]. Apart from that, innate 
antibacterial properties have been observed for this polymer. Chitosan has shown to reduce the 
infection rate caused by S. aureus in rabbits. This has been correlated to association of amino groups 
46 
Chapter 2: Literature Review 
with anions on the cell wall of bacteria and a resultant suppression of biosynthesis. It also disrupts the 
mass transport across the bacteria cell wall and accelerates its death [129]. 
Overall, chitosan has been investigated in different forms in orthopaedics; bone cement 
additive, composite biodegradable scaffolds for drug and cell delivery system and functionalisation of 
metallic implants are examples of different chitosan forms [13]. The interest in this polymer as a 
scaffold arises from the fact that it can be moulded into porous structures with controllable pore size, 
thus providing infiltration of the scaffold with bone cells and blood vessels. Apart from that, in vitro 
investigation of scaffolds containing osteoblast cells, demonstrated differentiation and proliferation of 
cells and deposition of a mineral rich matrix [130]. Freeze-dried scaffolds [131] and sponges [132] of 
chitosan loaded with platelet-derived growth factors (PDGF) as well as scaffolds of chitosan combined 
with collagen [133] and coral [134] containing transforming growth factor-β1 (TGF-β1) and PDGF 
have been studied for bone and periodontal bone applications. Recently chitosan scaffolds are more 
extensively being studied for delivery of bone morphogenetic proteins to support the function of 
osteoblastic cells [135, 136]. 
2.4.2.2. Chitosan coatings 
Chitosan has excellent film forming properties. Owing to this and other biocompatible 
characteristics of chitosan explained above, it has been applied to metallic implants as coatings. The 
following five coating techniques have been reported in the literature. 
Solution casting is the most straightforward method. In vivo and in vitro studies on Ti implants 
solution cast with chitosan film combined with osteogenic compound recombinant human bone 
morphogenetic protein-2 (rhBMP-2), have shown that the films support cellular growth and enhance 
osseointegration [137, 138].  
Another coating trend examined has been successive deposition of polycations and polyanions 
(such as alginate or hyaluronic acid) to achieve a self-assembled layers of coating known as 
polyelectrolyte complex (PEC). Electrostatic interaction between these polyelectrolytes and their pH 
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dependent charge density facilitates assembly of coatings with distinct structural characteristics. [139-
141]. Nanostructured films of chitosan-alginate with rigid to viscoelastic behaviours have been 
fabricated with this technique [142].  
A third approach is to use a saline + glutaraldehyde molecule to attach chitosan to the 
substrate. Application of a silanation reaction has shown to increase the bond strength to substrate 
(1.5-1.8 MPa) compared to simple solution casting (0.5 MPa) [128]. To gain a better knowledge of the 
required surface chemistry for adequate chitosan/metal bonding, Martin et al.[143] have examined the 
effect of two Ti surface treatment and two different silane molecules on the chitosan coatings. Their 
results indicated a significant increase in the bulk adhesion of the chitosan coating by nitric acid 
passivation and piranha Ti surface treatments in addition to silanation.  
In a recent attempt, chitosan nanofibres have been electrospun as a mat. Comparison of this 
mat with solvent cast films indicated similar attachment of four types of cells in vitro [144].  
Electrodeposition have been utilised for surface functionalisation of metallic implants with 
polysaccharides such as chitosan (CS), alginate (Alg), hyaluronate (HY).and gelatin. As these 
biopolymers behave as polyelectrolytes in the solution, they can respond to electrical stimulation. In 
aqueous solutions, CS is positively charged while Alg and HY gain negative charge, therefore 
cathodic (on negative electrode) and anodic (on positive electrode) deposition of these polymers can 
be obtained respectively. The deposition mechanisms of chitosan, alginic acid (AlgH) and hyaluronic 
acid (HYH) have been outlined in the literature [145-147]. CS dissolution in acidic medium as well as 
sodium alginate and sodium hyaluronate dissolution in water happen according to the following 
reactions: 
Cs-NH2 + H3O+ → Cs-NH3+ + H2O 
AlgNa → Alg- + Na+ 
HYNa → HY- + Na+ 
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On the other hand, in the electrochemical cell, at voltages above 1.24 V the cathodic reduction 
and anodic oxidation of water results in a pH gradient near the electrodes. Hence, pH increases at the 
cathode and decreases at the anode: 
2H2O + 2e-→ H2 + 2OH-   (Cathode) 
2H2O → O2 + 4H+ + 4e-     (Anode) 
Electrophoretic motion of the charged polyelectrolytes toward the opposite electrode and their 
neutralisation due to pH variation results in formation of coatings on the electrodes: 
CS-NH3+ + OH-→ CS-NH2 + H2O  (Cathode) 
Alg- + H+ → AlgH    (Anode) 
HY- + H+ → HYH    (Anode) 
In a publication based on the results presented in Chapter 4 of this thesis, we have explored for 
the first time the effect of solution pH on kinetics of deposition of chitosan [148]. To continue this 
study, Altomare et.al. [149] have investigated the effect of three different water-based acid baths on 
CS coatings morphology, pore size and film growth rate. In situ quantitative visualisation of CS 
electrodeposition has demonstrated precisely the pH and time-dependent growth profile of CS films 
[150]. According to this study, the boundary of the CS hydrogel is controlled by the migration of the 
electrochemically induced OH- ions, while the density distribution of the hydrogel is governed by the 
electrophoretic migration of CS macro-molecules. Moreover electrostatic interaction between 
positively charged CS and negatively charged gelatin [151] or silk fibroin [152] and formation of PEC 
have been exploited to electrochemically deposit CS composite coatings for biofunctionalisation of 
titanium substrates. 
The electrical stimuli-responsive behaviour of CS have also been utilised to obtain spatially 
selective deposition of CS on patterned surfaces which have potential for biosensing applications [153, 
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154]. In the same context, glucose oxidase protein has been anodically conjugated on CS coated gold 
wires to be used for electrical detection of electrochemically active compounds [155]. In a similar 
study CS-glucose oxidase coatings have been applied over Pt-Pb nanoparticle-coated needles for 
glucose biosensing [156]. Even anodic deposition of CS for biosensing applications has been reported 
[157]. In a novel approach the principles of polysaccharide electrodeposition have been used to 
prepare freestanding CS and Alg membranes in microfluidic devices [158]. Other interesting 
applications of polysaccharide electrodeposition reported are EPD of HYA-bovine serum albumin 
(BSA) composite films [159] and collagen-based nanotubes [160], all of which indicate the versatility 
offered by this techniques. 
One feature that all polymer structures currently in use in tissue engineering have in common 
is the lack of mechanical strength and stiffness. To address this issue it is a convenient approach to 
combine them with bioactive ceramics and glasses as a composite system, which is the topic of the 
next section. 
2.4.3. Composite bioactive coatings 
As described before, bone can be considered as a natural composite of a polymer (collagen) 
and nano ceramic particles (nano HCA). This combination confers proper toughness as well as 
stiffness to the bone. Polymers are flexible but lack mechanical strength while inorganic materials 
such as ceramics are stiff and brittle. On the other hand, although processing of polymers into complex 
shapes is easier, they are not bioactive and cannot provide osseointegration. Therefore, one promising 
tissue engineering approach to mimic the structure of the bone is the fabrication of biodegradable 
polymer/bioactive ceramic (or bioactive glass) composite materials [12]. The first advantage of this 
trend is an improved mechanical property of the biomedical device in terms of strength, stiffness and 
fracture toughness. Secondly, increased bioactivity and bone bonding capability of the structure due to 
incorporation of bioactive ceramic or glass is expected. Moreover the bioactive phase introduces a 
specific topography on the polymer surface (nano or micro roughness), which if tuned, can be 
favourable for cell adhesion and deposition of ECM [161]. Additionally degradable polymers are 
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resorbed by hydrolysis of the polymer chains which for most of them is an acidic behaviour and has 
autocatalytic effect on polymer degradation. Addition of a material such as bioactive glass leads to 
rapid exchange of protons for alkalai in the glass. Such glass dissolution buffers the surrounding 
medium and controls the fast degradation rate of polymer [162, 163]. Finally, not only polymer 
degradation kinetics is controlled by higher amount of water absorption at the interfaces between the 
polymer and the more hydrophilic bioactive phase [164], but also the ionic release rate of the bioactive 
ceramic can be controlled, resulting in better bone growth [165]. 
As there is an increasing interest to add surface functionality to bioinert metallic implants, 
more efforts are concentrated on developing polymer/inorganic composite coatings. These coatings 
can enhance bioactivity, chemical stability and antimicrobial function of the implants [166]. 
Furthermore the need for sintering and densification of ceramic coatings is resolved, as the polymer 
provides a suitable template in which the ceramic particles embed and guaranties their adhesion to the 
substrate. 
There are different techniques available to produce polymer matrix composite coatings. 
Composite CS/apatite coatings have been fabricated on Ti alloy substrates by mixing different ratios 
of CS and apatite powders, followed by dip coating of metal and a subsequent alkaline transformation 
at room temperature [167]. In a novel approach, silica xerogel/CS film was spin-coated on Ti discs at 
room temperature. These hybrid films displayed more hyrophilicity and improved osteoblastic 
proliferation compared to pure chitosan [168]. 
Bioactive ceramic coated implants can also be infiltrated by the polymer to attain a composite 
structure [169]. CS infiltrated plasma sprayed HAp coatings on Ti alloy substrates have displayed 
improved antibacterial activity proportional to the CS concentration [170]. Degradable and non-
degradable sutures have been dip-coated with Bioglass®/PDLLA films for bioactive wound healing 
applications. A two step coating process has been shown to improve the adherence of glass particles to 
the substrate [171]. Tamjid et.al.[172] have demonstrated a significant increase in the elastic modulus 
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of PCL polymer by reinforcing it with bioactive glass particles. In a similar study, 20% increase in the 
Young’s modulus of CS films has been obtained by addition of montmorillonite nanoparticles. This 
effect has been attributed to the formation of hydrogen bonds and van der Waals interactions between 
the two phases [173]. 
Another approach is layer by layer (LBL) deposition by which polyelectrolyte multilayers of 
nanostructured organic/inorganic composites can be obtained. The idea to construct these structures 
has been inspired by nacre; a natural material that has a regular brick-and-mortar arrangement of 
aragonite (CaCO3) crystals infiltrated by tight layers of a protein. Although 95% of nacre is made of 
ceramic, it demonstrates excellent toughness and inelasticity [174]. Based on LBL methodology 
composite coatings have been generated by sequential deposition of CS (as polycation) and bioactive 
glass nanoparticles (as anionic component) [175]. This approach has been used to form polysaccharide 
coatings of Alg-CS on Si wafers on which calcium phosphate carbonate was nucleated and grown to 
mimic the composite structure of the bone [176]. Composite coatings with antibacterial properties can 
also be produced by LBL deposition. It has been achieved by coating poly (ethylene terephthalate) 
substrate with multifunctional CS/heparin films. These films have been loaded with TiO2 nanoparticles 
as contact-active antibacterial agent and nano-silver as a release-active antibacterial agent [177]. 
Electrodeposition techniques have been extensively used to produce polymer/inorganic 
composite coatings [16]. This is due to the low cost, tuneable deposition properties and low 
temperature processing this method provides. Electrodeposition can be divided into two methods: (1) 
electrochemical deposition (ED); and (2) electrophoretic deposition (EPD). A summary of the 
published research based on these two techniques will be outlined in the following paragraphs. 
The Co-ED of calcium phosphates with CS on Ti alloy has been reported [178-180]. 
Compared to electrodeposited calcium phosphate coatings, these composites display higher 
proliferation rate, increased alkaline phosphatase activity and higher collagen expression of osteoblast-
like cells [179]. Likewise collagen/octacalcium phosphate coatings have been electrodeposited [181]. 
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The coatings possessed hierarchically porous structures in nano/micro-meter scale, similar to bone 
structure. Additionally, when immersed in simulated body fluid, the coatings stimulated formation of 
an apatite that in terms of crystalline orientation and structural composition was very similar to natural 
bone apatite. 
Considering EPD-based techniques, different polymer-based composite coatings have been 
achieved. Silicon-substituted HAp/PCL composite coatings were prepared by EPD to bioactivate Ti 
substrates. PCL enhanced the bonding strength of HAp to Ti [182], Ti implants have been coated via 
constant voltage EPD with CS reinforced apatite-wollastonite films. These homogenous coatings were 
found to have interconnected pores and the adhesive strength of the coating was evaluated by nano-
indentation (Young’s modulus = 9.23 GPa). It was found that the presence of CS triggers sheet like 
apatite formation due to provision of a dense negatively charged surface. Suspension pH and EPD 
current density were recognised as the most important factors [183, 184]. Implantation of these coated 
Ti in rabbit tibia demonstrated good hemocompatibility and faster bone healing [185]. 
There is an increasing interest in EPD of composites based on polysaccharides. This is due to 
an investigation showing the role of these natural polymers in forming interfaces between organic and 
inorganic components in bone and governing crystallisation of HAp nanoparticles [186]. Moreover 
EPD provides low-temperature preparation of these coatings. HAp/Alg [146], multiwalled carbon 
nanotubes (MWCNT)/Alg and MWCNT/ HYH coatings [187] are examples of them.  
Among polysaccharides, various studies have utilised CS as the organic matrix for HAp 
containing composite coating. A significant finding is that HAp/CS films deposited by EPD have 
preferred HAp c-axis crystallographic orientation, similar to natural bone [166]. By varying EPD 
parameters, monolayer and functionally graded coatings of HAp-silica-CS have been deposited on 
different substrates such as Ti foil and 316L stainless steel [188]. In another study the biocompatibility 
and physiological corrosion resistance of Ni Ti shape memory alloys have been enhanced by three 
phase component EPD of chitosan/MWCNT/HAp [187]. EPD of CS also has enabled co-deposition of 
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HAp and CaSiO3 at room temperature. CS molecules adsorbed on HAp nanoparticles provided 
electrosteric stabilisation of HAp. In order to explain the non-linear increase in deposit yield with 
particle concentration, the authors have presented a mathematical model. These coatings also 
improved the physiological corrosion resistance of AISI 316L SS substrate [189]. 
Of significant interest is the EPD of composite coatings containing bioactive glasses [17-19, 
147]. The aqueous suspension stability of Bioglass® particles has been improved by electrosteric and 
electrostatic effects of positively charged CS molecules in the solution and hence better deposition rate 
was achieved on the cathode. [17, 19]. Similarly polyanions of Alg [17] and HY [147] provide anodic 
deposition of bioactive particles. Water electrolysis and consequent hydrogen and oxygen gas releases 
at the electrodes, respectively results in pH increase at the cathode and pH decrease at the anode. At 
the vicinity of the electrode CS deposits due to alkaline pH and AlgH and HYH deposit due to acidic 
pH. We have investigated the influence of EPD parameters on co-deposition of Bioglass® 45S5 and 
CS from aqueous medium [190], details of which will be presented in Chapter 4. Recently in a similar 
effort, sol-gel bioactive glass particles and CS have been deposited from ethanol-water suspensions 
[191]. 
A novel application of EPD is that coatings can be deposited in the form of laminates 
comprising layers of different functionality [19, 189, 192]. HAp/silver/CS monolayers and multi-
layers of individual HAp/CS and silver/CS layers; as shown in Figure  2.7; have been fabricated [192]. 
Sun et.al. [193] have successfully applied EPD to prepare multilayers of HAp/CS and heparin/CS. 
Incorporation of heparin in these functionally graded coatings can improve the blood compatibility of 
the implants.  
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Figure  2.7 - Multilayer composite coating with chitosan/HAp (H) and chitosan/AgNO3 (A) layers 
deposited by EPD [192]. 
2.4.4. Mechanical properties evaluation of bioactive coatings 
Apart from bioactivity, one major aspect of developing coatings for biomedical devices is 
mechanical characterisation of the deposited film. The bonding strength of the coating to the substrate, 
its abrasive wear resistance and its stiffness are critical to the successful application of the biomedical 
implant. 
According to Lewis et al. [194] the mechanical tests evaluating the adhesion of a polymer thin 
film on a metallic substrate can be categorised as (1) conventional adhesion tests, such as pull-off, peel 
and lap-shear tests; (2) nanotechnology tests, such as scratch and nanoindentation test; and (3) 
deformation tests, such as tensile and 3 or 4- point bending test. 
Among the above mentioned methods, shear testing has been used to measure the shear 
strength of HAp/polymer coatings [182, 195]. Lap-shear and tensile testing have also been applied to 
EPD coatings of chitosan/gelatin [151] and chitosan/silk fibroin [152]. Nevertheless the presence of 
porosity in these coatings can complicate interpretation of the results. Similar tests on HAp EPD 
coatings estimated interfacial shear strength of ~22 MPa on 316L SS and ~12 MPa on Ti substrates. 
Lower adhesion to Ti was associated with lower coefficient of thermal expansion of Ti compared to 
HAp which results in tensile residual stresses [196]. Recently Lin et al. [197] have performed tensile 
testing on biomimetic composite coatings. Their results revealed a composite tensile strength 4 times 
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higher than that of pure polymer coating as well as a tensile modulus 1 order of magnitude higher. In 
another research, pull-off testing of EPD nanocomposite coatings was utilised to determine variations 
in adhesive strength with coating thickness [105] and sintering conditions [198]. Nanoindentation has 
also been applied to mechanically evaluate hardness [143, 183] and Young’s modulus [199, 200] of 
polymer-matrix composite coatings. Scratch test [201, 202], tape testing [184] and abrasive wear [202] 
are other characterisation techniques discussed in the literature.  
Although these methods have provided qualitative as well as quantitative data to assess the 
bonding between the biomedical implant and bioactive composite coatings prepared by wet 
techniques, Nijhuis et.al.[14] believe that a proper comparison between these measurements can 
hardly be made; because crucial parameters such as coating thickness, adhesive strength and surface 
roughness are measured with methods which do not usually allow direct comparison. Coating 
thicknesses vary in the range of hundreds of nanometers (e.g sol-gel coatings) to tens of microns (e.g. 
ED coatings). On the other hand standard methods used for tensile and shear testing of coatings have 
been devised mainly for sintered calcium phosphate coatings and therefore most of recent polymer-
matrix composite films do not fulfil their testing criteria. Scratch and tape tests only provide a 
comparative study rather than an absolute measurement. Compared to enamelling and plasma 
spraying, the large variation in analytical data is one of the main reasons wet-deposition techniques 
outlined in this review have not yet been commercialised. 
2.4.5. Therapeutic orthopaedic coatings 
Implantation of a biomedical device in the body is always associated with a risk of bacterial 
adhesion to the implant surface and consequent microbial infection which is more severe in open-
fractured bones and joint revision surgeries [8]. More importantly, formation of bacterial biofilms on 
the implant presents additional complication, as these are extremely resistant to both the immune 
system and antibiotics. A biofilm is a population of bacteria living in an organised structure 
encapsulated by an extracellular polymeric matrix. Factors conferring antibiotic resistance to biofilms 
are compact nature of biofilms structure, presumed reduced cellular growth, respiration of biofilms 
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bacteria and the protection provided by the polymeric matrix [203]. While systemic drug 
administration is used to address implant-related infections, it is not sufficiently effective due to 
impaired blood circulation at the injury site and low local concentration of drug. Therefore local 
delivery of drugs and biomolecules can be a promising approach to effectively treat such conditions. 
With this approach high local levels of drug concentration with long-term controlled release can be 
administered without the risk of systemic toxicity or formation of biofilms [204]. 
For metallic implants, strategies explored for local drug delivery employ surface grafting of 
the drug or biomolecules. Surface loading is feasible (1) by dipping and drying; (2) by immobilisation 
with chemical bonds and (3) by applying a coating. Drawbacks such as poor control over release in the 
case of dipping technique or limited available sites for chemical bonding of pharmaceuticals in the 
case of immobilisation, render coating approach more promising [205]. 
As outlined by Simchi et.al. [205], implants with therapeutic-coatings are categorised as drug-
loaded coatings and antibacterial coatings. The first category comprises of organic and inorganic films 
loaded with therapeutic biomolecules while the second group contains antimicrobial active 
components such as silver, nitric oxide (NO) and TiO2 developed as a coating. In the following, the 
first group and the silver-containing coatings will be briefly discussed. 
2.4.5.1. Organic and inorganic drug-loaded coatings 
There is a wealth of literature on organic and inorganic drug delivery systems for orthopaedic 
applications [25, 206]. Various polymeric systems have been utilised for drug administration. PLGA 
coatings on stainless steel fracture plates containing 20 wt% gentamicin were successfully applied 
against S. aureus bacteria strain [207]. In another study, chemically functionalised surface of Ti was 
dip-coated with CS/vancomycin films. The antibacterial effectiveness of released vancomycin on S. 
aureus was found to be similar to the standard vancomycin [208]. CS nanoporous membranes have 
shown selective permeability to ionic and non-ionic water soluble drugs which is an interesting aspect 
for transport of drugs with controlled diffusion manner [209]. Biodegradable polyelectrolyte 
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multilayers (PEM)/gentamicin coatings have displayed synergistic treatment of osteomyelitis infection 
in vivo [210]. In an interesting approach electrical stimulation has been utilised to control release of 
penicillin/streptomycin and dexamethasone drugs from electrically conductive nanostructured 
polypyrrole (PPy) [211]. Apart from antibiotics and anti-inflammatory drugs, polymeric delivery 
platforms for growth factors [212] and multi-component release systems for antibiotic and growth 
factors [213] have also been investigated. Moreover EPD technique has been used in few studies for 
drug loading. Model protein BSA [159], heparin (anti-coagulant) [193] and salicylic acid (anti-
inflammatory) [147] are examples of components electrophoretically loaded in CS and HYH 
polymers. 
As inorganic delivery system, antibiotics of vancomycin, gentamicin, tobramycin, amoxicillin, 
cefamandol, cephalothin and carbenicillin have been biomimeticaly incorporated in carbonated HAp 
coatings [214]. It has been demonstrated that antibiotics with carboxyl groups such as cefamandol, 
cephalothin and carbenicillin are more prone to bind/chelate with calcium in HAp and therefore have a 
slower release rate. Gentamicin release from sol-gel HAp spin-coated on Ti alloy have been modelled 
by three non-linear mathematical methods [215]. As a novel structure, calcium apatite coatings 
presented higher degree of retention of osteogenic rhBMP-2 and induced osteogenic 
transdifferentiaiton of C2C12 cells [216].  
Composite release systems have also been studied. Zhou and co-workers[217] demonstrated 
that the release of gentamicin from electrochemically deposited CS/CaP coating is controlled by its 
component ratio and surface topography. In another study, Ti alloy was dip-coated with gelatin/HAp 
composite coatings and loaded with ibuprofen anti-inflammatory drug [218]. The coatings had a thin 
dense outer layer and thick porous inner layer. The in vitro release rate from this system was always 
zero-order and lasted for 30 days. CS/nano HA film capped with poly(β-amino ester) based film 
incorporating physiological amounts of rhBMP-2 exhibited increased rate of mesenchymal stem cells 
differentiation [219]. 
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2.4.5.2. Silver-release coatings 
As increased antibiotic resistance is a major medical concern, silver; an agent which has not 
developed bacterial resistance; is emerging as a high potential antibacterial component. It works 
against a broad range of gram-positive (e.g. S. aureus, S. epidermidis) and gram-negative (e.g. E. coli, 
P. aeruginosa) bacteria [220]. Silver exhibits bactericidal effect at very low concentrations (as low as 
35 ppb) without toxicity to human cells [221]. One mechanism  suggested is that Ag+ reacts with 
bacteria cell membrane and metabolic proteins and enzymes, and disrupts there function by binding to 
DNA and thiol groups of proteins [222]. 
Silver has been incorporated in a variety of organic matrices. Silver/polyamide composite 
films were shown to actively release silver ion due to interaction between diffused water and silver 
particles in the matrix [223]. In a recent approach, intrinsically antibacterial polyurethane anionomers 
were prepared by neutralising its backbone carboxyl groups by metal ions of Ag(I), Cu(II), Zn(II), 
Al(III) and Fe(III) [224]. The best result was obtained by silver ion containing-polymer which 
inhibited S. epidermidis growth up to 16 days. It was shown silver nanoparticles have larger surface 
area to come in contact with bacterial cells and hence have a higher level of interaction and faster 
release rate [225]. LBL films of CS-nano silver/heparin have shown antibacterial effects to E. Coli 
without cytotoxicity to osteoblast cells within 48 h culture, although the levels of silver ion released 
during this period were not measured [226]. 
Many different inorganic silver containing coatings have been studied. Among them there has 
been more focus on Ag-containing HAp coatings. Impregnating HAp films with Ag [227], co-
sputtering [228] and plasma spraying [229] of Ag-containing HAp coatings have all conferred 
antibacterial property to metallic implants. Slow release of silver from microporous HAp has been 
achieved through immobilisation of Ag ions by ion exchange [230]. According to Chung et.al. [231] 
addition of 100 ppm Ag ions to sol-gel HAp coatings on Ti alloy inhibits growth of S. mutans. Ag-
doped HAp/PEEK composite coating cold-sprayed on glass slide inhibited the growth of E.coli [232]. 
Pang et.al [192] have applied EPD to co-deposit multi-layers of composite chitosan/silver /HAp nano 
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particles. They have reported formation of amorphous Ag-chitosan complexes in their coatings and 
have controlled the release kinetics of ionic silver from these coatings by application of an additional 
chitosan film.Apart from HAp, other inorganic structures have been studied. Roy et.al. [233] coated Ti 
with TCP and then electrodeposited silver on it using three different concentrations of AgNO3. The 
intermediate AgNO3 concentration (0.1 M) yielded coatings with sufficient antibacterial effect without 
cytotoxic interaction with osteoblast cells. Moreover, bactericidal behaviour of Ag containing sol-gel 
bioactive glasses has also been investigated [234, 235]. 
2.4.6. Live tissue-bioactive material interaction 
2.4.6.1. Osteogenesis 
A critical phase in formation of new bone is rapid attachment, proliferation and differentiation 
of osteoblast progenitor cells [236]. It has been proved that bone regeneration or osteogenesis happens 
faster by applying class A bioactive materials (e.g. Bioglass® 45S5) rather than class B materials (e.g. 
HAp) [237]. This phenomenon has been attributed to a shift in the cell cycle of primary human 
osteoblasts due to a genetic control [236]. 
Xynos et al. [238] for the first time, attempted to correlate osteogenesis on a bioactive 
substrate with a temporal sequence of biological events involving cell morphology, proliferation and 
differentiation. In their study, human primary osteoblasts were seeded onto both bioinert and 
Bioglass® substrates and the comparison of cell culture results evidenced an increase in the osteogenic 
differentiation of the cells in the presence of the bioactive glass. The reason of this increase has been 
attributed to a higher activity of alkaline phosphate (ALP) with Bioglass®; an enzyme associated with 
osteoblast differentiation. Further investigations confirmed that ionic by-products of bioactive glass 
dissolution are influential on gene expression of insulin-like growth factor II (a factor capable of 
inducing bone formation) and proliferation of human osteoblasts [239, 240]. Apart from Bioglass®, 
constructs with other compositions of bioactive glass; either in monolithic or composite form; have 
been reported to induce cell differentiation and tissue growth [241, 242]. How bioactive materials 
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interact with living cells especially at the nano-scale and what modifications should be applied to these 
materials to stimulate appropriate cellular cues, are currently active fields of research. 
2.4.6.2. Angiogenesis and neovascularisation 
For the integration of the engineered bone tissue with the host tissue, presence of an active 
blood vessel network is inevitable. The vasculature system plays a critical role in supplying tissue with 
nutrients, oxygen and in transporting various biological factors and cell types in the body. Therefore, 
as the tissue engineered orthopaedic structure aims at regeneration of new bone, it should be designed 
and equipped with means of stimulating formation of blood vessels. Angiogenesis is formation of new 
blood vessels form the already existing vasculature, while neovascularisation means formation of new 
blood vessels. 
Trueta [243] first reported that a vascular stimulating factor (VSF) is naturally released at the 
site of a bone fracture in the body. Since then, extensive research has been conducted on exploring 
different factors involved in angiogenesis and methods of introducing them in orthopaedic devices 
[20]. Some of the main biochemical factors known to be involved in the process of angiogenesis are: 
Vascular Endothelial Growth Factor (VEGF), basic Fibroblast Growth Factor (bFGF), Transforming 
Growth Factor beta (TGFβ) family members, hypoxia (Hypoxia-inducible transcription factor, HIF), 
angiopoietins, Hepatocyte Growth Factor (HGF), Platelet-derived Growth Factor (PDGF-BB), Insulin-
like growth factor family (IGF-1, IGF-2) and Neurotrophins [244]. As a better vascularisation leads to 
enhanced bone growth, recent efforts have been concentrated on incorporation of these growth factors 
along with other osteogenic agents and drugs within the orthopaedic scaffold [245-249]. Upon 
degradation of the implanted material, growth factors are released and provide a favourable condition 
for bone morphogenesis. A recent study has shown the potential of angiogenesis in the bioactive 
coatings of titanium implants. Recombinant human (rh)VEGF-loaded copolymeric hydrogel coating 
on the Ti implant has maintained a release of the growth factor in vitro. As a result of it the 
osteointegration of the implant has been improved [250]. 
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Although attempts have been made to enhance neovascularisation of the tissue engineered 
constructs by incorporation of growth factors, problems regarding the delivery and exposure duration 
persist. Alternatively, recent in vitro studies indicate that low concentrations of bioactive glass cause a 
considerable increase in the release of VEGF and bFGF from human cells in culture [251, 252]. This 
angiogenic effect of bioactive glass remains even when particles are embedded in a polymer matrix 
composite structure [245, 253, 254]. The histological studies on an irradiated cavarial defect in a rat, 
filled with bioactive glass loaded collagen, have revealed a promoted bone regeneration due to 
bioactive glass induced angiogenesis [255]. Therefore the application of bioactive glass not only as an 
osteogenic, but also as an angiogenic agent seems to be a promising route to an ideal orthopaedic 
therapy. 
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2.5. Electrophoretic deposition 
2.5.1. Introduction 
Among the various methods available for surface coating of metallic implants; some of which 
have been mentioned in section  2.4; electrophoretic deposition (EPD) is particularly attractive because 
it can be utilised to produce uniform coatings with controlled microstructure and properties on 
complex-shaped parts and porous structures at ambient temperature without the need for expensive 
processing equipment. Co-deposition of polymers and ceramics is also another interesting feature of 
EPD [15, 256]. 
In electrophoretic deposition, particles of the coating material are suspended in a liquid 
medium. Upon suspension, a surface charge develops on the surface of the particles as a result of 
different mechanisms. This surface charge enables particles to move toward an oppositely charged 
electrode (i.e. the substrate) under an applied electrical field. Accordingly, a cathodic or anodic film is 
deposited on the substrate which is in turn dried and if necessary consolidated by sintering (Figure 
 2.8). The morphology and deposition rate of the coatings can be controlled by adjustment of either (1) 
suspension-related or (2) process-related EPD parameters. 
 
Figure  2.8 - Schematic electrophoretic deposition setup, displaying the movement 
(electrophoresis) of positively charged particles to the cathode. 
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As reviewed by Ferrari et.al. [257] different attempts have been made to describe the 
deposition kinetics in EPD in terms of various parameters involved. The first attempt was done by 
Hamaker [258] in which  the deposit weight (w) is: 
 w=𝐶𝐶𝑠𝑠 .𝜇𝜇.𝐴𝐴.𝐸𝐸. 𝑡𝑡 Equation  2.1 
where µ is the electrophoretic mobility, E is the electrical field strength, A is the surface area of the 
electrode, Cs is the particle mass concentration in the suspension and t is the deposition time. 
Avgustinik et al. [259] presented a similar equation for cylindrical, coaxial electrodes and defined 
electrophoretic mobility in terms of permittivity (ε), the zeta potential (ξ) and the suspension viscosity 
(η). Further analytical studies of EPD, have led to consideration of boundaries between three distinct 
phases; namely deposit phase, suspension phase and a phase containing little or no particles. The 
movement of these phases with time explains the deposition. This fact requires involvement of 
additional terms in the equations including volumetric concentration of particles in the suspension (
) and the deposit ( ) [260]. 
Hamaker equation is only applicable to short deposition times, because the linear variation of 
mass with time in this equation implies that all other parameters remain constant during deposition. To 
consider other experimental conditions, Sarkar and Nicholson [261] proposed that for infinitesimal 
time intervals, a modified Hamaker equation holds: 
 dw
dt
= 𝑓𝑓. 𝜇𝜇.𝐴𝐴.𝐸𝐸.𝐶𝐶𝑠𝑠 Equation  2.2 
in which f ≤ 1 is an efficiency factor suggesting that not all the particles brought to the electrode 
surface will participate in deposition. Based on this assumption, they modelled variation of deposit 
weight as a function of time for four different conditions as depicted in Figure  2.9 [261]. One 
noteworthy fact is drawn from this plot by comparison of curves A and C. It reveals that although the 
φ s φ d
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rate of deposition in curve C (constant voltage) decreases dramatically with time, it remains constant 
in curve A (constant current) and the final yield is considerably higher in the latter. This deviation of 
curve C from A is not due to suspension concentration, since in both cases it remains constant with 
time. It is because of formation of an insulating layer of coating which causes the voltage drop per unit 
length of suspension to decrease with time during constant voltage deposition (curve C). 
 
Figure  2.9 - Schematic of EPD kinetics: (A) constant current/constant suspension concentration; 
(B) constant current but decreasing concentration; (C) constant voltage/constant concentration 
and (D) constant voltage but decreasing concentration [261]. 
Both aqueous and organic solvents can be used for EPD. Advantages of the application of 
water-based suspensions are lower cost, less environmental issues concerned with disposal of the 
liquid, lower electrical field required and a faster kinetic [15]. In spite of these facts, one major 
problem of aqueous suspensions is electrolysis of water at low voltages (theoretically above 1.24 V). 
This causes evolution of oxygen and hydrogen gases at the anode and the cathode, respectively, and 
renders the deposited films porous. Moreover, high current densities in the process causes Joul heating 
of the system, deposition instability and corrosion of the metallic substrates [262]. The above-
mentioned problems can be resolved by using organic solvents. Low dissociating power of these 
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liquids to develop particle surface charge can be compensated for by employing higher electrical field 
strengths. 
2.5.2. Characteristics of the suspension  
Different parameters related to the suspension influence the EPD process, the most important 
of which are briefly stated below. 
Fine dispersion of particles in the suspension is critical to obtain a homogenous deposition. 
Therefore as the particle size increases, they tend to settle due to gravity, causing a non-uniform 
coating thickness [15]. Reducing down the particle size also aids a better control of shrinkage cracks 
during drying phase [263]. 
The relative permittivity (or dielectric constant) of the liquid medium; ε; should have an 
optimal value. A liquid with a too low dielectric constant will have insufficient dissociative power and 
hence no deposition occurs, while a liquid with a high dielectric constant will have high ionic 
concentration and consequently the size of the double layer region (explained in section  2.5.4) and 
hence the electrophoretic mobility of the particle reduces [264].  
The suspension conductivity should be in a certain range to be favourable for deposition. As 
the ions in the suspension are carrying most of the current in EPD, the electrical conductivity of the 
suspension gains importance. It should be adjusted in a way that on one hand the mobility of the 
particles is not retarded due to presence of too many ions and on the other the loss of stability due to 
electronically charging of particles (in a too resistive liquid) is avoided [265]. Also a low suspension 
viscosity is favoured as high viscosity values results in lower particle mobility [15]. 
The zeta potential of the particles is influential in establishing the stability of the particles in 
the suspension, direction of particles motion, particles mobility and finally green density of the film. 
The overall stability of the system is governed by electrostatic and van der Waals forces between the 
charged particles. While a low electrostatic repulsion leads to particles agglomeration, a very high one 
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does not allow deposition at the electrode to take place. Therefore the zeta potential should be tuned 
by addition of certain charging agents such as acids, bases and specifically adsorbed ions or 
polyelectrolytes [266]. 
As mentioned above, although a high suspension stability should be maintained through 
parameters such as a small particle size and an adequate zeta potential, it has been reported that for the 
deposit to form, an unstable condition should be provided at the vicinity of the electrodes [261]; this 
instability can be caused by the formation of ions from electrolysis or particles discharging. 
2.5.3. Characteristics of the EPD process 
Deposition time, electrical field strength, concentration of particles and substrate conductivity 
are process-related parameters which are of considerable importance in EPD. As shown in previous 
sections, the deposit yield increases with time, and yield rate depends on the process conditions. 
It has been observed that at a constant applied voltage, the deposition rate in EPD is initially 
constant and then decreases by deviation from the linear trend [267]. As discussed earlier, this 
phenomenon has been explained by the formation of an insulating layer (coating) on the electrode 
which shields the effect of electric field and hence causes a drop in the electrical current. 
Although the amount of deposited coating normally increases with a rise in the applied 
voltage, electrical current stability and the quality of the coating are adversely affected. Under a too 
high electric field, the particles deposit at a high rate which does not give them the opportunity to 
position themselves efficiently in the deposit. As a result of that, it is suggested to use moderate 
applied voltages appropriate for the material under study [15]. 
According to Hamaker’s equation [258], the particles concentration in suspension is directly 
related to the EPD yield. In EPD of suspensions containing different components, the rate of 
deposition of various particles depends on the volume fraction of the solids in the medium. At high 
67 
Chapter 2: Literature Review 
volume fractions, the solids deposit at an equal rate while at low volume fractions, they deposit at 
distinct rates dependent on the particle mobility [268]. 
In terms of the substrate property, as reported [269, 270], a high conductivity is desirable to 
achieve an acceptable deposition rate and a uniform coating. 
2.5.4. Electrophoretic mobility 
When solid powders become in contact with a polar liquid such as water, an electrical charge 
is developed on the surface of the particles via five different mechanisms: (1) dissociation or 
ionisation of surface groups on the particles which depends on the pH of the suspension; (2) re-
adsorption of potential-determining ions; (3) adsorption of ionised surfactants; (4) isomorphous 
substitution and (5) charged crystal surface fracturing [261]. The first mechanism is commonly 
observed in oxide surfaces. In these surfaces the degree of charge and its sign depend on pH. Because 
oxide surfaces consist of a large number of amphoteric hydroxyl groups, the following reactions can 
occur: 
(𝑀𝑀 −𝑂𝑂𝑂𝑂)𝑠𝑠𝑠𝑠𝑠𝑠𝑓𝑓𝑠𝑠𝑠𝑠𝑠𝑠0 + 𝑂𝑂+ ⇔ (𝑀𝑀−𝑂𝑂𝑂𝑂2+)𝑠𝑠𝑠𝑠𝑠𝑠𝑓𝑓𝑠𝑠𝑠𝑠𝑠𝑠     at low pH 
(𝑀𝑀 −𝑂𝑂𝑂𝑂)𝑠𝑠𝑠𝑠𝑠𝑠𝑓𝑓𝑠𝑠𝑠𝑠𝑠𝑠0 + 𝑂𝑂𝑂𝑂−⇔ (𝑀𝑀 −𝑂𝑂−)𝑠𝑠𝑠𝑠𝑠𝑠𝑓𝑓𝑠𝑠𝑠𝑠𝑠𝑠 + 𝑂𝑂2𝑂𝑂   at high pH 
Due to this surface charge, a layer of ions with opposite charge (counter-ions) is formed 
around the particles, while the similarly charged ions (co-ions) in the medium are repelled from the 
solids surface. This configuration of particles and ions is called the “electrical double layer”. Under an 
applied electric field, the counter ions and the particles should move in opposite directions, but owing 
to the attraction forces exerted on the counter ions, a fraction of them moves along with the particle, 
which is called the “stern layer” [256]. The more broadly distributed counter ions form a “diffuse 
double layer”. The electrical potential difference between these two layers is called the “zeta (ξ) 
potential” [15], as illustrated in Figure  2.10. The zeta potential has a pivotal role in the velocity at 
which the particle moves and their mobility. The mobility is defined as: 
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 μ=
23 𝜀𝜀0. 𝜀𝜀𝑠𝑠 . 𝜉𝜉𝜂𝜂 𝑓𝑓(𝜅𝜅𝑠𝑠) Equation  2.3 
where ε0 is the vacuum permittivity, εr is the relative permittivity of the solvent, ξ is the zeta potential, 
η is the solvent viscosity and f (κr) is the Henry coefficient which depends on the relation between the 
thickness of the double layer (1/κ) and the core radius (r) of the particle [15]. 
 
Figure  2.10 - Schematic of the double layer surrounding a charged particle in a suspension, (a) 
surface charge, (b) Stern layer and (c) diffuse layer of counter ions [271]. 
The velocity of the charged particles moving under an electric field is under the influence of 
four distinct forces: (1) the accelerating force exerted by the applied electrical field to the charged 
particles; (2) viscous drag of the liquid; (3) retardation force exerted by the applied electric field to the 
counter ions and (4) relaxation force caused by the distortion in the double layer when the positive and 
negative charge centre are displaced [256]. 
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2.5.5. Suspension stability and mechanisms of film deposition 
The “DLVO theory” of colloidal systems is a quantitative theory named after researchers 
Derjaguin, Landau, Verwey and Overbeek who established it [272, 273]. According to this theory the 
stability of the suspended particles is determined by the interaction between attractive Van der Waals 
forces and the repulsive electrostatic forces between particles. The total potential energy of this 
interaction at a certain inter-particle distance exhibits different forms based on the ionic strength of the 
system (Figure  2.11). At appropriate ionic strength values, “electrostatic stabilisation” of the colloids 
happens. On the other hand in the presence of hydrophilic polymers, another important factor should 
be considered. In case of adsorption of these macromolecules on the particles, the repulsive forces 
between them cause a “steric stabilisation” which improves the dispersion of the solid powders. 
 
Figure  2.11 - Total potential energy versus interparticle distance between two particles (A to E: 
increasing suspension ionic strength); A=spontaneous dispersion; B=no primary coagulation due 
to high energy barrier; C,D=weak secondary minimum coagulation; E=fast coagulation into 
primary minimum [274]. 
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Various mechanisms have been suggested for the formation of the deposit in EPD. 
Flocculation by particle accumulation, particle charge neutralisation, electrochemical particle 
coagulation and finally electrical double layer distortion and thinning are four main mechanisms 
presented by different researches. A detailed review of these mechanisms can be found in reference 
[275]. 
2.5.6. EPD of bioactive coatings 
Despite the simplicity of the process, as explained in the previous sections many parameters 
influence the deposition rate and quality of the deposited layer in EPD. The characteristics and 
concentration of solid particles in the suspension, the electrophoretic mobility, the suspension 
conductivity, pH, electrical field, and deposition time control the EPD rate [15]. Therefore, in order to 
obtain a controlled deposition rate leading to desirable coating microstructure, de-convolution and 
optimization of the processing parameters is necessary. In most current EPD activities, a trial-and-
error approach is followed to determine the “best” process parameters [276]. As outlined in previous 
sections, Krause et al. [102] showed that a uniform layer of Bioglass® coating on 304 stainless steel 
and Nitinol® substrates can be achieved for a defined combination of time, concentration and voltage. 
Stojanovic [277] has recently shown that by controlling the EPD voltage and deposition time, 
functionally graded bioactive glass-apatite composite coatings can be fabricated on Ti alloy substrates. 
The effect of processing parameters on EPD of calcium phosphate [278], apatite-mullite [279] and 
bioactive glass [17, 104] suspensions to fabricate biomedical coatings has also been reported. As 
discussed in detail before, the EPD of biopolymer and biopolymer/bioceramic composite coatings has 
also been investigated. Studies of EPD of HAp/chitosan [166, 189] and Bioglass® reinforced alginate, 
chitosan and PEEK polymers [17, 18] have revealed the importance of an accurate control of the 
processing parameters. We have reported the effect of EPD parameters on deposition of chitosan and 
Bioglass® components [106, 148, 190]. Evidently, EPD of composite suspensions is more difficult 
than that of single-phase suspensions because of differences in the electrophoretic mobility of the two 
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or more phases. Therefore, fine-tuning of the processing parameters is required to fabricate bioactive 
composite coatings with a controlled microstructure. 
2.6. Summary 
Although bioactive glass containing structures are emerging as future orthopaedic materials 
particularly in the form of scaffolds, as documented in this review the need for improvement of 
biocompatibility and bioactivity of bioinert implants currently in use, persists. Therefore, the goal of 
this research project has been set to investigate the fabrication, characterisation and improvement of 
resorbable natural polymer/bioactive glass composite coatings. Owing to the advantages it offers, EPD 
has been selected as the fabrication route. On one hand, the optimisation of polymeric composite 
coatings containing micron-sized bioactive glass particles and on the other hand enhancement of 
antibacterial and drug delivery properties of these coatings is central to this study. The novel features 
of these films should be tested in vitro so that cellular interaction and anti-bactericidal activity of the 
material can be compared with similar studies on other orthopaedic coatings. This investigation can 
contribute to a better understanding of the interaction between body and these novel materials. 
2.7. Scope of the thesis 
In the light of the above, specific goals of this PhD project are: 
1. Study of electrodeposition kinetics of the chitosan film. 
2. Investigation of the influence of EPD parameters on deposition of the micro-Bioglass® 
particles from aqueous suspensions and optimisation of its deposition. 
3. Co-electrophoretic deposition of chitosan/Bioglass® films from aqueous suspensions and the 
effect of EPD factors on the properties of coatings. 
4. Microstructural evaluation of the prepared EPD chitosan and composite chitosan/Bioglass® 
coatings. 
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5. Bioactivity assessment and dissolution study of the composite chitosan/Bioglass® coatings. 
6. Mechanical characterisation of the developed EPD films. 
7. Multifunctionalisation of bioactive composite coatings by incorporation of antibacterial agents 
in the EPD process, their microstructural as well as bioactivity characterisation and study of 
antibacterial release rate. Two types of agents are considered: 1) silver-release films; and 2) 
gentamicin-release films. 
8. Comparing preliminary cellular proliferation and bacterial responses of the developed 
coatings. 
Figure  2.12 schematically displays the type and functionality of different components which 
have been determined to be incorporated in the coatings by EPD technique: 
  
Figure  2.12 - Schematic of the EPD coating under study and its various components. 
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Chapter 3: Processing and Characterisation Techniques 
This chapter includes processing as well as characterisation techniques commonly applied to 
electrophoretically deposited coatings developed through this research. The characterisation methods 
and test conditions specific to some coatings are presented in their corresponding chapters. Unless 
otherwise stated, all chemicals were purchased from Sigma-Aldrich Company Ltd. (Dorset, UK). 
3.1. General experimental methods for EPD 
3.1.1. Materials 
Bioglass® 45S5 powder (melt-derived) with nominal composition: 45 SiO2, 24.5 Na2O, 24.5 
CaO, 6 P2O5 (wt %) (produced by NovaMin USA) was kindly supplied by Dr. I. Thompson (Kings 
College London, UK). Figure  3.1 a shows SEM image of Bioglass® particles. Two batches of the same 
glass were used during this study. The particle size distributions for these batches are shown in Figure 
 3.2 a and b and indicate only a small variation in particle size. A CILAS 1180 particle size analyser 
(CILAS, Orleans, France) was used to measure particle size distributions from a 2 wt% suspension of 
particles in distilled water. 
Medium molecular weight chitosan (200-800 cP viscosity for 1wt% in 1% acetic acid) with a 
degree of deacetylation in the range 75-85% and acetic acid (>98%) were used. Acetic acid was used 
to adjust the pH of EPD suspensions to the desired values. Figure  3.1 b shows SEM image of chitosan 
powder. 
 
Figure  3.1 - SEM images of (a) Bioglass® particles and (b) chitosan flakes. 
74 
Chapter 3: Processing and Characterisation Techniques 
 
Figure  3.2 - Particle size distribution of Bioglass® particles, (a) batch 1: particle size in the range 
1.3 and 16.5 µm with a median particle size of 6.4 µm and (b) batch 2: particle size in the range 
1.6 and 26.7 µm with a median particle size of 9.8 µm. 
For preparation of suspensions, solutions of chitosan in deionised water/acetic acid were 
prepared by magnetic stirring at room temperature for 24 h. Suspensions containing Bioglass® were 
prepared by dispersing the particles in the chitosan solutions via magnetic stirring and sonication 
(USC 300 sonicator, VWR International, Malaysia) for periods of 10 min each. 
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3.1.2. EPD setup 
After the preparation of each suspension type; details of which will be presented individually 
in each chapter; the pH was measured by JENWAY 3510 pH Meter (Essex, UK). In electrophoretic 
deposition, planar AISI 316L stainless steel (Advent Research Materials Ltd, Oxford, UK) working 
electrodes with dimensions 20 mm × 10 mm × 0.2 mm were utilised as deposition substrate. It is 
pertinent to point out that as long as the substrate is electrically conductive the electrophoretic 
deposition (EPD) rate is independent of the substrate properties. Therefore the methodology applied 
here is extendable to other conductive implant substrate materials including Ti alloys. The counter 
electrode was planar and of similar dimension to the working electrode. In order to clean the 
substrates, they were sonicated in distilled water and acetone and were dried prior to deposition. 
The EPD cell consisted of 25 ml of suspension which was gently stirred (100 rpm) during 
deposition by a magnetic stirrer (Fisher Scientific, Loughborogh, UK). As shown in Figure  3.3, the 
electrodes were held in parallel configuration by alligator clips at a constant distance from each other. 
The alligator clips were fixed to two copper bars which were connected to a holder, capable of 
adjusting electrodes distance. The deposition area was adjusted to ~10×10 mm2 by immersing the 
electrodes in the suspension and avoiding any clip-suspension contact to prevent contamination. To 
prevent the deposit being washed off the substrate after deposition, a jack was used to slowly lower the 
suspension and remove the electrodes from it. 
For constant-voltage EPD, a specific electric voltage was applied on the electrodes for a short 
period of time (≤ 600 s) at room temperature. The electric voltage was applied by a Thurlby Thandar 
Instruments (TTi) EL561 power supply (Cambridgeshire, UK) and the current through the suspension 
during EPD was recorded using a TTi 1906 Computing Multimeter. The power supply and the 
multimeter were connected in a series arrangement to the cathode (negative electrode) and the anode 
(positive electrode). 
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Figure  3.3 - (a) Experimental set-up employed to perform EPD; and (b) deposition in parallel 
electrodes configuration. 
After the deposition, the samples were gently rinsed with deionised water, dried overnight and 
depending on the accuracy required, deposit weight-gain per substrate area was measured by an 
accurate balance with 0.1 mg (Adventurer Pro AS214, Switzerland) or 0.01 mg resolution (Mettler AE 
163, Leicester, UK). The samples were then stored in a desiccator for further analysis. 
The change in the conductivity of the suspensions versus suspension concentration, deposition 
time or suspension pH was determined according to the procedure in reference [280]: 
 𝐸𝐸𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 𝐼𝐼𝛬𝛬𝐴𝐴 Equation  3.1 
where Esusp (V/m) is the electric field in the suspension, I (A) is the current passing through the 
deposition cell at time 0, A (m2) is cross sectional area of the deposition cell and Λ (S/m) is the 
medium conductivity. 
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3.2. SEM/EDX 
Scanning electron microscopy (SEM) (JEOL 5610 SEM) was used to analyze the 
microstructure of the films. An SEM accelerating voltage of 10 kV was applied. The samples were 
coated with gold using a EMITECH K550 sputter coater (Emitech Ltd., UK) before SEM examination 
to avoid any charging artefacts during imaging. 
Additionally, for high resolution imaging (HR-SEM) of microstructure and cross-sectional 
thickness of the deposits, field emission scanning electron microscopy (LEO Gemini 1525 SEM) with 
5 kV accelerating voltage was utilised. The samples were coated with chromium using EMITECH 
K575X sputter coater (Emitech Ltd., UK). The HR-SEM was fitted with an Oxford Instruments INCA 
energy dispersive X-ray spectrometer (EDS) which was used for qualitative elemental analysis of the 
coatings at 20 kV SEM operating voltage. 
For cross sectional imaging of coatings, EPD was performed on gold coated glass slides (emf 
Evaporated Metal Films, USA) which were cleaved after deposition to view the cross section. 
3.3. TEM 
Transmission electron microscopy (TEM) was used in order to study the morphology and 
structure of silver nanoparticles (Ag-np) in the antibacterial coatings. For this purpose, thin cross 
sections of CS/Ag and CS/BG/Ag samples were prepared with a focused ion beam (FIB) dual beam 
system (FEI™ helios™ NanoLab™) using the in situ lift-out technique [281]. After coating with a 
chromium layer to provide a conductive surface and a platinum strap to protect surface features, the 
selected area of the coating was milled using 30 kV accelerated Ga+ ions to create a lamella. The 
extracted lamella was attached to copper TEM grid and thinned down to electron transparency with 
the Ga+ beam at successively lower accelerating voltages, with the final voltage set at 2 kV and a 
beam-defining aperture corresponding to a 3.2 pA beam current. The microstructure was examined 
using a JEOL 2010F TEM and a Philips CM200 TEM, both operated at 200 kV in bright field mode 
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and selected area electron diffraction (SAED) patterns were obtained to confirm the crystallinity of 
Ag-np.1 
3.4. XRD 
The crystalline phases present in the EPD coatings were identified with X-ray diffraction 
(XRD) analysis using PANalytical X’Pert Pro MPD instrument with an X’Celerator detector. Ni 
filtered CuKα radiation at 40 kV/40 mA was used. For XRD analysis, the EPD coated substrates were 
attached to an amorphous silicon disk. A step size of 0.04º for the 2θ range of 5º to 70º and with a 
count rate of 50 s per step was employed for XRD examination. 
3.5. FTIR 
Fourier transform infrared spectroscopy (FTIR) was applied to determine the type of covalent 
bonds and thus composition of EPD coatings before and after immersion in simulated body fluid. The 
test was performed in transmission mode using a Perkin-Elmer Multiscope spectrometer 
(Massachusetts, USA). 20 spectral scans were repeated in the mid-IR region (4000-320 cm-1) and at a 
resolution of 4 cm-1. For FTIR analysis the coatings were removed from the substrates, mixed and 
finely ground with potassium bromide with a weight ratio of 1:100 and pressed into pellets with 7 
tonnes of pressure. Pure KBr pellet was used to collect background spectrum. 
3.6. TGA/DSC 
In order to estimate the composition of composite coatings in terms of weight percentage of 
polymer and glass, thermogravimetric analysis (TGA) was performed. Along with TGA, differential 
scanning calorimetry (DSC) was carried out to elucidate the thermal phenomena attributed to weight 
loss during TGA. For this purpose, a simultaneous thermal analyzer (NETZSCH STA 449 C, 
1 TEM imaging performed by Mr. J. B. Gilchrist (Department of Materials, Imperial College London). 
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Germany) was utilised. The coatings were removed from the substrates and were heated in a platinum 
crucible, from room temperature up to 800 °C at a heating rate of 10 °C/min in air 2. 
3.7. Electrophoretic mobility and zeta potential measurements 
The surface charge of Bioglass® particles in aqueous suspensions was investigated using 
Agilant 7020 ZetaProbe (Foster City, USA) which employs ultrasonic and electroacoustic sensor to 
measure zeta potential. A Bioglass® suspension of 2wt% previously ultra-sonicated for 5 min was used 
for measurements. The pH of suspension was altered by adding 1M HCl and 1M NaOH in the acidic 
and basic range (pH 2 to 12), respectively.3 
Additionally, the electrophoretic mobility of chitosan polyelectrolyte in solution and 
chitosan/Bioglass® particles in the composite suspensions were measured. A Zetasizer Nano ZS (Nano 
Series, Malvern Instruments, UK) was utilised for this purpose which measures mobility by laser 
doppler micro-electrophoresis.4 
3.8. SBF test 
Bone-bonding ability of a material is often examined by immersion in simulated body fluid 
(SBF) which is an acellular fluid with ionic concentration nearly equal to those of human blood 
plasma. It has been shown that formation of hydroxycarbonate apatite (HCA) on materials surface in 
SBF is indicative of its bioactivity and is the first step for bonding to living bone in vivo [282]. 
To investigate the level of in vitro bioactivity of EPD coatings SBF test as proposed by 
Kokubo et.al.[282] was performed. The following reagents were used to prepare simulated body fluid 
(SBF) solution: NaCl, NaHCO3, KCl, K2HPO4.3H2O, MgCl2.6H2O, CaCl2, Na2SO4, Tris-
hydroxymethyl aminomethane and HCl (1.0 M). Samples of EPD coatings with 10mm×10mm×0.2mm 
dimensions were immersed in 30 ml of SBF and were then incubated at 37 ºC for 2, 5, 7, 14, 21 and 28 
2 Experiments performed in collaboration with Mr. R. Sweeny (Department of Materials, Imperial College 
London). 
3 Experiments carried out by Mr. D. Meng (Josef Stefan institute, Slovania). 
4 Experiments carried out in collaboration with Mr. M. Michelazzi (University of Modena, Italy). 
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days. At each time point the sample was removed from SBF, rinsed with ion-exchanged and distilled 
water, left to dry in air and were then stored in desiccator. The formation of HCA was examined with 
SEM/EDX, XRD and FTIR techniques before and after SBF immersion. Each sample was measured 
in triplicate. 
3.9. ICP-OES 
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) has been used to 
evaluate the elemental concentration of solutions. The change in concentration of sodium, calcium, 
phosphorous and silicon ions in the SBF and dissolution studies, as well as concentration of silver ions 
in the EPD suspensions before and after deposition and in release studies was measured by a Thermo 
Scientific iCAP 6300 Duo ICP-OES instrument coupled with an autosampler. The collected samples 
were filtered with 0.2 µm syringe filters and further diluted by deionised water to avoid saturating the 
detector. The instrument was calibrated using mixed standards of sodium, calcium, phosphorous and 
silicon at 0, 1, 5, 10 and 20 ppm at the beginning of each test series. The detection limit for ICP-OES 
technique depends on the type of element but for all elements concentration in the order of ppb (part 
per billion) can be measured [283]. 
3.10. WLI 
White light interferometry (WLI) is a technique for analysis of surface morphology/roughness. 
A schematic of a WLI instrument is shown in Figure  3.4. Light is directed toward the objective lens 
through the upper beam splitter. The lower beam splitter in the objective lens splits the light into two 
separate beams, one of which is directed toward the sample and the other toward an internal reference 
mirror. The two beams are recombined and the resultant beam is sent to the detector. The maximum 
interference is found by the detector as the objective lens is actuated in the vertical axis. Fringe 
envelope obtained from the intensity of the light detected is used to calculate position of the surface. A 
WLI analysis software is used to display results as a three dimensional map of the surface or as 
numeric representations such as Ra and rms values. To measure the numeric surface roughness, a 
central line is defined by removing the best fit surface from the data (an option in the software) and 
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estimating the weighted average for each data point resulting in equal areas above and below the line 
[284]. 
 
Figure  3.4 - Schematic of a typical WLI instrument (adapted from [284]). 
In this regard, arithmetic mean deviation (Ra or the average roughness) which is the deviation 
of all points from the central line (Figure  3.5): 
 𝑅𝑅𝑠𝑠 = 𝐼𝐼
𝑁𝑁
�|𝑍𝑍𝑖𝑖 |𝑁𝑁
𝑖𝑖=1  Equation  3.2 
where N is the number of measured points in the sampling length and Z is the deviation from the 
central line. Also root mean squared deviation (rms) is the root mean square deviation of the measured 
height from the central line: 




𝑖𝑖=1 � Equation  3.3 
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Figure  3.5 - Representation of roughness average on a surface (adapted from ref [285]). 
In this study, Zygo® Interferometer with MetroPro™ software was used in order to perform 
surface structure analysis of chitosan and different chitosan/Bioglass® composite coatings prepared by 
EPD. Due to low reflectance of the polymer phase of EPD coatings, samples were sputter coated with 
a thin layer of gold (20 nm) prior to testing (Emitech Ltd., UK). For all samples, a magnification of 
20x (2 zoom × 10x Mirau lens) was used which represents a sample area of 0.36 × 0.27 mm2 analysed 
with around 3.07 × 105 pixels. To define the central line, a cylinder shape was removed from the 
surface profiles obtained, due to the curvature caused by guillotine during cutting of EPD steel 
substrates. rms and Ra values were measured at different locations for three samples per coating 
condition and the average results with standard deviations were reported. 
3.11. Micro-hardness testing 
The Micro-hardness of chitosan and composite chitosan/Bioglass® EPD coatings at different 
loadings of Bioglass® was evaluated by a microindentor ZHV/zwicki-Line instrument (Zwick-Roell, 
Germany) equipped with a Vickers diamond indenter. The lowest load of the instrument was used to 
minimise the effect of substrate in hardness readings. The measurements were carried out under a load 
of 0.098 N (10 g) held for 10 s at maximum load. Samples were analysed in triplicate, 10 hardness 
values were measured per sample and the results were averaged. Vickers hardness of 316L SS 
substrate was also measured as a reference. 
3.12. Tape test 
To qualitatively compare adhesion of chitosan and chitosan/Bioglass® EPD composite 
coatings with different Bioglass® loadings to the steel substrate, tape testing (cross cut adhesion test) 
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according to ASTM D3359 method B [286] was performed. 4 samples per condition were tested. This 
technique is suitable for coatings which are up to 125 µm thick and consists of the following steps: 
1) With a sharp razor blade (Agar Scientific, Stansted, UK), a grid of 6-11 straight cuts 
on each direction with 90° between them were applied and it was checked by light reflection that the 
cutting edge had reached the substrate. This cutting pattern provides a free edge for coating peeling 
initiation without overcoming the cohesion of the film. 
2) The coating surface was brushed gently to remove any detached parts of the coating.  
3) A piece of approximately 75 mm long of pressure sensitive Elcometer 99 adhesive 
tape (elcometer® Ltd., Manchester, UK) was cut and the centre of it was applied to the patterned part 
of coating. To confirm good contact, it was rubbed firmly with the eraser on top of a pencil. 
4)  Within 90 ± 30 s of tape application, the tape was removed by pulling in a single 
smooth action at an angle of 180° to the coating surface (Figure  3.6). 
 
Figure  3.6 - Schematic of tape testing (adapted from reference [287]). 
5) The coating adhesion was qualitatively assessed by comparing the lattice of cuts with 
the illustrations shown in Table  3.1. 5 specimens were tested for each process condition. This method 
only demonstrates if the coating adhesion is in an adequate level but is not able to distinguish between 
higher levels of adhesion. 
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Table  3.1 - Classification of the adhesion test result (adapted from ASTM D3359 method B). 
 
3.13. Statistical Design of Experiment (DOE): Taguchi Design 
In optimisation of an experimental study, one approach is successively varying each factor 
over its range while other factors are kept constant. The main disadvantage of this strategy is failing to 
detect any possible interaction among the factors. To overcome this shortcoming, design of 
experiment (DOE) technique (or factorial design) is utilised which is a powerful statistical tool for 
optimisation of the performance output. It involves simultaneous variation of experimental factors and 
studying the effect on the output response. DOE can be in the form of full or fractional factorial 
design. In a full factorial design all possible combinations of different levels of factors are taken into 
account; whereas a fractional factorial design measures the response at a subset of all possible 
combinations and hence is more economical in terms of time and resources [288]. 
Taguchi DOE method is a fractional factorial design which is commonly used for optimisation 
of product quality in engineering applications. In Taguchi method the optimization process is eased by 
using orthogonal arrays of factor levels and also by introduction of signal/noise ratio concept. The 
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former limits the number of experimental runs while the latter allows for achievement of targeted 
response with minimal sensitivity to variation and/or noise (uncontrollable factors) [289]. 
Theoretically, Taguchi design involves these several steps [289]: 
1) The output response most relevant to the problem should be identified. 
2) The experimental parameters and their levels need to be recognised. The aim is 
studying the effect of variation of these parameters on the output response. These parameters are 
called control factors.  
3) An appropriate orthogonal array (OA) of different levels of control factors is 
designed. OA means that the design is balanced and therefore factor levels are weighed equally across 
the entire matrix. This feature facilitates independent evaluation of each factor without influence of 
other factors. The columns of the OA will be control factors which have different levels and the rows 
are different combinations of factor levels which determine conditions of experimental runs. Based on 
the OA, the experiments are performed and the output response at each condition is measured. 
An example is provided below to elucidate the concept of OA [290]. Table  3.2 displays a L8 
Taguchi design which means 8 runs of experiments for 7 control factors each having 2 levels. A full 
factorial design in this case requires 27 (128) runs while this has been reduced to 8 runs by Taguchi 
DOE. 
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Table  3.2 - L8 Taguchi orthogonal array [290]. 
  A   B C D E F G 
1 1  1 1 1 1 1 1 
2 1  1 1 2 2 2 2           
3 1  2 2 1 1 2 2 
4 1  2 2 2 2 1 1           
5 2  1 2 1 2 1 2 
6 2  1 2 2 1 2 1           
7 2  2 1 1 2 2 1 
8 2  2 1 2 1 1 2 
In the above example, levels 1 and 2 occur 4 times in each factor in the array. If the levels in 
factor A with the levels in factor B are compared (highlighted columns), one will see that B1 and B2 
each occur 2 times in conjunction with A1 and 2 times in conjunction with A2. Each pair of factors is 
balanced in this manner, allowing factors to be evaluated independently. 
4) In Taguchi method, a signal/noise (S/N) ratio definition is used to quantitatively 
identify the control factors that reduce variability of output by minimising the effect of uncontrollable 
factors. In this manner, the process is resistant to variation from the noise factors or in other words is 
robust. There are three definitions of S/N ratio: 




= -10 log � 1x  � �  1𝑦𝑦𝑖𝑖2𝑥𝑥𝑖𝑖=1 �� Equation  3.4 




= -10 log � 1x  � �  𝑦𝑦𝑖𝑖2𝑥𝑥
𝑖𝑖=1  �� Equation  3.5 
Nominal response is the better characteristic: 
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= -10 log � 1x  � �(𝑦𝑦𝑖𝑖 − 𝑠𝑠)2𝑥𝑥
𝑖𝑖=1 �� Equation  3.6 
where yi is the output response from each experiment, x is the number of replications and a is the 
target output value. The unit of S/N ratio is decibel (dB), as frequently used in communication 
engineering. 
Due to orthogonality of Taguchi design, the mean S/N ratio as well as the mean output at each 
level of each control factor can be estimated in order to separate the effect of each control factor at 
different levels. These mean values form “response table” in Taguchi design. In this way, Taguchi 
employs a two step optimisation process: first the factor levels at which the S/N ratio is the highest are 
considered to be the preferential choices as they minimise variation in output response. Once the 
variation is reduced; in the second stage of optimisation; the remaining factors are used for adjusting 
the output on the target value. The latters are called “scaling factors” as they have relatively small 
effect on the S/N ratio  
5) Furthermore, analysis of variance (ANOVA) is implemented to investigate the 
significance of control factors and their interactions. This assists the researcher in determination of the 
optimum combination of factor levels for the target response value. Definitions of degrees of freedom 
(DF), total sum of squares (SST), sequential sums of squares (Seq SS), adjusted sums of squares (Adj 
SS), adjusted mean squares (Adj MS), the F-test statistic (F) and probability value (p) are used in 
ANOVA. Some of these terms are outlined below. For a design with n experimental runs and c control 
factors, where control factor k has l levels: 
Overall mean output: 𝑦𝑦 �= 1
𝑛𝑛
 �𝑦𝑦𝑖𝑖𝑛𝑛
𝑖𝑖=1  Equation  3.7 
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Mean output at each level of 
each control factor: 
(𝑦𝑦𝑙𝑙� )𝑘𝑘 = 1𝑁𝑁  �(𝑦𝑦𝑘𝑘𝑙𝑙 )𝑖𝑖𝑁𝑁
𝑖𝑖=1   Equation  3.8 
where N is the number of times level l of factor k appears in the experimental runs. 
Total sum of squares: 𝑆𝑆𝑆𝑆𝑇𝑇  =�(𝑦𝑦𝑖𝑖 − 𝑦𝑦�)2𝑛𝑛
𝑖𝑖=1  Equation  3.9 
Sequential and adjusted sum of 
squares: 
𝑆𝑆𝑠𝑠𝑆𝑆 𝑆𝑆𝑆𝑆𝑘𝑘= Adj 𝑆𝑆𝑆𝑆𝑘𝑘=�𝑁𝑁[(𝑦𝑦𝑘𝑘���)𝑙𝑙 − 𝑦𝑦�]𝑙𝑙2𝑁𝑁
𝑙𝑙=1  
Equation  3.10 
Adjusted mean squares 
𝐴𝐴𝐴𝐴𝐴𝐴 𝑀𝑀𝑆𝑆 =  𝐴𝐴𝐴𝐴𝐴𝐴 𝑆𝑆𝑆𝑆𝑘𝑘
𝐷𝐷𝐷𝐷𝑘𝑘
 
Equation  3.11 
Error sum of squares 
𝑆𝑆𝑆𝑆𝐸𝐸 =  𝑆𝑆𝑆𝑆𝑇𝑇 −�(𝐴𝐴𝐴𝐴𝐴𝐴 𝑆𝑆𝑆𝑆𝑘𝑘)𝑖𝑖𝑠𝑠
𝑖𝑖=1  
Equation  3.12 
F-test statistic 
𝐷𝐷 =  𝐴𝐴𝐴𝐴𝐴𝐴 𝑆𝑆𝑆𝑆𝑘𝑘
𝐷𝐷𝐷𝐷𝑘𝑘
 ÷  𝑆𝑆𝑆𝑆𝐸𝐸
𝐷𝐷𝐷𝐷𝐸𝐸
 
Equation  3.13 
Seq SS measures the reduction in the residual sums of squares provided by each additional 
control factor in the model, while Adj SS measures the reduction in the residual sums of squares 
provided by each control factor relative to a model containing all the other control factors. The 
sequential and adjusted sums of squares will be the same for all terms if the design matrix is 
orthogonal. 
6) Once the levels at which the output response is supposed to be optimum are identified, 
the output at those level combination will be predicted: 
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𝑖𝑖=1  Equation  3.14 
where [S/N]m is the overall mean S/N ratio and [S/N]i is the mean S/N ratio at the optimal level of 
each control factor. To verify the optimisation process, a confirmation test needs to be performed. An 
experiment at the optimum factor levels will be conducted and the result is compared to the predicted 
value. 
In the present research, Taguchi DOE has been utilised to investigate the effect of various 
EPD parameters on deposition of Bioglass® and composite chitosan/Bioglass® coatings. The detailed 
analyses in each case will be fully addressed in Chapter 4. 
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Chapter 4: EPD of Orthopaedic Coatings 
4.1. Introduction 
The need for improved integration between an implanted device and its adjacent bone calls for 
the development of bioactive coatings for orthopaedic devices. A pertinent step in achieving this goal 
is implementation of a suitable coating technique. 
Recently, EPD has gained considerable attention in biomedical applications owing to the 
simplicity of its application and ability to produce controllable uniform coatings on complex-shaped 
substrates at ambient temperatures, without any need to expensive equipment [16]. Despite the 
technological simplicity of the EPD process, many parameters influence the deposition rate and 
quality of the deposited layer. Therefore, in order to obtain a controlled deposition rate and to achieve 
a desirable coating microstructure, the optimization of the processing parameters is necessary. In most 
current EPD-based development of coatings, a trial-and-error procedure is used which is a time-
consuming, costly and an inefficient approach [276]. In order to ease the optimization process by 
limiting the number of experiments, employing statistical methods such as the Taguchi Design of 
Experiment (DOE) approach can be very useful. DOE approaches have only recently started to be 
applied in EPD [291-297]. 
In this chapter, electrophoretic deposition kinetics of chitosan and its pH-related deposition 
has been investigated. This has been followed by studying deposition from Bioglass®-only and finally 
from chitosan/Bioglass® composite suspensions. The effect of different deposition parameters; 
including suspension-related parameters such as pH and also process-related ones such as particle 
concentration, electrical field strength and deposition time; on EPD yield have been considered. 
Taguchi DOE has been utilised to minimise the number of experiments for optimising the deposition 
parameters either from glass-only or composite suspensions. Coating weights, SEM imaging and 
TGA/DSC analyses were applied to compare the different coatings obtained. 
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4.2. Experimental methods 
4.2.1. Materials 
45S5Bioglass® powder used in this study had a particle size in the range 1.3 and 16.5 µm with 
a median particle size of 6.4 µm. 
4.2.2. Chitosan coatings by EPD 
Cathodic electrophoretic deposition was performed using dilute solutions of chitosan (0.1-0.5 
mg/ml or 0.016-0.08 vol.%) in a mixture of deionised water-acetic acid solutions with pH ranging 
from 2.9 to 4.1. Constant voltage EPD was performed at an electric field of 10 V/cm and at 21 ± 1 °C. 
The variation of current density during deposition was monitored. Based on the variation of the 
deposited weight with time, the kinetics of EPD was studied. 
4.2.3. 45S5 Bioglass® coatings by EPD 
For EPD, suspensions with composition of 2, 5, 8, and 10 mg/ml Bioglass® particles in 
deionised water were prepared. The pH of the Bioglass® suspensions was adjusted in the range 3.2-9 
by acetic acid addition. The fresh suspensions were then transferred to the EPD cell. Constant voltage 
electrophoretic deposition was performed at two voltage levels of 10 and 20 V at 24 ± 2 °C. The 
distance between the electrodes in the EPD cell was maintained at 2 cm for all tests. Electrophoretic 
deposition at constant voltage was performed for five different short periods of deposition times (< 
600 s) in order to determine the mean deposition rate and the standard deviation. The cathodes were 
dried overnight and the weight gain per substrate area was determined. 
4.2.4. Composite coatings of chitosan/45S5 Bioglass® by EPD 
Dilute solutions of chitosan (0.5 mg/ml) in 1 vol% acetic acid were prepared. 1 vol% acetic 
acid solutions (pH=3) were used because chitosan is fully soluble below pH 5. Suspensions containing 
0.4, 0.8, 1.2, 1.6 and 2 mg/ml of Bioglass® powder were prepared by dispersing the particles in the 
chitosan solutions. EPD was performed at voltage levels of 10-30 V, for time periods of 200-600 s and 
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at 21 ± 2 °C. The distance between the electrodes was adjusted to 1.5 cm. The cathodic films 
deposited were dried overnight and the weight gain per substrate area was determined. 
4.3. Statistical analysis: Taguchi design of experiment 
As discussed in Chapter 2, numerous parameters are involved in the EPD process. These 
include suspension-related (medium viscosity, pH, dielectric constant and conductivity) and process-
related (particles concentration, electrical field strength and deposition time) factors. Therefore 
studying the influence of all parameters on the deposition rate and product quality is time-consuming, 
costly and inefficient; many trials have to be carried out especially when the relevant parameters are 
inter-related. Hence efforts must be placed on developing effective, analytical methods to optimise the 
EPD process. In the present work, the Taguchi DOE method was employed for the first time to study 
the electrophoretic deposition of Bioglass® particles and Bioglass®/chitosan films from aqueous 
suspensions. The aim is to elucidate the effect of the key EPD parameters on the deposition rate in 
order to determine which control factors are more important in their effect on deposition rate and to 
what extent these are effective in controlling the kinetics of EPD; i.e. it allows determination and 
optimisation of the dominant factors. The general principles of Taguchi DOE was introduced in 
section  3.13. The detailed procedure will be explained in the results section presented in the following 
paragraphs. The analyses were carried out using MINITAB 15 statistical software. 
4.4. Chitosan coatings 
4.4.1. Results 
In this study dilute solutions of chitosan were used because these chitosan dilute solutions are 
likely to exhibit Newtonian flow without sensitivity of the absolute viscosity to pH and ionic 
conductivity [298]. Under these circumstances, the electrophoretic mobility of macromolecules 
depends on their charge unit and the aggregate size and not on viscosity variations. 
Figure  4.1 a shows the deposition yield (deposition weight per area, Y) as a function of time at 
different pH values for the chitosan concentration of 0.08 vol. %. The deposition yield varies linearly 
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with time up to 400 s. A decrease in the deposition yield at higher times was noticed, which is ascribed 
to the shielding effect of the deposited mass [299], therefore experimental results up to 400 s were 
used in this study. The following first-order kinetics equation is thus suggested for the EPD of 
chitosan macromolecules at relatively short times: 
 𝐴𝐴𝑑𝑑
𝐴𝐴𝑡𝑡 = 𝑘𝑘 Equation  4.1 
where k is the deposition rate. The experimental results on the effect of pH on the deposition rate are 
shown in Figure  4.1 b. The results imply that the electric charge and therefore the electrophoretic 
mobility of the macromolecules are influenced by the pH. If the charged molecule is represented by a 
sphere with radius r, the balance between the electrical field and the opposite force against the motion 
yields [300]: 
 𝜇𝜇 = 𝑍𝑍6𝜋𝜋𝑠𝑠𝜂𝜂 Equation  4.2 
where µ is the electrophoretic mobility of the macromolecule, Z is the electric charge, and η the 
viscosity of the liquid. On the other hand, the linear function of the deposition rate with chitosan 
volumetric concentration (φ) as shown in Figure  4.1 c, gives the following equation which is similar to 
the kinetic equation introduced by Zhang et al. [301]; assuming a constant concentration of chitosan 
during EPD: 
 𝑘𝑘 = 𝑓𝑓𝑍𝑍𝑓𝑓𝑓𝑓6𝜋𝜋𝑠𝑠𝜂𝜂 (𝐸𝐸 − ∆𝐸𝐸) Equation  4.3 
where E is the electric field, ΔE the possible electric potential drop across the deposited layer, and ρ 
the film density. One can consider ρ as chitosan polymer density assuming a dense layer of film 
deposits on the electrode. f is a correlation factor that takes into account that not all macromolecules 
brought to the electrode are incorporated in the deposit (f ≤ 1). 
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Experimental results show that the deposition rate varies in the range of 1-5 μg.cm-2.s-1 for 
chitosan in dilute aqueous solutions (Figure  4.1 b and c). For a uniform and dense packing of deposit, 
it is easier to model the deposit thickness growth rather than the deposit weight growth. Considering 
Y(t)=h(t)ρ which relates deposit weight per substrate area at time t to its thickness (t) and density, the 
film thickness growth rate (𝑘𝑘′ ) can be estimated by: 
 𝑘𝑘′ = 𝑘𝑘
𝑓𝑓
 Equation  4.4 
Using Equation  4.4, the film growth rate was estimated to be in the range of 0.02-0.08 µm.s-1 
depending on the pH value and the macromolecules concentration in the solution (considering an 
average chitosan density of 0.6 g.cm-3 [302]). Figure  4.2 shows SEM images of the cross-section of 
films deposited at different growth rates. It can be seen that at relatively low growth rates (≤ 0.05 
µm.s-1), a dense layer is obtained. Therefore, the estimation of film thickness from Equation  4.4 is in 
reasonable agreement with the experiments (Figure  4.2 a and b). The difference between the model 
and experiment becomes significant at high growth rates due to the pore formation in the film during 
deposition (Figure  4.2 c) and the consequent variation of the film density. 
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Figure  4.1 - Effect of pH on (a) deposition yield and (b) deposition rate of chitosan at a constant 
concentration of 0.08 vol%; (c) Effect of chitosan concentration on the deposition rate. 
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Figure  4.2 - SEM micrographs showing cross sections of chitosan coatings deposited at growth 
rates: (a) 0.025 µm.s-1, (b) 0.05 µm.s-1 and (c) 0.08 µm.s-1. The deposition time was 400 s. The 
films are indicated by arrows. 
4.4.2. Discussion 
The deposition mechanism of chitosan macromolecules; explained by Zhitomirsky and co-
workers [303]; was outlined in Chapter 2 (section  2.4.2.2). It is suggested that the protonated amine-
groups of chitosan lose their charge in the high pH region at the cathode surface to form an insoluble 
deposit. In solution, the salt form of chitosan dissociates to poly-cations with a charge density that 
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depends on its molecular weight, degree of deacetylation (DDA) and concentration of negatively 
charged counter-ions [304]. The dissociation degree of chitosan (α) in solution represents the charged 
groups fraction on the polymer chain and it is traditionally determined by conductivity measurements 
[305]. The relationship between the linear charge density parameter (ζ), the dissociation degree and the 
equivalent conductance (ε) can be expressed as (DDA is 0.85 for the chitosan used in this study): 
 𝜁𝜁 = 1.38.𝐷𝐷𝐷𝐷𝐴𝐴.𝛼𝛼 = 1.38 × 0.85.𝛼𝛼 ≅ 1.17 𝜀𝜀
𝜀𝜀0  Equation  4.5 
where ε0 is the limit equivalent conductance, which can be obtained from the variation of conductivity 
versus φ0.5 according to the procedure described by Bobreshova et al. [304]. 
Figure  4.3 shows that the measured conductivity of chitosan solution increases with 
decreasing pH. Firstly, in acidic pH, the free amino groups of chitosan polyelectrolyte are protonated 
and the molecule becomes fully soluble below ~pH 5. Thus more protonated sites are expected at 
lower pH. The high charge density caused by high degree of dissociation, forces the linear chitosan 
chain to extend into a semi-rigid rod conformation [306] and the strong electrostatic field generated by 
charged macromolecule affects the distribution of counter ions. Secondly, lower pH means presence of 
higher concentration of counter ions (acetate ions). The interaction between the two effects discussed 
above, determines the overall conductivity of the solution to increase at lower pH. Upon increasing the 
pH, amino groups are increasingly deprotonated, electrostatic repulsion between monomeric units 
decreases and polymeric chain association occurs due to hydrogen bonding and hydrophobic 
interactions [150]. Wu et al. [307] have stated that the chitosan chain is slightly extended in aqueous 
solution and that even in dilute solutions chitosan still forms a small amount of large sized aggregates. 
So the bulky helical structure traps acetic acid inside the helix, which in turn reduces the net charge 
and leads to lower conductivity. 
The apparent electrophoretic mobility of macromolecules (Fµ) have been estimated from 
deposition rate by Equation  4.3. As Figure  4.3 displays, this parameter increases with an increase in 
the pH of solution. As stated above, deprotonation and deposition of chitosan in aqueous solutions 
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requires cathodic reduction of water, formation of hydroxyl ions and a local increase in pH. Therefore 
the less protonated aggregates at the higher pH are more susceptible to neutralisation by pH variation 
at the cathode surface, resulting in relatively fast deposition of the insoluble chitosan film and hence 
higher apparent mobility is achieved. 
 
Figure  4.3 - Conductivity and apparent electrophoretic mobility (Fµ) of chitosan dilute solutions 
as a function of pH at concentration of 0.08 vol%. 
Reduction of water and production of hydrogen gas at the cathode surface leads to formation 
of hydrogen bubbles at the electrode. Therefore, when the growth rate is relatively low, a dense film is 
formed (Figure  4.2 a and b). However, at high growth rates the hydrogen gas entrapment in the 
growing film causes pore formation (Figure  4.2 c) and deposition of a non-uniform coating.5 
4.5. 45S5 Bioglass® coatings 
4.5.1.  Taguchi design 
In the present work, the effect of processing parameters on the electrophoretic deposition rate 
of Bioglass® coatings from aqueous suspensions was studied using the Taguchi DOE method. In DOE, 
5 Note that results of section  4.4 have been published in reference [148]. 
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the most important stage is the selection of control factors. Based on the Hamaker model [258], the 
deposition weight per unit substrate area is proportional to the concentration of the suspension, 
deposition time, electric field, and electrophoretic mobility of the particles. Therefore, the deposition 
rate; i.e. weight of deposit per unit area of substrate per unit time; should directly be related to the 
Bioglass® powder concentration and applied voltage (for a constant distance between electrodes). On 
the other hand, the electrophoretic mobility of particles is influenced by the zeta potential, which is 
pH-dependent [15]. Hence, the Taguchi’s orthogonal array was used by choosing the three control 
factors (concentration of Bioglass® powder, pH and applied voltage) that could influence the 
deposition rate. Table  4.1 shows the parameters and levels used in this study. 
Table  4.1 - Control factors and levels of variables used in this study 
Symbol Control factor Levels 1 2 3 4 
A Bioglass® concentration (mg/ml) 2 5 8 10 
B pH 3.2 4.1 7 9 
C Voltage (V) 20 10 -- -- 
Two four-level parameters (Bioglass® powder concentration and pH) and one two-level 
parameter (voltage) were positioned as a mixed L16 (4221) orthogonal array design (columns two to 
four of Table  4.2). A total of 16 runs were conducted, using the combination of levels for each control 
factor (A-C) presented in Table  4.2. Each run was repeated at least three times and the average value 
was recorded with standard deviation. 
The results of experiments under design conditions are reported in Table  4.2. In this design 
two responses are considered: 1) mean deposition rate of Bioglass® particles; and 2) its standard 
deviation. The signal-to-noise (S/N) ratio was calculated for these two responses considering that a 
high mean deposition rate with a low standard deviation is desirable.  
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Table  4.2 - Taguchi L16 orthogonal array, experimentally measured values for mean deposition 
rate and standard deviation and their S/N ratios for EPD of Bioglass® coatings (numbers 1-4 
indicate different levels of a factor as assigned in Table  4.1). 
Run 
Control factors levels Mean deposition rate Standard deviation 
A B C Value (mg/m2s) S/N ratio (dB) Value (±mg/m2s) S/N ratio (dB) 
1 1 1 1 0.25 -12.04 0.15 16.48 
2 1 2 1 6.85 16.71 0.02 33.98 
3 1 3 2 2.48 7.89 0.97 0.26 
4 1 4 2 1.84 5.30 0.43 7.33 
5 2 1 1 1.15 1.20 0.20 13.98 
6 2 2 1 12.45 21.90 1.56 -3.86 
7 2 3 2 9.58 19.63 7.36 -17.34 
8 2 4 2 5.08 14.12 1.42 -3.05 
9 3 1 2 2.25 7.04 0.58 4.73 
10 3 2 2 3.07 9.74 0.19 14.42 
11 3 3 1 11.04 20.86 2.97 -9.46 
12 3 4 1 10.89 20.74 2.35 -7.42 
13 4 1 2 1.21 1.66 0.19 14.42 
14 4 2 2 1.44 3.17 0.71 2.98 
15 4 3 1 30.94 29.81 1.30 -2.28 
16 4 4 1 4.18 12.42 1.10 -0.83 
Since the experimental design is orthogonal, it is possible to separate the effect of each control 
factor at different levels by averaging responses or their S/N ratios at each level. For example, the 
mean S/N ratio for deposition rate at levels 1, 2 and 3 of control factor A (Bioglass® concentration) 
can be calculated by averaging the S/N ratios for the runs 1-4, 5-8 and 9-12, respectively. S/N ratio 
mean results for the deposition rate and standard deviation are summarized in Table  4.3 (S/N ratio 
response table). The maximum-minimum value for the pH has the highest value; hence, pH is the most 
significant parameter affecting the deposition rate whereas the applied electric field has the least 
effect. 
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Table  4.3 - S/N ratio response (dB) table for the Bioglass® deposition rate and its standard 
deviation. 
Parameter Symbol Level 1 Level 2 Level 3 Level 4 Maximum-minimum 
Deposition 
rate 
A 4.46 14.22 14.60 11.76 10.13 
B -0.54 12.88 19.55 13.14 20.08 
C 13.95 8.57 -- -- 5.38 
Standard 
deviation 
A 14.51 -2.57 0.57 3.57 17.08 
B 12.40 11.88 -7.20 -0.99 19.60 
C 5.07 2.97 -- -- 2.10 
Based on the average mean deposition rates and their mean S/N ratios at each level, the effect 
of control factors on the deposition rate were plotted (Figure  4.4). The aim of “analysis of 
experiments” is to find out a combination of factors which provides the maximum deposition rate with 
minimum variance around the desired value. It is evident that the deposition rate increases with 
increasing the Bioglass® concentration; hence, the optimum deposition condition at a given Bioglass® 
concentration should be obtained at B3 (pH=7) and C2 (electric field of 5 V/cm). Nevertheless, the 
analysis of results based on mean S/N ratios for standard deviations (Figure  4.5) reveals a low S/N 
ratio at pH=7, indicating that achieving a uniform and constant deposition rate over time is more 
difficult at pH=7 compared to the lower pH values. 
 
Figure  4.4 - Effect of control factors on (a) mean Bioglass® deposition rate and its (b) S/N ratio. 
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Figure  4.5 - Effect of control factors on S/N ratio of standard deviation. 
In order to find out the statistical significance of different factors on the deposition rate, 
multivariate analysis of variance (MANOVA) was performed, which is a procedure for testing the 
equality of vectors of means from multiple responses. Table  4.4 shows the results of MANOVA. The 
p-values reported in the last column of the table indicate that applied voltage is highly significant (at 
significance level α = 0.1) whereas the other parameters (particularly the Bioglass® concentration and 
pH) seem to be not significant which might be due to their inter-relation; a matter which can induce 
uncertain errors in the analysis. Figure  4.6 shows the interaction graphs for the control factors. Non-
parallel lines indicate interaction between the factors. The results determine that the Bioglass® 
concentration-pH interaction is highly significant. Since the control factors are highly correlated, the 
relationship between the response (mean deposition rate) and the control factors could be evaluated by 
partial least square method. The analysis of variance (ANOVA) for the response is reported in Table 
 4.5. The low p-value (<α = 0.05) confirms that the factors are highly significant and inter-related. A 
complete study including the interaction effects among factors is an interesting avenue for future 
research, but it was considered to be beyond the scope of the present work. 
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Table  4.4 - MANOVA analysis for the effect of control factors on the deposition rate 
Source DF1 Seq SS2 Adj SS3 Adj MS4 F5 p6 
Bioglass® concentration (mg/ml) 3 89.41 89.41 29.80 0.76 0.548 
pH 3 313.47 313.47 104.49 2.66 0.120 
Voltage (V) 1 161.29 161.29 161.29 4.10 0.077 
Error 8 314.38 314.38 39.30   
Total 15 878.55     
1 DF: Degree of Freedom 
2 Seq SS: Sequential Sums of Squares 
3 Adj SS: Adjusted Sums of Squares 
4 Adj MS: Adjusted Mean Sums of Squares 
5 F: F-test statistic 
6 P: p-value (probability value) 
 































Interaction plot for mean deposition rate (mg/m^2.s)
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Table  4.5 - Regression analysis of deposition rate versus control factors 
Source DF SS1 MS2 F p 
Regression 1 320.691 320.691 8.05 0.013 
Residual error 14 557.962 39.847   
Total 15 878.553    
1 SS: Sums of Squares 
2 MS: Mean Sums of Squares 
The final step in the design of experiment approach is to conduct confirmation experiments for 
the optimal parameters determined. As explained above, the optimum design was determined to be A4 
(10 mg/ml Bioglass®), B3 (pH=7) and C2 (10 V). Table  4.6 shows the comparison of the predicated 
deposition rate and standard deviation (using Equation  3.14) with the experimental results using the 
optimal control factors. A convincing agreement between the predicted and experimental rate was 
obtained.  
Table  4.6 - Results of the confirmation experiments for the deposition rate and standard 
deviation 
 Level 
Deposition rate Standard deviation 
Value 
(mg/m2s) S/N ratio (dB) 
Value 
(±mg/m2s) S/N ratio (dB) 
Experiment A4 B3 C2 6.62 16.42 2.78 -8.88 
Predication A4 B3 C2 7.37 17.36 2.72 -8.70 
4.5.2. Results 
Figure  4.7 shows the variation of zeta potential with pH for the examined suspensions. The 
isoelectric point of Bioglass® particles is about pH=11.5. Therefore, as we approach the isoelectric 
point, it is expected that the stability of particles in the suspension would decrease, making it more 
difficult to achieve a stable deposition rate with increasing time. It should be highlighted that the zeta 
potential measurements below about pH = 5 were not reliable because of increased dissolution of 
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Bioglass® at lower pH values. Therefore the zeta potential values should be considered along with 
suspension conductivity for interpretation of particles deposition behaviour. 
 
Figure  4.7 - Zeta potential of Bioglass® particles in aqueous suspension as a function of pH. 
As an example, Figure  4.8 shows the variation in the current density of 5 mg/ml Bioglass® 
suspensions versus deposition time at different pH values. Because of the partial solubility of 
Bioglass® in aqueous suspensions [308], a higher current density was measured at lower pH values. 
The increase in the conductivity of the suspensions during EPD also indicates the progressive 
dissolution of Bioglass®. 
 
Figure  4.8 - Current density of 5 mg/ml Bioglass® suspensions as a function of deposition time at 
different pH values. 
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The conductivity of suspensions also depends on both pH and concentration of particles. As 
Figure  4.9 shows the effect of pH and Bioglass® concentration on the conductivity of the suspensions, 
it is confirmed that conductivity increases with higher particle concentration and lower conductivity 
values are achieved at high pH values. 
 
Figure  4.9 - Effect of pH and particles concentration on the conductivity of Bioglass® 
suspensions. 
SEM images of the Bioglass® films deposited at different pH values are shown in Figure  4.10 
as an example for a 10 mg/ml Bioglass® suspension. The effect of pH on the quality of the deposition 
layer is visible at the SEM magnification selected. A more uniform deposition of glass particles is 
achieved at pH=7. The microstructure and cross section image of the optimum coating is also 
displayed in Figure  4.11. 
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Figure  4.10 - SEM micrographs showing the top surface of Bioglass® deposits at concentration of 
10 (mg/ml), voltage 20 (V) and pH values of (a) 3.2, (b) 4.1, (c) 7, and (d) 9. 
 
Figure  4.11 - Microstructure of the top surface of (a) optimal Bioglass® coating and (b) its cross 
section. 
4.5.3. Discussion 
The experimental results showed that the pH of the suspension has a profound effect on the 
deposition rate. In aqueous media, the pH of the suspension is the most important factor affecting the 
particles’ zeta potential. Zeta potential measurement for the present Bioglass® suspension is shown in 
Figure  4.7. The values of zeta potential at the working pH reveal that the particles have positive charge 
in the suspension; hence, they move toward the cathode during EPD (cathodic deposition). By 
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increasing the pH, the surface ionization is suppressed and the thickness of the electrical double layer 
decreases [309]; hence, the zeta potential decreases. However; in addition to the zeta potential; the 
electrical conductivity (or ionic strength) of suspension also influences the electrophoretic mobility. At 
lower pH, a more extensive dissolution of Bioglass® occurs, leading to a higher ionic concentration of 
suspension. High ionic concentration results in surface charge screening of suspended particles, 
formation of large agglomerates and current being predominantly carried by large amount of free ions; 
all of which leads to a lower electrophoretic mobility of particles [310]. Therefore in this study, it can 
be concluded that the interactions between the parameters of glass concentration and pH and the effect 
of this interaction on the solubility and mobility of the particles, determines the optimum deposition 
yield to be at pH=7. 
DOE analyses also reveals that a high deposition rate is obtained at higher voltages; however, 
it is suggested that EPD of Bioglass® suspensions should be performed at a low electric field, e.g. 5 
V/cm. Although the confirmation test showed that applying a low electric field reduces the deposition 
rate remarkably (Table  4.6), a more uniform deposition rate can be obtained (least variability with a 
low standard deviation). This result may be due to the fact that at relatively high electric fields, Joule 
heating of the suspension during EPD contributes to the deposition instability and leads to changes in 
electrical conductivity. In addition, water dissociation can occur in high electric fields which also 
influences the deposition process. Hence high electrical fields should ideally be avoided or minimized 
by employing the lowest possible voltage.6 
4.6. Composite chitosan/45S5 Bioglass® coatings 
4.6.1. Taguchi design 
For EPD of composite bioactive coatings, the control factors were selected as the Bioglass® 
concentration, applied voltage (at a constant distance between electrodes), and deposition time. The 
levels of each factor are reported in Table  4.7. One six-level parameter (Bioglass® concentration) and 
6 Note that results of section  4.5 have been published in reference [106]. 
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two three-level parameters (voltage and time) were utilised. An orthogonal Taguchi array of L18 type 
was constructed by applying these three control factors. Columns two to four of Table  4.8 shows the 
details of L18 (6132) orthogonal array design. Each run was repeated at least three times and the 
average value was recorded with standard deviation. 
The results of experiments to determine the average deposition yield of chitosan/Bioglass® 
composite films under the various conditions along with their standard deviations are reported in Table 
 4.8. The two responses considered are: 1) mean deposition yield; and 2) its standard deviation. As 
before, the S/N ratio was added to the table considering that a high mean deposition yield with a low 
standard deviation is desirable. 
Table  4.7 - Control factors and levels of variables used in this study 
Symbol Control factor 
Levels 
1 2 3 4 5 6 
A Biogalss® concentration (mg/ml) 0 0.4 0.8 1.2 1.6 2 
B Voltage (V) 10 20 30 -- -- -- 
C Time (s) 200 400 600 -- -- -- 
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Table  4.8 - Taguchi L18 orthogonal array, experimentally measured values of mean deposition 
yield, standard deviation and their S/N ratios for EPD of chitosan/Bioglass® composite coatings. 
Run 
Control factors 
levels Mean deposition yield Standard deviation 
A B C Value (mg/cm2) S/N ratio (dB) 
Value 
(±mg/cm2) S/N ratio (dB) 
1 1 1 1 0.50 -5.95 0.04 28.94 
2 1 2 2 1.52 3.65 0.33 9.60 
3 1 3 3 1.97 5.89 0.25 12.17 
4 2 1 1 0.08 -22.05 0.01 43.46 
5 2 2 2 0.57 -4.85 0.13 18.06 
6 2 3 3 1.26 2.01 0.01 39.90 
7 3 1 2 0.35 -9.19 0.12 18.38 
8 3 2 3 1.02 0.19 0.13 17.67 
9 3 3 1 1.26 2.037 0.20 14.08 
10 4 1 3 0.71 -3.00 0.12 18.27 
11 4 2 1 0.80 -1.94 0.05 26.69 
12 4 3 2 2.05 6.24 0.43 7.36 
13 5 1 2 0.80 -1.96 0.02 35.81 
14 5 2 3 2.12 6.51 0.21 13.71 
15 5 3 1 2.29 7.20 0.06 23.76 
16 6 1 3 1.25 1.93 0.30 10.45 
17 6 2 1 1.68 4.49 0.18 14.70 
18 6 3 2 3.66 11.28 0.36 8.92 
By separating out the effect of each control factor and averaging S/N ratios at each level, S/N 
ratio response table for deposition yield and standard deviation was prepared (Table  4.9). 
Table  4.9 - S/N (dB) response table for the composite coating deposition yield and its standard 
deviation. 
Parameter Symbol Level 1 Level 2 Level 3 Level 4 Level 5 Level 6 Maximum-minimum 
Deposition 
yield 
A 1.19 -8.29 -2.32 0.43 3.92 5.90 14.20 
B -6.70 1.34 5.78 -- --  12.48 
C -2.70 0.86 2.25 -- --  4.96 
Standard 
deviation 
A 16.90 33.81 16.71 17.44 24.43 11.36 22.45 
B 25.89 16.74 17.70 -- -- -- 9.15 
C 25.27 16.36 18.70 -- -- -- 8.92 
Results were analysed to find out a combination of factors which provides the maximum 
deposition yield with minimum variance around the desired value. Figure  4.12 shows the effect of 
control factors on the deposition yield and standard deviation. One would notice that the influence of 
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Bioglass® concentration and voltage is very significant while the effect of deposition time is less 
important. This fact can also be concluded from the maximum-minimum values presented in Table 
 4.9. The variation of standard deviation (Figure  4.12 c and d) also determines that the variance of data 
is very sensitive to the bioactive glass concentration. 
 
Figure  4.12 - Effect of control factors on (a) mean deposition yield; (b) mean S/N ratio for 
deposition yield; (c) standard deviation; (d) mean S/N ratio for standard deviation. 
To find out statistical significance of different factors on the deposition yield MANOVA was 
performed (Table  4.10). The probability values (p) indicate that Bioglass® concentration and applied 
voltage are highly significant (p<0.1) at α=0.1, whereas the deposition time seems to be not significant 
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which might be due to the inter-relative nature of these EPD factors; a matter which may induce 
uncertain errors in the analysis. 
Table  4.10 - MANOVA analysis for the effect of control factors on the deposition yield. 
Source DF Seq SS Adj SS Adj MS F P 
BG concentration (mg/ml) 5 4.86 4.86 0.97 7.19 0.008 
Voltage (V) 2 6.49 6.49 3.25 24.01 0.000 
Time (s) 2 0.49 0.49 0.24 1.81 0.225 
Residual error 8 1.08 1.08 0.13   
Total 17 12.92     
Figure  4.13 shows the interaction graphs for the control factors. The results determine that the 
interaction between Bioglass® concentration and time is significant. Since the control factors are 
highly correlated, the relationship between the response (deposition yield) and the control factors 
could be evaluated by the partial least square method. The ANOVA for the response is reported in 
Table  4.11. The low probability value (p < 0.05) confirms that the factors are highly significant and 
inter-related. A complete study including the interaction effects among factors is an interesting avenue 
for future research, but it was considered to be beyond the scope of the present work. 
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Figure  4.13 - Interaction plot between the EPD control factors for mean deposition yield of 
chitosan/Bioglass® composite films. 
Table  4.11 - Regression analysis of the mean deposition yield versus control factors (R2=0.73) 
Source DF SS MS F P 
Regression 1 9.41 9.41 42.88 0.000 
Residual Error 16 3.51 0.22   
Total 17 12.92    
In the light of the results presented so far, one can predict the appropriate EPD conditions 
based on the mean of the mean values of deposition yield and standard deviation shown in Figure 
 4.12. The analysis of the results shows that a high deposition yield with a low standard deviation may 
be obtained at levels of A5 (1.6 mg/ml Bioglass®), B2 (20 V) and C3 (600 s). To evaluate the validity 
of the analysis, a statistical analysis based on the predicted S/N ratio (using Equation  3.14) and a set of 
experiments were conducted. The experimental results at A5 B2 C3 condition were compared with the 
predicated values in Table  4.12. A convincing agreement between the predicted and experimental rate 


































Interaction plot for mean deposition yield (mg/cm^2)
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of standard deviations for deposition yield at levels of B2 and C3 (Figure  4.12 d) which can cause 
error in estimation of predicted values. 
Table  4.12 - Results of the confirmation experiment to achieve a high deposition yield for EPD of 
chitosan/Bioglass® composite coatings 
 Level 
Deposition yield  Standard Deviation 
Value (mg/cm2) S/N ratio (dB) Value (±mg/cm2) S/N ratio (dB) 
Experiment A5 B2 C3 2.12 6.51 0.21 13.71 
Prediction A5 B2 C3 1.75 7.23 0.11 19.64 
4.6.2. Results 
The microstructure of the optimum deposited composite film is shown in Figure  4.14. 
Observation at low magnifications (Figure  4.14 a) indicates that the bioactive glass particles are 
embedded in the chitosan matrix but their distribution is not uniform. Specifically, islands of 
Bioglass® particles, showing massive deposition of the particles during EPD, are noticeable. 
Evaluation at higher magnification (Figure  4.14 c) and a detached part of the film (Figure  4.14 e) 
reveals that in the coating the bioactive glass particles are covered by the chitosan. The coating 
thickness varies in the range 5-15 µm, revealing non-uniform deposition. It appears that the high 
deposition rate led to non-uniform co-deposition of the polymer/bioactive glass system. This is a 
criterion which has not been considered in the DOE approach explained above. As it will be discussed 
in the next section, the electrophoretic deposition mechanism of chitosan is different than that of the 
bioactive glass particles that eventually leads to different deposition rates during co-electrophoretic 
deposition. 
To achieve a uniform Bioglass® deposition, therefore it is suggested to use lower Bioglass® 
concentration in order to avoid massive deposition of the bioactive glass particles. Returning to Figure 
 4.12 reveals that, EPD at A2 B2 C3 condition yields relatively low deposition rate but with high 
confidence (low standard deviation). A confirmation experiment was thus performed using A2 B2 C3 
condition. The validity of the predication can be noticed from the results presented in Table  4.13. 
115 
Chapter 4: EPD of Orthopaedic Coatings 
Figure  4.14 b and d show the microstructure of film prepared under the new condition at different 
magnifications. As it can be seen, Bioglass® particles are uniformly distributed through the chitosan 
matrix. Figure  4.14 f shows the uniformity of the coating thickness (~10 µm). These results confirm 
that a uniform distribution of the bioactive glass particles in the chitosan matrix can be obtained at the 
new test condition. The difference between prediction and experiment in Table  4.13 can be due to 
lowest mean S/N ratio for deposition yield at level A2 (Figure  4.12 b) which can cause error in 
estimation of predicted values. Similar composite coating microstructure was obtained on titanium 
substrate to display the capability of EPD in coating different conductive substrates. Additionally, the 
increase in deposition yield of the optimised composite coating with deposition time was investigated. 
These results have been presented in the Appendices A.1 and A.2. 
Table  4.13 - Results of the confirmation experiment to achieve a high deposition yield along with 
uniform microstructure during EPD of chitosan/Bioglass® composite coatings. 
 Level 
Deposition yield  Standard Deviation 
Value (mg/cm2) S/N ratio (dB) Value (±mg/cm2) S/N ratio (dB) 
Experiment A2 B2 C3 1.07 0.62 0.0625 24.12 
Prediction A2 B2 C3 0.65 -4.97 0.0616 29.03 
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Figure  4.14 - SEM images showing the microstructure of chitosan/Bioglass® composite film 
prepared at (a, c, e) Bioglass® concentration of 1.6 mg/ml, voltage of 20 V and time of 600 (the 
images display non-uniform distribution of Bioglass® particles in the chitosan matrix); and 
prepared at (b, d, f) Bioglass® concentration of 0.4 mg/ml, voltage of 20 V and time of 600 (the 
images display uniform distribution of Bioglass® particles in the chitosan matrix). Images at low 
(a, b) and high (c, d) magnifications are displayed. The cross sections of a detached part of the 
films from the substrate (e, f) are presented. 
Figure  4.15 shows simultaneous thermal analysis (STA) of the two coatings mentioned above. 
Thermogravimetric analysis (TGA) displays different stages of weight loss which correspond to 
evaporation of moisture at low temperatures (<100 °C), and two-stage burning out of chitosan at 
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temperature ranges of 220-350 °C and 360-500 °C. The exothermic peaks of chitosan burning out 
occur at around 250 °C, 300 °C and 470 °C [17], which are more significant in the DSC curve of 
Figure  4.15 c due to higher chitosan content of these coatings. The amount of bioactive glass particles 
embedded in the composite films was determined to be 61.2 wt% and 27.2 wt% for suspensions with 
1.6 mg/ml and 0.4 mg/ml Bioglass®, respectively. It is worth noting that composite films containing a 
high amount of Bioglass® particles can provide higher levels of bioactivity. Films with more chitosan 
content are expected to have better mechanical integrity and are interesting for applications where 
incorporation and controlled release of other biomolecules such as drugs and growth factors are 
preferable. 
 
Figure  4.15 - TGA (a,b) and DSC (c, d) curves for chitosan/Bioglass® composite films prepared 
from suspensions containing 0.4 mg/ml (a, c) and 1.6 mg/ml (b,d) Bioglass® particles. A constant 
voltage of 20 V and deposition time of 600 s was used. The solid and dashed lines show TGA and 
DSC curves, respectively. 
Experimental measurements confirmed that the dissolution of Bioglass® in the medium alters 
the pH and ionic strength of the aqueous solution. The slight increase of the suspension pH with the 
glass concentration is shown in Figure  4.16. The variation of current density versus time for 0.5 mg/ml 
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chitosan suspensions containing various amounts of Bioglass® particles is also shown in Figure  4.17 a. 
Although the current density shows a decreasing trend for chitosan medium due to formation of an 
electrically insulating layer, a small increase in the current density with time is visible in the presence 
of bioactive glass particles. This effect is more pronounced at higher Bioglass® concentrations. The 
variation of the suspension conductivity at the start of EPD with the Bioglass® concentration is shown 
in Figure  4.17 b. Meanwhile, ion-release studies (which will be presented in Chapter 5) have shown 
that the change in the pH and ionic strength predominantly takes place during the suspension 
preparation stage rather than during electrophoretic deposition. 
 
Figure  4.16 - Effect of the concentration of bioactive glass particles on the pH of chitosan/ 
Bioglass® composite suspensions. 
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Figure  4.17 - Effect of Biogalss® concentration on (a) the current density during deposition at 
constant voltage of 20 V and (b) conductivity of the composite suspensions. 
It was also observed that in composite suspensions, both the measured electrophoretic 
mobility (μ) (Table  4.14) and the estimated apparent electrophoretic mobility (Fμ) of the suspensions 
(Figure  4.18); in the range of pH used in this work (pH 3 to 4); only vary slightly with the Bioglass® 
concentration. Here, the apparent electrophoretic mobility was determined as in section  4.4.2. 
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Table  4.14 - Measured electrophoretic mobility values of the chitosan/Bioglass® suspensions 
versus the concentration of Bioglass® particles. 
Bioglass® concentration 
(mg/ml) Mean mobility ± error (10
-3 cm2/V.s) 
0 0.63 ± 0.01 
0.4 0.46 ± 0.04 
1.6 0.39 ± 0.03 
2 0.38 ± 0.01 
 
 
Figure  4.18 - Estimated apparent electrophoretic mobility of chitosan/Biogalss® suspension (Fμ) 
versus the concentration of bioactive glass particles in 0.5 (mg/ml) chitosan solution. Each data 
point is an average apparent electrophoretic mobility obtained at different voltages (10-30 V) at 
a constant time of 200 s. 
4.6.3. Discussion 
Cathodic EPD of chitosan/ Bioglass® particles has successfully been performed. It was shown 
that the deposition yield, the film composition, and microstructural homogeneity are altered by the 
primary control factors (particle concentration, applied voltage and time). To describe these 
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observations, the co-deposition mechanism of chitosan and bioactive glass particles should be 
explored. 
Chitosan macromolecules are protonated in the aqueous solution to form polycations [121]. 
During the EPD process, electrolysis of water occurs that increases the local pH at the cathode. 
Consequently, the protonated amine-groups of chitosan lose their charge in the high pH region to form 
an insoluble deposit. As described in section  4.4.2, the electrophoretic mobility of chitosan depends on 
the pH and conductivity of the suspension.  
On the other hand, considering the non-bridging oxygen bonds in the structure of bioactive 
glass particles, several surface reactions can occur in the aqueous medium. Due to presence of cations 
(R) such as Na+, a negative surface charge can develop on the particles surface according to the 
following reaction [311]: 
𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑅𝑅(𝑔𝑔.𝑠𝑠) ⇌ 𝑆𝑆𝑖𝑖 − 𝑂𝑂(𝑔𝑔.𝑠𝑠)− + 𝑅𝑅(𝑠𝑠 .𝑠𝑠)+         (i) 
in which (g.s) and (a.s) denote glass surface and aqueous solution, respectively. On the other hand, the 
proton ions in the solution move into the glass, forming a positively charged surface with the cationic 
groups: 
𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑅𝑅(𝑔𝑔.𝑠𝑠) + 𝑂𝑂(𝑠𝑠 .𝑠𝑠)+ ⇌ 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑂𝑂𝑅𝑅(𝑔𝑔.𝑠𝑠)+         (ii) 
The surface cationic and anionic groups can neutralise each other according to: 
𝑆𝑆𝑖𝑖 − 𝑂𝑂(𝑔𝑔.𝑠𝑠)− + 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑂𝑂𝑅𝑅(𝑔𝑔.𝑠𝑠)+ ⇌ 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑅𝑅(𝑔𝑔.𝑠𝑠) + 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑂𝑂(𝑔𝑔.𝑠𝑠)     (iii) 
The above surface reactions imply that for the suspension under study in this research, the pH 
determines the concentration of cationic and anionic surface groups and hence the surface charge. At 
pH below the isoelectric point of Bioglass® (pH = 11.5), the concentration of surface Si-OHR+ is more 
than Si-O- and positive surface charge is obtained (Figure  4.7). These particles are moved toward the 
cathode by the electric field and form a deposit by coagulation [261]. 
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When a mixture of chitosan and Bioglass® particles in the aqueous solution in prepared, 
according to the above descriptions, the composite suspension has positively-charged species. This has 
been confirmed by electrophoretic mobility measurements (Table  4.14). The co-deposition mechanism 
is governed by the interaction between the charged chitosan macromolecules and the solid charged 
Bioglass® particles.  
The analysis of results demonstrated that although pH, conductivity and change in current 
density during EPD, alter with concentration of Bioglass® particles in the composite suspension, the 
electrophoretic mobility does not change significantly. Therefore, the co-deposition rate of chitosan 
and the bioactive glass particles are mainly controlled by the concentration of Bioglass® particles 
itself; because the effect of other suspension-related parameters (such as conductivity and 
electrophoretic mobility) were shown to be marginal.  
On the other hand, the deposition rate of chitosan should be highly sensitive to pH and ionic-
strength, as described before (section  4.4.2). Partial dissolution of the bioactive glass particles in the 
acidic suspension increases the pH and conductivity of the suspension, which results in a lower 
electrophoretic mobility and deposition rate of the polymer dependent on the bioactive glass 
concentration. This implies that at low Bioglass® concentrations, the co-deposition of 
polymer/bioactive glass system occurs and hence a uniform distribution of the BG particles through 
the polymeric matrix is obtained. However, at high concentrations of Bioglass® (and at a constant 
chitosan level), massive deposition of the glass particles is favourable due to: 1) high conductivity 
values of the suspension which restricts chitosan deposition; 2) lower chitosan concentration as 
compared to that of Bioglass® in the suspension; and 3) increase in deposition rate of Bioglass® due to 
higher concentration according to Hamaker equation [258] (note SEM images at Figure  4.14). Under 
this latter condition, it becomes more difficult to deposit uniform films with high confidence and low 
123 
Chapter 4: EPD of Orthopaedic Coatings 
standard deviation with regard to the deposition yield (see Figure  4.12). A suitable deposition is thus 
achieved when almost equal concentrations of chitosan and Bioglass® particles are utilised.7 
4.7. Summary 
In this chapter, eletrophoretic deposition from three types of suspensions were investigated: 
chitosan polyelectrolyte solution, Bioglass® particles suspension and composite suspension of 
chitosan/Bioglass®. 
The kinetics of EPD of chitosan from aqueous solutions at dilute concentrations showed that 
the electrophoretic deposition rate depends on the linear charge density of the macromolecules, the 
size of aggregates, and the polymer concentration and varies in the range of 1-5 μg.cm-2.s-1. The 
mobility of the macromolecules was found to be influenced by the pH (concentration of acetic acid). 
Increasing pH resulted in a decrease in the degree of ionization and in lower net charge density. The 
film growth rate was estimated to be in the range 0.02-0.08 µm.s-1. At growth rates higher than 0.05 
µm.s-1, a porous film was obtained due to the hydrogen-gas entrapment.  
EPD of Bioglass® suspensions to fabricate bioactive coatings on metallic implants was also 
investigated. The effect of processing parameters, including the suspension concentration, pH and 
electric field on the deposition rate was studied using a Taguchi DOE approach. It was shown that the 
control factors are inter-related and the pH of the suspension has a critical role on the deposition rate 
and the stability of the EPD process. A high deposition rate was attained at pH=7. A low electric field 
is more suitable to obtain a stable EPD process. The predication of Taguchi design approach was in 
good quantitative agreement with the experimental results.  
Finally, EPD was successfully applied to prepare bioactive composite coatings of 
chitosan/45S5 Bioglass® on 316SS substrates. To optimize the EPD process and to study the effect of 
control factors, Taguchi DOE approach was considered. It was elucidated that the protonated polymer 
macromolecules and the charged bioactive glass particles in the suspension have different 
7 Note that results of section  4.6 have been published in reference [190]. 
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electrophoretic deposition mechanisms, which lead to dissimilar deposition rates during co-deposition. 
It was shown that partial dissolution of the bioactive glass particles in the acidic suspension increases 
the pH and conductivity of the suspension, which results in a lower deposition rate of the polymer 
dependent on the bioactive glass concentration. On the other hand, deposition rate of Bioglass® 
particles increases with increasing the particles concentration according to the Hamaker equation. 
Estimation of apparent electrophoretic mobility of the composite particles confirmed these ionic 
strength-controlled and concentration-controlled deposition behaviours at different Bioglass® 
concentrations. An optimum condition for controlled co-deposition of chitosan/ Bioglass® suspensions 
was obtained at almost equal concentrations of chitosan and Bioglass® particles.  
It is pertinent to point out that the investigations in this chapter present initial efforts for 
obtaining a microstructurally uniform composite orthopaedic coating based on suitable biomaterials 
such as chitosan and Bioglass®. For an ultimate optimisation of the films, other characteristics, such as 
in-vitro bioactivity and cellular response of these composite coatings should also be considered; which 
are the focus of the next chapters. 
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Chapter 5: Characterisation of Chitosan/Bioglass® Coatings 
5.1. Introduction 
Bioactivity of orthopaedic coatings is of significant importance as it indicates the level of 
hydroxyapatite formation when the coating is in contact with biological environment and hence it is a 
pertinent step in osseointegration. In this regard, the rate of bioactive glass dissolution and the 
resultant change in the ionic concentration of the surrounding physiological fluid becomes crucial. 
Based on the findings presented in Chapter 4, in this chapter composite coatings were developed at 
different electrophoretic deposition conditions. The amount of incorporated Bioglass® particles was 
determined and the microstructural and surface properties of the coatings before and after immersion 
in SBF were evaluated. Ion release studies have been performed to compare the dissolution behaviour 
of different composite coatings. More importantly, the significance of ionic dissolution of glass 
particles during the preparation of EPD suspensions and its influence on coatings bioactivity was 
highlighted. Finally, the variation of the mechanical properties of a series of EPD coatings with 
respect to the Bioglass® content was elucidated. 
5.2. Experimental methods 
5.2.1. Materials 
The particle size of 45S5 Bioglass® powder used in this section was in the range 1.6 and 26.7 
µm with a median particle size of 9.8 µm. 
5.2.2. Electrophoretic deposition 
Dilute solutions of chitosan (0.5 mg/ml) in 1 vol% acetic acid were prepared and Bioglass® 
particles were dispersed in it to make composite suspensions. AISI 316L stainless steel foils were 
utilised as deposition substrate (cathode). The distance between the electrodes was kept constant at 1.5 
cm and EPD was performed at a temperature of 21 ± 2 °C. To compare different EPD coatings, 
chitosan and chitosan/Bioglass® composite coatings were prepared. The EPD experimental conditions 
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for each coating used in this chapter are outlined in Table  5.1. Plain chitosan coatings (CS) were 
prepared to assess the effect of Bioglass® addition on properties of the composite coatings. CS/0.4BG 
and CS/1.6BG are the optimised composite coatings discussed in Chapter 4 (section  4.6), and CS/5BG 
and CS/8BG are composite coatings prepared at higher concentrations of Bioglass® particles in order 
to study the effect of increased particles loading on coating properties. For these latter coatings, the 
EPD conditions (voltage and time) had to be varied via trial and error to achieve a more uniform 
deposition. 
Table  5.1 - EPD parameters for deposition of coatings from 0.5 mg/ml chitosan solutions. 
Coating type Coating name Bioglass
® 
(mg/ml) Voltage (V) Time (s) 
Chitosan  CS 0 10 800 
Chitosan/Bioglass®  CS/0.4BG 0.4 20 600 
" CS/1.6BG 1.6 20 600 
" CS/5BG 5 10 400 
" CS/8BG 8 7 400 
The wt% of Bioglass® in each composite was determined by TGA and microstructural features 
as well as surface roughness were examined with SEM/EDX and Zygo® WLI, respectively. 
5.2.3. Ionic dissolution study and SBF testing 
5.2.3.1. Bioglass® powder studies 
The release of ions from Bioglass® particles into the suspension during the EPD process was 
evaluated. For this purpose suspensions of CS/1.6BG and CS/5BG (a suspension of 1.6 or 5 mg/ml 
Bioglass® in 0.5 mg/ml chitosan solution (1 vol% acetic acid))) were prepared by 10 min respective 
intervals of stirring, sonication and stirring (30 min is a typical time scale for performing EPD in this 
work). At specific time intervals during this procedure (0.5, 1, 2, 3, 4, 5, 7, 10, 15, 20, 25, 30 min), 10 
ml of suspension was filtered through 0.2 µm syringe filter and the release of ions from bioactive glass 
was determined by ICP-OES. 
Additionally, to evaluate the effect of this suspension preparation procedure on the bioactivity 
of Bioglass® particles, the glass particles of CS/1.6BG suspension used in the experiment explained 
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above, were collected and were dried in a desiccator. This batch will be referred to as “filtered” 
Bioglass® particles. 300 mg of the as-received and filtered Bioglass® particles were immersed in 150 
ml of SBF solution pre-heated to 37 °C and were incubated in an orbital shaker (120 rpm and 37 °C) 
for 2, 6, 12 and 30 h [312]. At each time point the pH of the solution was measured, samples were 
taken for dissolution study via ICP-OES test, the powder was filtered through medium porosity filter 
paper (5 µm particle retention, VWR International), rinsed with acetone and left to dry for further 
analyses. 
5.2.3.2. EPD coatings studies 
The bioactivity of different EPD coatings prepared was evaluated via SBF testing. 
Furthermore, to compare the degradation and ionic dissolution from different coatings, samples of 
CS/0.4BG, CS/1.6BG and CS/5BG (10 mm × 10 mm × 0.2 mm) were immersed in 10 ml SBF 
solution at 37 ºC. At specific time points (3h, 6 h, 12 h, 1, 2, 3 and 5 days), aliquots of 2 ml were 
removed from samples and refreshed by fresh SBF. The ionic concentration of the sampled solutions 
was measured by ICP-OES. The change in weight of the coatings at the end of study was also 
recorded. Each sample was tested in triplicate. 
5.3. Microstructural characterisation 
SEM images of different EPD coatings are presented in Figure  5.1. CS film displays a smooth 
and uniform microstructure (Figure  5.1 a and b; cracks are due to damage by the accelerated 
electrons). In the composite coatings obtained from suspensions with lower glass concentrations 
(Figure  5.1 c and e which correspond to CS/0.4BG and Cs/1.6BG, respectively) the microstructures 
feature a continuous matrix of chitosan polymer with glass particles embedded in it. As the amount of 
glass in the suspension increases (Figure  5.1 g and i which correspond to CS/5BG and CS/8BG, 
respectively), the chitosan matrix continuity reduces and a larger amount of glass is deposited, hence 
cracks develop in the coatings. Also due to water hydrolysis and formation of hydrogen bubbles at the 
surface of the cathode, pores are induced in the coatings; a phenomenon which is more severe in the 
case of CS/8BG. 
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Figure  5.1 - SEM images of (a,b) CS, (c, d) CS/0.4BG, (e, f) CS/1.6 BG, (g, h) CS/5BG and (i,j) 
CS/8BG composite coatings at (a,c,e,g, i) lower and (b, d, f, h, j) higher magnifications. The 
pores in the coatings microstructure are indicated by white arrows. 
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The WLI results obtained from coating surfaces clearly display the variation in surface 
topography in different coatings. (Figure  5.2). As Table  5.2 shows the measured roughness values 
(both Ra and rms values) have a positive correlation with the amount of glass incorporated. The 
deposition yields estimated also verify the increase in the amount of deposited material at higher glass 
concentrations. It should be noted that at higher glass concentrations due to more non-uniformity of 
deposition, the measurement errors for roughness values are larger. 
 
Figure  5.2 - Surface topographies for samples showing increasing roughness with increasing 
amount of Bioglass® in the coatings (labelled); the size of areas examined correspond to the 
higher magnification SEM images in Figure  5.1. 
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Table  5.2 - Deposit yield, suspension pH and roughness values for different coatings. 
Coating Deposit yield (mg/cm2) pH Ra (µm) rms (µm) 
CS 1.5 ± 0.3 3.05 ± 0.06 0.034 ± 0.003 0.051 ± 0.008 
CS/0.4BG 1.20 ± 0.07 3.39 ± 0.09 0.51  ± 0.04 1.21 ± 0.08 
CS/1.6BG 1.79 ± 0.08 3.92 ± 0.01 2.2  ± 0.4 3.2 ± 0.5 
CS/5BG 4.4 ± 0.3 4.46 ± 0.02 13.0 ± 0.7 15.5 ± 0.5 
CS/8BG 9.3 ± 0.4 4.94 ± 0.06 41 ± 1 51 ± 2 
The variety of microstructure of composite coatings obtained can be explained by considering 
basic EPD principles. Measurement of suspension pH for different EPD conditions under study 
indicates an increase in pH with glass concentration (Table  5.2). This implies a concentration-
dependent partial dissolution of glass particles and introduction of more ions in the chitosan solution 
during preparation of the suspension. According to the DLVO theory of colloidal systems [274], 
higher medium ionic strength leads to formation of flocculates with weakly bound particles which is 
due to appearance of a secondary minimum in the potential energy of suspended particles. This will 
affect the uniform dispersion of particles in the suspension. On the other hand, according to a model 
developed by Cordelair et.al [313] formation of a deposit and its packing density is also a function of 
particle concentration, suspension pH and ionic strength and for particles in flocculated or coagulated 
state, films with non-uniform packing structure will deposit. Moreover, electrolytic dissociation of 
water results in the formation of a pH profile at the surface of cathode as well as formation of 
hydrogen bubbles which can further increase the porosity and non-uniformity of coatings deposited. 
Simultaneous thermal analysis (STA) of the coatings is shown in Figure  5.3. The TGA curve 
of CS shows that the coating undergoes several stages of weight loss with increasing temperature. 
Below 100 °C the moisture in the coating evaporates. Following that, the two-stage burning out of 
chitosan polymer occurs in the range 220-350 °C and 380-600 °C. The DSC data of CS coating has 
two exothermic peaks at ∼300 °C and ∼500 °C corresponding to these two stages [17]. On the other 
hand the, the TGA of Bioglass® particles shows a slight weight loss (~2.25wt%~) up to 800 °C which 
is attributed to the moisture evaporation below 100 °C, followed by removal of atmospherically 
absorbed carbonate impurity at higher temperatures. Additionally, the endothermic event at ~605°C 
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and the exothermic peak at ~670°C in the DSC curve of Bioglass® represent glass transition and peak 
crystallisation temperatures [314]. Accordingly the weight loss in composite coatings can be 
correlated with chitosan burning out and hence it can be concluded that the amount of glass particles 
incorporated in the coatings under study increases with the concentration of particles in the 
suspension. The amount of glass is estimated to be 27.2, 61.2, 70.1, 71.2 wt% for CS/0.4BG, 
CS/1.6BG, CS/5BG and CS/8BG coatings; respectively. 
 
Figure  5.3 - TGA and DSC curves comparing CS, Bioglass® particles (BG), CS/0.4BG, 
CS/1.6BG, CS/5BG and CS/8BG coatings, showing increase in the wt% of incorporated 
Bioglass® in the coatings with increased Bioglass® particles concentration in the EPD suspension. 
5.4. Bioactivity evaluation 
5.4.1. Acellular in vitro bioactivity testing 
SBF immersion studies revealed the in vitro bioactivity of developed coatings in terms of 
HCA formation in physiological fluid. SEM examinations on coatings after treatment in SBF indicated 
no microstructural changes in CS and the appearance of signs of coating degradation in CS/0.4BG 
after 28 days of immersion (Figure  5.4 a and b). Whereas after 7 days of SBF immersion, formation of 
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a nanostructured needle-shaped phase on top of the CS/5BG and CS/8BG coatings was recorded 
(Figure  5.4 c and d). 
 
Figure  5.4 - SEM images of EPD coatings; (a) CS and (b) CS/0.4BG after 28 days of SBF 
immersion, (c) CS/5BG and (d) CS/8BG after 7 days of SBF immersion. Inset SEM images show 
higher magnification microstructures. 
EDX analyses of the as-received coatings (Figure  5.5) display the presence of carbon and 
oxygen in the CS coating which are the main components of chitosan polymer. In addition to carbon 
and oxygen, the composite films contained Si, Na, Ca and P which are due to the Bioglass® structure. 
After 28 days of SBF immersion, EDX spectrum of CS coating only shows addition of chlorine 
element which has been incorporated from the SBF solution. A similar spectrum was obtained for 
CS/0.4BG after 28 days which displayed lower intensities of Si and Na. On the other hand after 7 
days, CS/5BG and CS/8BG demonstrated that the newly-formed phase is deficient in Si and Na and 
contains increased levels of Ca and P elements which are the main components of hydroxyapatite 
(HAp). The Mg peaks can be from the ions incorporated in the HAp structure from the SBF solution. 
It has been reported that the crystal structure of HAp can accommodate substitutions by various other 
ions for the Ca2+, PO43- and OH- groups leading to formation of non-stoichiometric HAp [52]. It should 
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be noted that Cr, Fe, Ni and Mo peaks are due to the steel substrate and the Cr sputter-coated on 
samples prior to SEM. 
 
Figure  5.5 - EDX spectra of EPD coatings before and after immersion in SBF. Immersion times 
and sample areas examined correspond to the ones indicated in Figure  5.4. 
134 
Chapter 5: Characterisation of Chitosan/Bioglass® Coatings 
Among the composite samples, CS/1.6BG was of specific interest. After 28 days of SBF 
immersion, the coating displayed two distinct regions (Figure  5.6): (a) a white region at the lower part 
of the sample which showed formation of a Ca and P-rich nanostructured phase; and (b) a colourless 
region which only contained C, O and low levels of Na and Cl. Similar to CS/0.4BG, the SEM image 
of the latter region displayed a degraded chitosan matrix with very few or no glass particles present on 
the surface of the coating. This might suggest that the glass particles on the surface have dissolved out 
of the coating without providing sufficient local changes in the ionic concentration and in pH to 
promote formation of HAp. 
 
 
Figure  5.6 - CS/1.6BG composite coating after 28 days of immersion in SBF has two regions: (a) 
SEM image of region without HAp formation and (b) region with HAp formation. White arrow 
shows a section which appears to be less crystalline than the surroundings. EDX of the day 0 
sample and the two regions at day 28 are also shown. 
The XRD results from the SBF samples are shown in Figure  5.7. While after 28 days of SBF 
immersion, CS only exhibits a broad peak at ∼20° corresponding to the semi-crystalline nature of 
chitosan [315], CS/0.4BG shows an amorphous structure. CS/1.6BG, CS/5BG and CS/8BG on the 
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other hand display formation of a new crystalline phase which is in good agreement with the standard 
HAp pattern (ICDD 00-001-1008). The additional peaks present are due to the X-ray diffraction of the 
steel substrate. It should also be noted that the high and very broad background observed in all XRD 
plots is due to substrate iron fluorescence. 
 
Figure  5.7 - XRD patterns of CS-based coatings after immersion in SBF. Immersion times 
correspond to the times indicated in Figure  5.4. and Figure  5.6 (316 SS peaks shown are from 
the metallic substrate). 
To elucidate the change in crystalline structure with SBF immersion time, the XRD patterns of 
CS/5BG coatings at different time points are displayed in Figure  5.8. The as-prepared composite 
CS/5BG coating has an amorphous structure displaying a very broad peak at ∼30°, which corresponds 
to the presence of Bioglass®. As soon as 2 days SBF immersion, formation of HAp crystals is 
evidenced. With further SBF immersion time, the crystal size and/or degree of crystallinity of the new 
phase increases. 
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Figure  5.8 - XRD patterns of CS/5BG coatings at different days of SBF immersion. 
Formation of HAp on surface of the composite coatings has been also explained by comparing 
FTIR spectra before and after SBF immersion. In order to fully characterise the obtained coatings, the 
FTIR spectra of CS coating and pure Bioglass® particles were also studied. As shown in Figure  5.9 
and considering the structure of chitosan presented in section  2.4.2.1, the main bands of chitosan 
appear in various ranges. The broad band in the range 3750-3000 cm-1 is due to overlaying of several 
bands; stretching vibration of O-H from carbohydrate ring and also adsorbed water (3500-3450 cm-1) 
plus N-H stretching in amine and amide (~3360 cm-1). This is followed by vibration bands of C-H 
bond in –CH2 (2930 cm-1) and –CH3 (2875 cm-1). Moreover, –CH3 symmetrical deformation and –CH2 
bending vibration occur at 1376 cm-1 and 1420 cm-1; respectively. The range of 1680-1480 cm-1 is 
attributed to two functional groups; vibration of carbonyl bond (C=O) in amide group at 1653 cm-1 and 
N-H bending vibration of amine group at 1580 cm-1. N–H has a vibration band at 1320 cm-1. Finally, 
the peaks in the 1160-1000 cm-1 range are assigned to CO groups. The band at 1154 cm-1 is for the 
asymmetric vibration of CO in oxygen bridge and the bands near 1080-1025 cm-1 are from CO of the 
ring COH, COC and CH2OH [173]. 
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Alternatively the main peaks in the spectrum of pure Bioglass® are attributed to Si-O-Si 
bending vibration (~500 cm-1) and stretching vibration (920 and 1030 cm-1; the dual peak is indicative 
of the presence of network modifiers such as Na and Ca in the structure of glass) [316]. The broad 
peak at 3500 cm-1 and the one at 1480 cm-1; respectively; are due to water and carbonate groups 
adsorbed from the atmosphere. In all spectra, the dual peak at about 2350 cm-1 is due to atmospheric 
CO2. 
The FTIR spectra of composite films (Figure  5.9) indicate the presence of peaks associated 
with both chitosan and Bioglass®. The intensity of Bioglass® peaks increases at higher particle 
concentrations because of higher weight% of glass incorporated. More importantly there is a shift of 
vibrations to higher frequencies in the range 3750-3000 cm-1 with a shoulder forming at 3645 cm-1 
(Figure  5.9 dashed line). This trend which is more prominent in CS/1.6BG, CS/5BG and CS/8BG 
coatings is attributed to the formation of hydroxyl groups [191] and hydrogen-bonding. The 
suspension of glass particles in aqueous medium leads to formation of free surface hydroxyl groups. 
For instance, the ionic exchange of glass alkali cations (R) with protons occurs according to the 
following surface reactions [311]:  
𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑅𝑅(𝑔𝑔.𝑠𝑠) + 𝑂𝑂2𝑂𝑂 ⇌ 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑂𝑂(𝑔𝑔.𝑠𝑠) + 𝑂𝑂𝑂𝑂(𝑠𝑠 .𝑠𝑠)− + 𝑅𝑅+       (i) 
The released hydroxyl ion from reaction (i) disrupts the siloxane bond in the glass structure: 
𝑆𝑆𝑖𝑖 − 𝑂𝑂 − 𝑆𝑆𝑖𝑖(𝑔𝑔.𝑠𝑠) + 𝑂𝑂𝑂𝑂(𝑠𝑠 .𝑠𝑠)− ⇌ 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑂𝑂(𝑔𝑔.𝑠𝑠) + 𝑆𝑆𝑖𝑖 − 𝑂𝑂(𝑔𝑔.𝑠𝑠)−       (ii) 
The NBO formed in reaction (ii) further reacts with water molecule to produce hydroxyl ions which 
are free to repeat the above reaction: 
𝑆𝑆𝑖𝑖 − 𝑂𝑂(𝑔𝑔.𝑠𝑠)− + 𝑂𝑂2𝑂𝑂 ⇌ 𝑆𝑆𝑖𝑖 − 𝑂𝑂𝑂𝑂(𝑔𝑔.𝑠𝑠) + 𝑂𝑂𝑂𝑂(𝑠𝑠 .𝑠𝑠)−         (iii) 
These surface hydroxyl groups can be involved in hydrogen-bonding with chitosan hydroxyl 
and carbonyl moieties [317]. Therefore a broadening of the O-H peak at 3645 cm-1 and the reduction 
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of C=O vibration at 1653 cm-1 (Figure  5.9 red arrow) compared to N-H vibration at 1580 cm-1 are 
observed. This hydrogen-bonding with charged chitosan macromolecules can provide electrosteric 
stabilisation of glass particles in the suspension and can aid the co-deposition of glass and polymer 
components. 
 
Figure  5.9 - FTIR spectra of different coatings before SBF immersion. 
Although FTIR spectra of CS and CS/0.4BG did not show any change after 28 days of SBF 
immersion, the other coatings exhibited the formation of new peaks corresponding to HAp phase 
(Figure  5.10). The P-O bending vibration dual peak at 560 and 603 cm-1 and the P-O stretching peak at 
1030 cm-1 are related to phosphate groups. Examination of the spectrum of HAp grown on the sample 
reveals the presence of C-O out of plane bending (873 cm-1) and C-O stretching (1530-1400 cm-1). 
This fact confirms that the developed HAp (in SBF) is hydroxyl carbonate apatite (HCA) which is 
similar to the mineral phase of bone. The O-H bending vibration at 1640 cm-1 is due to adsorbed water 
in the structure of the new phase. 
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Figure  5.10 - FTIR spectra of CS-based coatings after immersion in SBF. Immersion times 
correspond to the times indicated in Figure  5.4. and Figure  5.6. 
The FTIR spectra of the CS/5BG samples presented in Figure  5.11 show the formation of 
HCA phase with increasing SBF immersion time. The spectra display a reduction in the peaks of 
Bioglass® (Si-O-Si bending and stretching) and chitosan (N-H bending) with time. Consistent with the 
XRD data, new bands form within 2 days of SBF treatment. 
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Figure  5.11 - FTIR spectra of CS/5BG coatings at different days of SBF immersion. 
The various methods utilised in this section clearly proved the bioactivity (in terms of HCA 
formation) of the electrophoretically deposited composite coatings of chitosan/Bioglass® compared to 
polymer-only coatings at the higher range of glass loading under study. Conversely, composite 
coatings with lower amount of bioactive glass did not exhibit bioactivity. Exploring the reasons 
underlying this behaviour is the main topic of the next section. 
5.4.2. Effect of EPD suspension process on bioactivity of Bioglass® particles 
As outlined in the previous section, the SBF testing of EPD coatings demonstrated limitation 
in bioactivity and HCA formation for chitosan/Bioglass® composite coatings in the lower range of 
glass particle loading. In order to investigate this behaviour, the dissolution of ions from the coatings 
during SBF immersion was measured by ICP-OES. The three coatings in which bioactivity was 
expected but differences were observed; namely CS/0.4BG, CS/01.6BG and CS/5BG; were selected 
for this study. Also, as shown in Figure  5.11, the new calcium phosphate phase is expected to start 
forming in as short as 2 days immersion and therefore the ionic dissolution measurements were 
conducted up to 5 days. 
141 
Chapter 5: Characterisation of Chitosan/Bioglass® Coatings 
Figure  5.12 presents the concentration profile of calcium, sodium, phosphorous and silicon 
ions as a function of time in SBF solution for the three coatings investigated. While during the whole 
experiment the calcium ion concentration remained almost constant at the initial SBF concentration 
(76.2 µg/ml) for CS/0.4BG coating, initial spikes up to 99 µg/ml and 103 µg/ml were seen for 
CS/1.6BG and CS/5BG coatings; respectively; during the first 3h. This was followed by a gradual 
decrease in the Ca2+ concentration until the end of experiment. The extent of decrease after 5 days was 
larger for CS/5BG (63 µg/ml) compared to CS/1.6BG (73 µg/ml) coatings. The variation in Ca2+ 
concentration was concurrent with changes in phosphorous and soluble silica8 concentrations. The 
concentration of PO43- had a small rise up to about 36 µg/ml in 6 h for CS/0.4BG and CS/1.6BG 
coatings. Although CS/0.4BG coating remained at that level, the PO43- decreased for both CS/1.6BG 
and CS/5BG coatings and went as low as 4 µg/ml for the latter at day 5. All coatings demonstrated an 
initial sharp rise in soluble silica concentration followed by a plateau. The level of soluble silica 
plateau increased with the amount of glass in the coating. Na+ release showed a similar trend for 
CS/1.6BG and CS/5BG coatings (~7% drop in 5 days immersion). For CS/0.4BG coating there was an 
initial spike up to 3323 µg/ml after which it dropped to a plateau of 3170 µg/ml. Meanwhile it should 
be noted that no significant change in pH of SBF solution (7.4 at 37 C) was measured for all three 
coatings during immersion 
The sample weight measurements after 5 days of SBF immersion introduced a weight 
decrease. There was no significant difference between samples except for CS/5BG which showed 
weight reduction significantly higher than CS/0.4BG coatings (p < 0.15). 
In general, the dissolution of the silica network in CS/1.6BG and CS/5BG coatings is 
accompanied by the decrease in calcium and phosphorous ion concentrations. This result is indicative 
of deposition of a calcium-phosphate-rich phase on the samples immersed in SBF. Nevertheless, for 
CS/0.4BG samples, the calcium and phosphorous ion concentrations did no vary significantly with 
immersion time and hence no formation of calcium-phosphate-rich phase was expected. These 
8 In dissolution of Bioglass® in SBF, soluble SiO2 is lost in the form of Si(OH)4 [63]. 
142 
                                                     
Chapter 5: Characterisation of Chitosan/Bioglass® Coatings 
findings are in line with the SEM/EDX, XRD and FTIR data presented in the previous section (section 
 5.4.1). This might indicate that a critical glass particles loading is required to generate enough soluble 
ions to induce nucleation of HCA. 
 
Figure  5.12 - Concentration of different ions of (a) Ca2+; (b) Na+; (c) PO43-; and (d) soluble silica 
released as a function of time after incubation of CS/0.4BG, CS/1.6BG and CS/5BG coatings in 
SBF solution for up to 5 days. 
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Figure  5.13 – Weight loss of CS/0.4BG, CS/1.6BG and CS/5BG coatings after 5 days of 
incubation in SBF (*:p<0.15 for the marked bar vs. CS/5BG) 
As discussed above; compared to CS/5BG; in the case of CS/1.6BG, only parts of the coatings 
close to the lower edge of sample; where more glass is usually deposited due to stronger electrical 
field; were bioactive. Therefore it was considered that the explanation lies in the ability of the 
deposited glass particles to leach ions for provision of bioactivity. In fact, ICP-OES examination of 
EPD suspensions prepared for EPD of CS/1.6BG and CS/5BG coatings (Figure  5.14) reveals the 
dissolution of ionic species form the glass in the low pH of chitosan solution (pH ≈ 3) during 
suspension preparation. 
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Figure  5.14 – Concentration of different ions; namely Ca2+, Na+, PO43 and soluble silica; 
released from 1.6 and 5 mg/ml Bioglass® powder suspended in 0.5 mg/ml chitosan solution (1 
vol% acetic acid) for up to 30 min. 
ICP-OES measurements show a dramatic increase in the concentration of Ca2+ and Na+ ions 
within the first 30 s of dispersion of glass powder in chitosan solution which continues for about 3 min 
and then stabilises. As suspension of 5 mg/ml Bioglass® has about 3 times more glass particles in 
comparison to 1.6 mg/ml suspension, the extent of ion leaching is also about 3 times more in the 
former (Table  5.3 and Table  5.4). A parallel trend was observed in the leaching of phosphorous and 
soluble silica at both suspension concentrations, but compared to Ca2+ and Na+ ions, both of these 
ionic species display lower release rate with silicon having the lowest. 
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Considering a complete dissolution of glass particles in chitosan solution, in Table  5.3 and 
Table  5.4 the total ionic concentrations for 1.6 mg/ml and 5 mg/ml suspensions, respectively, have 
been estimated. These values have been compared with the measured concentration of released ions 
after 30 min suspension presented above and finally the percentage of remained ions capable of 
leaching has been calculated. 
Table  5.3- Ion concentrations and percentage of remained ions for 0.5 mg/ml chitosan EPD 
solutions containing 1.6 mg/ml Bioglass® after 30 min of suspension as well as assuming that 
glass completely dissolves. 
ions Soluble silica Ca2+ Na+ PO43- 
Total in glass (ppm) 336.4 280.1 291.4 41.86 
Released in 30 min (ppm) 11.1 ± 0.8 242 ± 4 240.5 ± 0.6 48.8 ± 0.4 
% remained in glass 96.7 ± 0.2 13 ± 1 17.5 ± 0.2 ~0 
 
Table  5.4- Ion concentrations and percentage of remained ions for 0.5 mg/ml chitosan EPD 
solutions containing 5 mg/ml Bioglass® after 30 min of suspension as well as assuming that glass 
completely dissolves. 
ions Soluble silica Ca2+ Na+ PO43- 
Total in glass (ppm) 1051.1 875.3 910.7 130.8 
Released in 30 min (ppm) 35 ± 2 881 ± 6 822 ± 6 141.2 ± 0.2 
% remained in glass 96.6 ± 0.2 ~0 9.7 ± 0.6 ~0 
The results suggest that although at both suspension concentrations the glass particles retain 
about 96% of their soluble silica, they are almost depleted of phosphorous ions after 30 min. 
Additionally, there is a dramatic decrease in the amount of available alkali and alkaline earth ions with 
the 1.6 mg/ml suspension having 13% Ca2+and 17.5% and the 5 mg/ml sample having about 10% Na+ 
and almost depleted of Ca2+ by 30 min. This major ionic dissolution has been reflected in the increase 
in the pH of suspensions from pH 3 to pH 3.9 and 4.5 for 1.6 and 5 mg/ml suspensions, respectively 
(Table  5.2). It is noteworthy that the study above is based on assuming the nominal composition for 
the Bioglass® under study (see Chapter 3), while the presence of impurities (not considered here) 
could affect the levels of available ions for leaching. 
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In spite of approximately similar percentage of ionic loss for 5mg/ml suspension compared to 
1.6 mg/ml suspension, the bioactivity of CS/5BG coating was not adversely affected, whereas 
CS/1.6BG coating could not provide HCA formation over the entire coating surface. Therefore the 
SBF immersion test was conducted on the glass powder filtered from the 1.6 mg/ml suspension and 
results were compared against the as-received Bioglass® 45S5. 
The ion release profile of the as-received and the 1.6 mg/ml filtered powders in SBF solution 
are presented in Figure  5.15 a, b, c and d. There is a relatively large difference among the release 
profiles of Ca2+ and PO43- in the as-received and filtered Bioglass®. In the first few hours of immersion 
of the as-received glass particles, Ca2+ concentration has a sharp increase from 76.2 µg/ml to 152 
µg/ml and then there is a gradual increase up to 166 µg/ml within 30 h of immersion. Simultaneously 
the PO43- concentration shows a large decrease from 33 µg/ml to 11 µg/ml in 30 h. These changes are 
attributed to the formation of a calcium-phosphate phase. Nevertheless the filtered glass displays no 
variation in Ca2+ and PO43- concentrations through the whole experiment. Meanwhile both powders 
exhibit dissolution of the silica network which happens at a faster rate for the filtered glass. Due to the 
previous dissolution of ions from the filtered glass in the chitosan solution, presence of more Si-OH 
bonds and faster release of soluble silica is expected. There was an initial increase in Na+ 
concentration for the as-received glass powder up to 2h immersion after which it reduced and 
stabilised. For the filtered glass the Na+ concentration displayed an initial reduction which reached a 
plateau after 12 h. 
The release of ions from the glass powders is reflected in the change in the pH of the SBF 
solutions as a function of immersion time (Figure  5.15 e). The immersion of the as-received glass 
resulted in rising of the pH from 7.4 to 7.9, which is associated with ion exchange between Ca2+ and 
Na+ and solution H+ or H3O+ ions. On the other hand, the pH of the SBF solution containing filtered 
glass had an initial drop which was later recovered and remained constant. Although filtered glass 
powder was rinsed with deionised water after filtration, this initial pH drop can be due to the 
remaining acetic acid of chitosan solution left on the glass during its preparation. 
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Figure  5.15 – Concentration of different ions, (a) Ca2+; (b) Na+; (c) PO43-; (d) soluble silica 
released; (e) and solution pH as a function of time after incubation of as-received and filtered 
Bioglass® powder in SBF solution for up to 30 h. 
The precipitation of HCA phase in the SBF treated as-received Bioglass® powder was 
confirmed by FTIR analysis. As shown in Figure  5.16 upon immersion in SBF there is a reduction in 
the bands of Si-O-Si bending vibrations (at 740 and 500 cm-1). Also the stretching vibration arising 
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from non-bridging oxygen at 920 cm-1 become broader and the Si-O-Si stretching bands become 
sharper at 1030 cm-1. These variations are due to leaching of alkali and alkaline earth ions, formation 
of Si-OH groups and formation of a silica-gel surface layer. After 30 h in SBF P-O stretching bands at 
about 1030 cm-1 and P-O bending at 560 cm-1 were observed which are related to formation of an 
amorphous Ca-P phase. Also a shoulder at 630 cm-1 was formed indicating start of crystallisation of 
the calcium phosphate phase. Additionally, carbonate and hydroxyl bands were noticed in the range 
1530-1400 cm-1 and 1648 cm-1, respectively, confirming formation of HCA. 
 
Figure  5.16 – FTIR spectra of as-received Bioglass® powder at different incubation times in SBF 
solution for up to 30 h. 
Alternatively, the FTIR analysis of the filtered glass did not support HCA formation in 30 h 
SBF immersion (Figure  5.17). Before SBF immersion, the spectrum already showed clear evidence of 
bands of Si-OH at 950 cm-1 and O-H bending of hydroxyl groups at 1648 cm-1. This indicated 
formation of extensive surface hydroxyl groups in the glass during the process of suspending particles 
in aqueous chitosan solution at pH 3. As anticipated before, the structure of the glass did not vary with 
SBF immersion time and formation of no new vibrational bands was detected. Here the aqueous 
treatment conducted on particles during filtration has retarded the formation of HCA. 
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Figure  5.17 – FTIR spectra of filtered Bioglass® powder at different incubation times in SBF 
solution for up to 30 h. 
The data presented above explains the reduced bioactivity behaviour of the glass powder due 
to the suspension preparation stage for EPD processing of the composite coatings. This is a factor 
which must be taken into account when designing the composite system to ensure adequate loading of 
Bioglass® particles. 
5.4.3. Discussion 
Precipitation of HCA on the surface of bioactive glasses in physiological fluid is regarded as 
the first step in bone bonding. Thus SBF testing is commonly used to check the HCA formation on 
biomaterials [282]. As discussed in section  2.4.1.1 of the literature review, HCA formation on 
Bioglass® in SBF consists of leaching, dissolution and precipitation steps which involve ion exchange 
processes and have been discussed extensively in the literature [63]. These steps are characterised as 
leaching of Na+ and Ca2+, formation of silanols (Si-OH), degradation of silica network, subsequent 
condensation and repolymerisation of a silica-rich layer, precipitation of calcium and phosphate ions 
from the both glass and the SBF solution on top of the silica rich layer and finally formation of 
amorphous calcium-phosphate and its crystallisation [63].  
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Lu et.al [318] have highlighted the importance of the surface charge of Bioglass® particles in 
the bioactive response and have explained the relationship between surface charge variation and 
formation of Ca-P surface layer. It has been demonstrated that during the stages of ion leaching, silica 
network hydrolysis and formation of a silica rich layer, the zeta potential of glass particles is negative 
due to the presence of surface hydroxyl groups. The negative surface charge results in accumulation of 
positively charged ions such as Ca2+ from the SBF solution and entrapment of cations leaching from 
the bulk glass; hence after 1 day of SBF treatment, a reversal of surface charge from negative to 
positive values was observed. This new surface charge attracts negatively charged phosphate ions and 
results in the formation of amorphous surface Ca-P phase. Conclusively a second zeta potential 
reversal from positive to negative values was noticed at day 3 due to accumulation of PO43- ions on the 
particles surface and crystallisation of apatite phase. Other studies have also emphasised on the 
importance of charge of surface groups on precipitation of apatite [319]. 
Additionally, SBF is a supersaturated solution towards apatite crystal and therefore changing 
the local supersaturation results in apatite precipitation [320]. Although results presented in the 
previous section shows extensive loss of Ca2+ and Na+ from the Bioglass® powder in the process of 
EPD suspension preparation, coatings containing higher amount of bioactive glass were bioactive in 
SBF. As shown by FTIR analyses, the process of suspending particles in aqueous chitosan solution 
results in formation of many Si-OH groups on the surface of glass. These surface groups have a major 
role on providing a negative surface charge in SBF solution on which Ca2+ ions of SBF can 
accumulate and facilitate deposition of apatite from the supersaturated solution. EPD coatings with 
higher bioactive glass loading contain many glass particles which are less covered by chitosan 
polymer and easily provide apatite nucleation sites, while at lower bioactive glass loadings there are 
less agglomerates of glass particles and mostly individual particles are covered by the polymer film; 
thus bioactivity is not favoured. The fact that HCA formed on edges of CS/1.6BG sample where larger 
lumps of glass were deposited, supports the above-mentioned hypothesis. 
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5.5. Mechanical characterisation 
The adhesion strength of the biomedical orthopaedic coatings is of great importance as the 
coating needs to withstand the interfacial loading imposed on it during implantation. Lap shear testing 
and tensile testing are the two techniques standardised to quantitatively evaluate the adhesive strength 
of sintered calcium phosphate coatings on implantable materials [321]. These tests involve application 
of an adhesive between a coated and a non-coated sample, which will then be loaded in tensile or 
shear mode to failure. One requirement of these tests is lack of porosities in the coatings to avoid 
penetration of the adhesive into the substrate surface; otherwise the adhesive strength of the applied 
adhesive material to the substrate will be measured which renders results inaccurate and often 
misleading. As the EPD coatings developed in this study contained porosity especially at higher 
bioactive glass loading, the aforementioned techniques could not be applied for their mechanical 
evaluation. 
On the other hand instrumented indentation technique can be applied to measure the elastic 
modulus of the coating [143, 183, 194]. In instrumented indentation tests, load-indentation depth 
curves are utilised to obtain the elastic modulus of samples. This technique requires application of 
indentation loading in a range which on one hand is low enough to avoid substrate contribution to the 
measured modulus and on the other hand is high enough to eliminate the surface roughness effect on 
penetration depth measurements. To fulfil the first condition, it is suggested to indent no further than 
10% of the film thickness and for the second condition,  the sample is required to have a polished 
surface [322]. In this study, the EPD coatings prepared with different Bioglass® content had different 
thicknesses; thus preliminary nanoindentation tests in depth-controlled mode were performed to 
measure the elastic moduli of the composite coatings. The test results were dependent on whether the 
indenter tip was positioned on a glass or a polymeric part and on the surface roughness level. Due to 
relatively high surface roughness and the presence of pores especially in coatings with high glass 
content, the load-indentation depth curves were not reproducible. Therefore no conclusive results 
could be obtained. 
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The approach taken here was to qualitatively compare adhesive strength and to measure the 
micro- hardness of the coatings. In the next section the results of these two mechanical tests performed 
on EPD coatings will be presented. 
5.5.1. Tape testing 
The aim of this study was to qualitatively compare the effect of different Bioglass® content on 
the adhesive strength of the EPD coatings developed. For this purpose the tape testing standard 
method was performed according to the procedure described in Chapter 3 (section  3.12) and the 
experimental results were compared with the illustrations in Table  3.1. Four samples for each 
composition were tested. 
According to the results obtained, EPD coatings demonstrate different behaviours depending 
on the bioactive glass content. Representative coating samples before and after tape testing plus 
adhesion classification are presented in Figure  5.18. Figure  5.19 displays low and high magnification 
SEM images after the test for each coating composition.  
For CS coatings, as it is shown in Figure  5.18 b, more than 65% of coating has detached from 
the substrate. The SEM image shows that darker areas of chitosan coating remained with surrounding 
film ruptured (Figure  5.19 a, b). Interestingly, addition of bioactive glass particles to the polymer 
matrix has resulted in improvement of adhesion in CS/0.4BG and CS/1.6BG coatings. In CS/0.4BG 
coating, except for limited detachments at the intersection of the cuts, the coating has remained almost 
intact and less than 5% of it has been removed. This can be confirmed by comparing low and high 
magnification SEM images of CS/0.4 coating in Figure  5.19 c ,d with that of Figure  5.1 c, d. 
CS/1.6BG coating also shows less than 15% of detachment in the edges of cuts and detachment of 
glass particles (white arrow in Figure  5.19 f), however the low magnification SEM microstructure 
(Figure  5.19 e) shows adequate attachment of the coating to the substrate. On the other hand CS/5BG 
coating demonstrated detachment of top clusters of glass/polymer in the coating and formation of 
more cracks in the structure (Figure  5.18 h and Figure  5.19 g, h). The glass/polymer lumps attached to 
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the tape from testing of CS/5BG coating are shown in Figure  5.20. This was more severe in the case of 
CS/8BG coating that even during cutting patterns on the sample and before testing, parts of the coating 
was detached (Figure  5.18 i) and after testing more of the top thick layer of the deposited composite 
film was removed (Figure  5.19 i, j). It is noteworthy that in both CS/5BG and CS/8BG samples, a thin 
layer of coating remained attached to the substrate after the test, which means the failure was within 
the coating layer and not at the coating substrate-interface. 
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Figure  5.18 – Optical images and classification of CS, CS/0.4BG, CS/1.6BG, CS/5BG and 
CS/8BG coatings before and after tape testing. 
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Figure  5.19 – Low and high magnification SEM images of CS, CS/0.4BG, CS/1.6BG, CS/5BG 
and CS/8BG coatings after tape testing. White arrows indicate where glass particles have been 
detached. 
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Figure  5.20 – SEM image of particles attached to the adhesive tape after tape testing of CS/5BG 
coating. 
The tape testing results demonstrated that by addition of bioactive glass particles to chitosan 
film up to a certain limiting concentration; the adhesion quality of the coating increased. This 
phenomenon can be explained by considering the mechanical attachment at the interface between the 
bioactive glass particles and the polymer matrix. When the film detachment crack reaches this 
interface its propagation can be hindered either by debonding of this interface (Figure  5.21 a) or 
deflection of the crack (Figure  5.21 b). Thus smaller portions of the coating separate off the substrate. 
Interestingly, this behaviour might be compared with particle-matrix debonding or crack deflection in 
particle-reinforced bulk composite materials which are regarded as energy-absorbing mechanisms and 
can lead to improved fracture toughness [323]. 
 
Figure  5.21 - (a) matrix-particle interface debonding; and (b) crack deflection; marked by white 
arrows in tape testing of CS/0.4 BG coatings. 
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With higher glass loading, the proportion of polymeric phase in the composite coating reduces 
and the coating thickness and its porosity increase. As a result of lower structural integrity of the 
coating, larger portions easily separate from the substrate and the adhesion of the coating to the 
substrate is adversely affected. 
5.5.2. Micro-hardness testing 
The Vickers indentation hardness of the different coatings developed and presented in this 
chapter are shown in Figure  5.22. The Vickers hardness of the 316L SS substrate has also been 
measured to identify the reason for some exceptionally high coating hardness measurements. 
It can be seen that as the amount of Bioglass® in the coatings increases, the measured hardness 
values increase. Additionally, the amount of scatter in the data rises. The reasons for the high scatter 
are the increase in surface roughness, the non-uniformity of deposition and the presence of a more 
porous coating with increasing amount of glass content in the deposited film. As in the case of 
CS/8BG coating, there are out of range data as high as the hardness value of 316L SS substrate, which 
can be indicative of the indentation having been performed at location of pores. The hardness of bulk 
Bioglass® 45S5 has been reported to be about 4.49 GPa [63] and it is higher than the chitosan polymer 
hardness, which has been measured to be 0.029 ± 0.007 GPa in this study. Therefore it is expected that 
the overall hardness of the composite coatings should increase with incorporation of a higher weight 
percentage of bioactive glass. A similar trend in the hardness measurement of polymer-matrix 
composite coatings by addition of ceramic filler has also been reported in the literature. It has been 
shown that addition of MWCNT [324] and montmorillonite [325] in chitosan films has resulted in 
increased hardness of the composite film. Additionally Misra et. al. [326] have reported increase in 
hardness of P3HB-based composite films by addition of micon-sized Bioglass® particles. These results 
are in line with the hardness measurement trend observed in the composite films investigated in this 
research. 
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Figure  5.22 - Boxplots (n=30 per sample): influence of composition of EPD coatings on their 
Vickers indentation hardness. Filled circles denote outliers (hardness value > 1.5 box length 
from the quartiles) (p<0.05: * is for the marked box vs. CS and CS/0.4BG coatings; § is for the 
marked box vs. CS/1.6BG coatings). 
5.6. Summary 
In this chapter composite chitosan/Bioglass® coatings prepared by electrophoretic deposition 
were characterised with respect to microstructure, bioactivity and mechanical properties. It was shown 
that increase in the amount of glass particles in the starting EPD suspension results in thicker coatings 
with higher glass particle loading which can adversely affect the surface roughness and uniformity of 
the deposits. 
SBF testing of coatings has shown that the incorporation of bioactive glass particles provided 
bioactivity and HCA formation to the otherwise non-bioactive chitosan films. HCA formation was 
detected on CS/5BG, CS/8BG and parts of CS/1.6BG coatings and it was confirmed by SEM/EDX, 
XRD and FTIR analyses. The lack of HCA formation on CS/0.4BG coating was elucidated with 
respect to the dissolution of ions from the coatings. It was demonstrated that introduction of Bioglass® 
particles in the aqueous chitosan solution during the EPD suspension preparation results in dissolution 
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of high proportions of alkali and alkaline earth ions of the glass particles. However, this procedure 
leaves the glass with high content of Si-OH groups on the glass surface. Consequently, in spite of 
loosing high amount of ions, the surface groups are capable of inducing apatite formation through 
surface charge. For CS/0.4BG films the low glass content and the complete coverage of the bioactive 
glass particles with chitosan film were the reasons of bioactivity suppression. 
Tape testing and micro-hardness evaluation were conducted to mechanically characterise the 
composite coatings. It was observed that in comparison to the plain CS coating, the addition of glass 
particles up to intermediate levels (~ 60 wt%) can enhance the adhesion of EPD film to the substrate. 
Additionally, the hardness of coatings had a positive correlation with the amount of Bioglass® weight 
percentage in the composite coatings. 
Although compared to CS/5BG and CS/8BG, coatings of CS/0.4BG and CS/1.6 BG exhibited 
smoother surface morphology, more deposition uniformity and better adhesion to the substrate, 
CS/5BG coating was selected as the composite coating for comparison purposes in the next chapter in 
order to ensure bioactivity. 
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Chapter 6: EPD of Antibacterial Composite Coatings 
6.1. Introduction 
Implantation of orthopaedic devices in the body is always associated with the risk of bacterial 
infection. Bacterial infection can lead to formation of bacterial biofilms on the biomedical device in 
vivo. These biofilms are very resistant to both the immune system and systemically delivered 
antibiotics. Apart from antibacterial agents, bone remedial methods involve application of other 
biomolecules such as growth factors and proteins. Therefore novel tissue engineering approaches 
focus on grafting of the therapeutic chemical in the structure of the medical device and maintaining 
long-term and controlled local release of the drug at the implantation site. This strategy is expected to 
be more efficient in addressing bacterial infection and thus lowers the risk of systemic toxicity often 
encountered in oral or parenteral drug administration. 
In line with the above trend, this chapter presents results on electrophoretic deposition of 
antibacterial and bioactive composite coatings with potential orthopaedic application. EPD was 
applied to incorporate two types of antibacterial agents (molecular and ionic) into the 
chitosan/bioactive glass composite coatings. One is nano-particulate silver (Ag-np) which is formed 
in-situ during EPD from composite suspension. The other is gentamicin, a glycosidic antibiotic that 
was used as a model drug to show the feasibility of EPD in deposition of drugs. 
To characterise the microstructure of coatings, SEM/EDX, XRD, FTIR and STA analyses 
were performed. In addition, formation of Ag-np was examined using TEM. Depending on its type, 
the release of each antibacterial agent in phosphate buffered saline (PBS) or simulated body fluid 
(SBF) was investigated with ICP-OES or high performance liquid chromatography (HPLC). 
Furthermore, to make sure that the bioactivity of coatings has not been adversely influenced, SBF 
bioactivity test was performed and formation of HCA was confirmed. The ability of coatings in 
preventing bacterial growth was tested against S. aureus bacterial strain and finally the proliferative 
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response of MG-63 osteoblast-like cells to the developed coatings and cellular attachment to them 
were explored. 
6.2. Experimental methods 
6.2.1. Materials 
The particle size of 45S5 Bioglass® powder used in this section was in the range 1.6 and 26.7 
µm with a median particle size of 9.8 µm. 0.05 M silver nitrate solution (AVS TITRINORM) from 
VWR was used. Gentamicin sulphate (BioReagent, 50 mg/ml solution in deionised water) and the 
reagents used in gentamicin derivatisation procedure (see section  6.2.4) were from Sigma Aldrich.  
6.2.2. Electrophoretic deposition 
Solutions of chitosan (0.5 mg/ml) in 1 vol% acetic acid were prepared and Bioglass® particles 
were dispersed in it to make composite suspensions. For coatings containing silver-nanoparticles (Ag-
np), silver nitrate solution was added to the prepared suspensions with a final concentration of 1 mM. 
In the case of gentamicin-loaded coatings, gentamicin sulphate solution was added to the prepared 
suspension to obtain a concentration of 2 mg/ml. 
For electrophoretic deposition, AISI 316L stainless steel foils were utilised as deposition 
substrate (cathode). Due to addition of silver nitrate and gentamicin sulphate solutions to the system, 
electrical conductivity of the suspensions was increased which in turn caused corrosion of stainless 
steel counter electrodes (anode) in initial tests. Therefore a gold counter electrode was used in the EPD 
cell to avoid contamination of coatings with corrosion products (slight oxidation of the Au was 
observed but the original surface could be recovered by annealing at 200 ºC). 
Constant-voltage EPD of antibacterial coatings was performed at 21 ± 2 °C. The distance 
between the electrodes was kept constant at 1.5 cm. The CS and CS/5BG coatings described in 
Chapter 5 were also prepared for comparison with the new antibacterial coatings. The EPD 
experimental conditions for each coating used in this chapter are outlined in Table  6.1. 
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Table  6.1 - EPD parameters for deposition of coatings from 0.5 mg/ml chitosan solutions. 













Chitosan  CS 0 0 0 10 800 
Chitosan/Bioglass®  CS/5BG 5 0 0 10 400 
Chitosan/Ag-np  CS/Ag 0 1 0 10 300 
Chitosan/Bioglass®/Ag-np  CS/BG/Ag 3 1 0 15 400 
Chitosan/Bioglass®/Gentamicin CS/BG/GS 5 0 2 10 400 
 
6.2.3. Silver release study 
The concentration of silver ions in the EPD suspension before and after deposition was 
estimated by ICP-OES. Furthermore, the in vitro release of Ag ions in SBF solution was investigated 
by incubating samples of CS/BG/Ag (10 mm × 10 mm × 0.2 mm) in 10 ml SBF at 37 ºC. At specific 
time points (3h, 6 h, 12 h, 1, 3, 5, 7, 14, 21 and 28 days), aliquots of 2 ml were removed from samples 
and refreshed by fresh SBF. For ICP-OES measurements, the collected samples were further diluted 
by deionised water. 
To investigate the possibility of controlling the release of Ag+ ions, a bilayer coating 
consisting of an initial layer of CS/Ag covered by a second layer of chitosan/Bioglass® composite 
(EPD parameters in Table  6.2) was electrophoretically deposited. The release of Ag+ ion in SBF from 
this bilayer film was compared with the release from the monolayer CS/BG/Ag film. 
Table  6.2 - EPD parameters for deposition of monolayer and bilayer Ag-np containing coatings 










(mM) Voltage Time 
monolayer 1 CS/BG/Ag as in Table  6.1 
bilayer 1 CS/Ag as in Table  6.1 2 CS/3BG 3 0 15 400 
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6.2.4. Gentamicin release study 
To determine the efficiency extent of EPD in incorporation of gentamicin, release of the 
antibiotic from another type of sample; called here the “pipetted sample”; was also investigated. To 
prepare the pipetted sample, 100 µl of gentamicin sulphate solution (2 mg/ml) was pipetted over 
coatings of CS/5BG and samples were left to dry at room temperature. The amount of antibiotic 
release from these samples was compared with the EPD samples. 
In order to quantify the amount of gentamicin incorporated in the coatings, coatings were 
scraped off the substrate and immersed in 1 ml deionised water (borate buffer pH=10.4). After 10 min 
sonication, the immersion samples were centrifuged and the supernatant was tested for dissolved 
gentamicin according to the procedure described below. 
On the other hand, the in vitro release of gentamicin antibiotic from the EPD and pipetted 
samples was studied by incubating coatings (10 mm × 10 mm × 0.2 mm) in 2.5 ml phosphate buffered 
saline (PBS, Sigma P4417-50TB, one tablet in 200 ml water, pH = 7.3 ± 0.2 at 25°C) at 37ºC. 
Aliquots of 2.5 ml (the total release volume) were withdrawn from samples at predetermined times (42 
h, 84 h, 7, 14, 21, 28, 35, 42, 49 and 56 days), and were replenished by fresh PBS. The reason PBS 
solution was used instead of SBF was that the high concentration of ions in SBF limits detection of 
released gentamicin by the quantification method used here which is high performance liquid 
chromatography (HPLC). 
The concentration of gentamicin incorporated in the supernatant of as-received coatings as 
well as the release samples was quantified by HPLC and ultra-violet absorption detection. For this 
purpose, the gentamicin in the solution had to be derivatised. As gentamicin is an aminoglocosdic 
compound, its derivatisation methods involve chemical reactions with the primary amino groups of the 
drug [327]. The method described in the following has been developed for derivatisation of 
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gentamicin in the present study 9. This procedure has been developed by some modification to 
gentamicin sulphate derivatisation proposed previously by Sampath et. al. [328]. 
The reactive solution (the gentamicin derivatizing agent) consisted of 130 mg ortho-
phthaladlehyde dissolved in 0.5 ml methanol. This solution was mixed with 3.8 ml borate buffer (30 
mM, pH=10.4) and 290 µl 2-mercaptoethanol was added to it. At the end the final volume was 
adjusted to 5ml by borate buffer. The obtained reactive solution was kept at 4°C in which it was stable 
for 2-3 days. For derivatisation, 0.4 ml of reactive solution was added to 1 ml of test sample and 1.2 
ml of 2-propanol (total volume of 2.5 ml). The solution was then heated in a 40 ºC bath for 5 min.  
HPLC was performed using a Thermo Scientific spectra SYSTEMS, SCM 1000 instrument 
(AS3000 autosampler and P4000 Quaternary pump). Separation of the derivatised solution was carried 
out on a reversed phase C18R column (50mm × 2mm, 3µm particle size) at a flow rate of 0.3 ml/min, 
at 20 °C and with the following flux of mobile phases (Table  6.3). The UV detection was performed at 
230 nm using Thermo Scientific UV 2000 (dual wave length) detector. For calculation of the area 
under HPLC peaks and estimation of the amount of gentamicin the software HPLC Thermo Scientific 
Chromatography Data Systems was utilised. 
Table  6.3 - Step gradient of mobile phases used in HPLC of gentamicin. 
Time (min) A (%)1 B (%)2 
0 65 35 
4 65 35 
6 75 25 
60 75 25 
1 A is 700 methanol: 250 water: 50 acetic acid (volume ratio) + 5 g octansulfonate 
2 B is methanol 
 
9 The HPLC-UV quantification of gentamicin was performed by collaborators at Department of Pharmaceutical 
Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. 
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6.2.5. Biocompatibility studies 
6.2.5.1. Microbiological study 
The effect of the incorporation of Ag-np and gentamicin in coatings on the viable counts of S. 
aureus (ATCC 25923) was investigated by conducting agar disk diffusion test on CS, CS/5BG, 
CS/BG/Ag and CS/BG/GS EPD samples with 316 SS, and PBS as controls. Prior to the study, 
coatings were sterilized using UV treatment for 45 min each side. Five samples of each series 
(10mm×10mm) were immersed at 37°C in PBS (5 ml) at pH 7.4 for 10 days. At predetermined time 
intervals (1, 2, 3, 5, 7 and 10 days) aliquots (5μl) of each series were removed and applied to paper 
discs and placed on the surface of Mueller-Hinton agar plates seeded with S. aureus through a 
modification of the agar disk diffusion method of CLSI (CLSI 2010). After each aliquot was taken, the 
remaining volume was replaced with fresh PBS to mimic physiological clearance. Approximately 107 
colony-forming units of S. aureus were inoculated on Mueller-Hinton agar plates. After 24h of 
incubation, the zones of inhibition were measured. Bacteria were streaked on Trypticase soy agar 
(Difco, USA) from -70°C stocks. Overnight agar cultures were transferred to tryptic soy broth (Difco, 
USA) and incubated at 37°C statically for 48 h. After centrifugation (8000×g, 4°C, 10 min), bacteria 
were re-suspended to 1.5×108 CFU/mL. 
6.2.5.2. In vitro cellular study 
MG-63 osteoblast, a human osteosarcoma cell line [329] was used to assess in vitro 
cytocompatibility of CS, CS/5BG, CS/BG/Ag, CS/BG/GS EPD coatings, uncoated 316 SS substrate 
and tissue culture plastic (TCP) were used as controls. Cells were cultured in low glucose (1g/l), L-
Glutamine containing, Dulbecco’s Modified Eagles Medium (DMEM)), supplemented with 10% (v/v) 
Fetal Bovine Serum (FBS) and 1% (v/v) antibiotic (penicillin/ streptomycin) solution (all from PAA, 
Coelbe, Germany) (which will be referred to as “complete medium”). Prior to testing, the samples 
(10×10×0.2 mm3) were UV-sterilised for 45 min each side. 
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80-85% confluent cultures were harvested for experiments with a solution of 0.05%/0.002% 
Trypsin/EDTA in Ca2+/ Mg2+-free PBS (PAA, Coelbe, Germany) and pelleted by centrifugation at 
1000 rpm for 5 min. Cell counting was done by trypan blue dye and haemocytometer. The test 
samples were seeded at a density of 20,000 cells/cm2 and were incubated in 1ml of complete medium 
at 37ºC in a humidified atmosphere (5% CO2 in 95% air). After an overnight period, samples were 
transferred to a new well plate and replenished with fresh medium. The cells were then allowed to 
grow on the coatings up to 7days, with the medium changed every 2 days. At specific time intervals, 
the cell proliferation measurement was carried out using the alamarBlue® assay (AbD Serotec, Oxford, 
UK). For this assay, at the end of each time point 100 μl of the culture medium was replaced with 
alamarBlue® indicator dye and incubated for 4 hours. Sample aliquots of 100 μl were then taken and 
its fluorescence was measured at excitation and emission wavelengths of 530 nm and 590 nm 
respectively (Thermo Labsystems Fluoroskan Ascent FL, Waltham, USA). The number of viable cells 
was estimated by interpolating fluorescence readings from a 6 point standard alamarBlue® curve. The 
standard curve (R2=0.9902) was obtained by 1:2 serial dilution of initial 1×105 cell number. The 
resultant number of cells for each coating was normalised against the number of cells on TCP at day 1 
culture and was reported in percentage. The results represent the mean ± standard deviation (SD) of 
two individual experiments each performed in quadruplicate. 
The attachment of MG-63 cells to coating samples under study at day 1 and day 7 was studied 
by SEM imaging. For this purpose, at the mentioned time points, samples were removed and fixed in 
3% glutaraldehyde in 0.1M cacodylate buffer for 12 hours at 4 °C. Then the samples were dried by 
subsequent washing with graded ethanol (50%, 70%, 90% and 100%) and finally critical point dried in 
hexamethyldisilazane for 2 minutes. Samples were left to dry in the fume cupboard for 2 hours after 
which they were attached to aluminium stubs and sputter-coated with Cr for SEM. 
6.2.5.3. Data analysis 
The experiments were performed in multiple numbers per series (4 or 5 samples) and the 
results were reported as mean ± standard deviation. One-way analysis of variance (ANOVA) with 
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p<0.05 as significant level was utilised for statistical analysis and Tukey test was used for comparison 
of means. The analyses were carried out using MINITAB 15 statistical software. 
6.3. Silver nanoparticle-containing composite coatings 
6.3.1. Results 
6.3.1.1. Microstructural characterisation 
The microstructural analyses of silver-containing coatings presented in this section are 
accompanied with CS and CS/5BG results for ease of comparison. SEM analyses of different coatings 
are shown in Figure  6.1. Although CS coatings have a smooth surface morphology (Figure  6.1 a, 
cracks are due to damage by the accelerated electrons), CS/Ag films (Figure  6.1 b) contain particulate 
structures embedded in the chitosan matrix. On the other hand, similar to CS/5BG, the microstructure 
of CS/BG/Ag films (Figure  6.1 c and d; respectively) consists of a chitosan polymeric matrix with 
micron-sized Bioglass® particles distributed in it. Higher magnification images of CS/BG/Ag coatings 
show areas in which clusters of a nano-particulate material are attached to each other by chitosan 
polymer. It is anticipated that these are silver nanoparticles. 
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Figure  6.1 - SEM images of CS (a); CS/Ag (b); CS/5BG (c); CS/BG/Ag (d) coatings; higher 
magnification images of Bioglass® micro-particles containing (e) and the new nano-particles 
containing (f) locations in a typical CS/BG/Ag coating. The new nano-particles (white arrows) 
and Bioglass® micro-particles (black arrows) have been indicated. 
Cross section of CS/Ag coating under SEM (Figure  6.2a) shows that the face of coating which 
is in contact with the substrate consists of clusters of nanoparticles, covered on top with a 2.5 µm 
chitosan layer. On the other hand, CS/BG/Ag film (Figure  6.2b) shows a composite coating with 
varying thickness, which reaches up to 15 µm. 
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Figure  6.2 - SEM images of (a) scraped CS/Ag showing the back of coating which has been in 
contact with substrate and (b) CS/BG/Ag coating cross section deposited on a glass substrate; 
inset in (a) shows a higher magnification image of nanoparticulate structure. 
EDX analyses of the deposited films (Figure  6.3 b and d) confirm the presence of silver in 
both CS/Ag and CS/BG/Ag coatings in comparison to CS coatings (Figure  6.3 a). The peaks of Si, Na, 
Ca and P in the EDX spectra (Figure  6.3 c and d) correspond to the Bioglass® component. 
 
Figure  6.3 - EDX spectra of CS (a); CS/Ag (b); CS/5BG (c) and CS/BG/Ag (d) coatings. 
According to the X-Ray diffraction patterns (Figure  6.4), the CS film exhibits a broad peak at 
∼20° corresponding to the semi-crystalline nature of chitosan [315]. The composite CS/5BG coating 
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has an amorphous structure displaying very broad peak at ∼30°, which corresponds to the presence of 
Bioglass®. On the other hand, silver nitrate addition to the EPD suspension has resulted in deposition 
of a new crystalline phase, the pattern of which matches that of silver metal with cubic crystalline 
structure. Therefore it is confirmed that the deposited nanoparticles in the films are Ag-np. 
 
Figure  6.4 - XRD patterns of CS, CS/Ag, CS/5BG and CS/BG/Ag coatings and the peaks 
corresponding to different phases (316 SS peaks shown are from the metallic substrate). 
Simultaneous thermal analyses (STA) of the coatings are depicted in Figure  6.5. As the TGA 
curves show, the coatings undergo several stages of weight loss with increasing temperature, which 
are due to moisture evaporation and chitosan burning out (details in Chapter 5, section  5.3). The 
decrease in weight loss from CS to CS/Ag and CS/Ag/BG respectively, evidences incorporation of 
silver and Bioglass particles in the films. The lower amount of weight loss in the CS/5BG deposit 
compared to CS/BG/Ag coating can be due to the higher concentration of Bioglass® particles in the 
EPD suspension of the former deposit. The amount of particles incorporated in composite films was 
determined to be 70.1 wt% Bioglass® in CS/5BG, 12.2 wt% silver in CS/Ag and 62.1 wt% of 
Bioglass®+ silver in CS/BG/Ag. 
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Figure  6.5 - TGA and DSC curves comparing CS, CS/Ag, CS/5BG and CS/BG/Ag coatings, 
showing the weight loss due to water evaporation and burning out of chitosan. 
6.3.1.2. Transmission electron microscopy 
TEM imaging revealed the presence of nanoparticles at the interface between coatings and 
substrate in the CS/Ag and CS/BG/Ag films (Figure  6.6). In CS/Ag coatings, 50-80 nm nanoparticles 
are covered with the layer of deposited chitosan (Figure  6.6 a). A thicker layer of finer-sized Ag-np 
(<50 nm) infiltrated with chitosan polymer is observed in CS/BG/Ag coatings (Figure  6.6 b). SAED of 
these TEM cross sections demonstrates the polycrystalline diffraction pattern of silver in addition to 
the diffraction pattern from the 316 SS substrate. The interplanar spacings of 0.23, 0.21, 0.15 and 0.13 
nm, correspond to the (111), (200), (220) and (311) planes of face-centred-cubic silver, respectively. It 
is noteworthy that due to larger scale of bioactive glass particles compared to silver nanoparticles, 
CS/BG/Ag TEM cross section was intentionally prepared from a small area not containing micro-
particles of Bioglass® (such as (f) area in Figure  6.1 d) and therefore only chitosan and Ag-np are seen 
in the TEM image. 
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Figure  6.6 - TEM cross-sections of CS/Ag (a) and CS/BG/Ag (b) films with their corresponding 
selected area diffraction patterns (insets). 
6.3.1.3. Acellular in vitro bioactivity testing 
As Figure  6.7 demonstrates, after 28 days of immersion in SBF, no deposition of HAp was 
detected by SEM/EDX on CS film. The chlorine detected from EDX of CS coating has been 
incorporated in the polymer from the SBF solution. The XRD analysis of SBF treated CS coating 
(Figure  6.8) confirms the amorphous structure of this CS film. On the other hand, a new nano-
structured phase has formed on the surfaces of both CS/5BG and CS/BG/Ag coatings in as short as 5 
days of SBF immersion. Comparison of the EDX spectra of these composite films before (Figure  6.3 c 
and d) and after (Figure  6.7 b and c) SBF immersion, shows that the new phase has increased amount 
of Ca and P atoms and no presence of Si and Na peaks can be found. XRD analyses of these coatings 
(Figure  6.8) thus confirm that the newly formed phase on composite coatings is HAp and its 
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crystallinity increases with SBF immersion time. A closer look at the HAp formed shows that the 
morphology of this phase on CS/5BG is different from the one formed on CS/BG/Ag (Figure  6.7 b and 
c, insets). While the HAp nano-crystals deposited on the former are rod-shaped, the ones grown on the 
latter have a plate-like morphology. Figure  6.7 c displays an area of Ag-np containing chitosan 
surrounded by parts in which HAp crystals have grown on the composite coating. The charging in 
SEM of Figure  6.7 b is due to the porous nature of the newly formed HAp layer. 
 
Figure  6.7 - SEM images and EDX analysis of coatings treated in SBF; CS after 28 days (a); 
CS/5BG after 5 days (b); and CS/BG/Ag after 5 days (c). Insets: higher magnification images of 
hydroxyapatite (HAp) phase. 
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Figure  6.8.-.XRD patterns of coatings treated in SBF; CS after 28 days (CS-28d); CS/BG after 5 
and 14 days (CS/BG-5d, CS/BG-14d) and CS/BG/Ag after 5 and 14 days (CS/BG/Ag-5d, 
CS/BG/Ag-14d). The standard pattern for HAp (00-001-1008) has been shown for comparison. 
Formation of HAp in the Ag-np containing composite coatings has been also elucidated by 
comparing FTIR spectra before and after SBF immersion. The main bond vibrations of chitosan and 
Bioglass have been explained in details before (Chapter 5, section  5.4.1) The CS/BG/Ag composite 
FTIR spectrum (Figure  6.9) indicates the presence of peaks associated with both chitosan and 
Bioglass®. There are changes in the relative intensities of the infra-red transmission at carbonyl (1653 
cm-1) and amine bands (1566 cm-1) (green arrows in Figure  6.9) and a shifting of amine band in 
CS/BG/Ag to lower wavelengths compared to amine band in CS coating (1580 cm-1) that can be 
indicative of interaction between chitosan and silver ions (silver ion has later deposited as Ag-np). 
Similar amine band shifting in complexation of chitosan and silver has been reported [330]. 
After immersion in SBF and formation of HAp phase, new peaks appear in the CS/BG/Ag 
spectrum (Figure  6.9). The P-O bending vibration dual peak at 560 and 603 cm-1 and the P-O 
stretching peak at 1030 cm-1 are related to phosphate groups. Additionally the spectrum indicates the 
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presence of C-O out of plane bending (873 cm-1) and C-O stretching (1530-1400 cm-1). This fact 
confirms that biomimetically developed HAp on CS/BG/Ag (in SBF) is HCA.  
 
Figure  6.9 - FTIR spectra of CS, pure Bioglass® and CS/BG/Ag before and after 5 days SBF 
immersion (CS/BG/Ag-0d and CS/BG/Ag-5d). Green arrows show wavenumbers at which 
change in intensity has occurred. HCA related bands are marked. 
6.3.1.4. Silver release study 
The amount of silver incorporated in the CS/Ag and CS/BG/Ag coatings was estimated to be 
362.5 ± 38.1 (µg) and 342 ± 24.8 (µg) respectively. As Figure  6.10 demonstrates, there is an initial 
burst release of Ag+ followed by reduced release rate. Additionally the monolayer releases more Ag+ 
ions suggesting the inhibitory effect of the outer layer (covering the inner CS/Ag layer) in the bilayer 
coating. This behaviour is more prominent after 24 hours during which the formation of HAp is 
expected. 
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Figure  6.10 - Cumulative release of silver ion from monolayer (CS/BG/Ag) and bilayer (CS/Ag-
CS/BG) coatings in SBF. 
Another interesting aspect is the release behaviour after the initial burst release. As Figure 
 6.11 shows after about 6 h, the release of silver ions follows a linear trend with respect to square root 
of immersion time in SBF solution. This can be indicative of a diffusion-controlled mechanism. 
 
Figure  6.11- Cumulative release of silver ion from monolayer (CS/BG/Ag) and bilayer (CS/Ag-
CS/BG) coatings in SBF versus square root of time. 
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6.3.2. Discussion 
The present results confirm the suitability of EPD as a processing method for the surface 
multi-functionalisation of metallic substrates for potential orthopaedic application. The mechanisms of 
electrodeposition of chitosan and EPD of chitosan/Bioglass® composite have been explained in details 
in Chapter 4. Chitosan electrophoresis toward the negative electrode occurs due to protonation of its 
amino groups at the low solution pH and it deposits at the electrode due to water electrolysis and 
subsequent raise in the local pH (above chitosan pKα). On the other hand, in the composite suspension, 
electrosteric effects lead to improved Bioglass® micro-particles dispersion and co-deposition of 
chitosan and glass particles which results in the formation of a composite film. This composite 
structure can improve the bioactivity and osseointegration of orthopaedic metallic devices. Another 
novel aspect of the present work is the addition of antibacterial functionality to the above-mentioned 
bioactive composite coatings. It involves in-situ formation of silver nanoparticles and simultaneous 
incorporation of Ag-np in the structure of the composite. This approach eliminates multiple steps 
required in conventional processing of such coatings, which involve preparing Ag-np; obtaining a 
stable suspension of them; and finally sequential deposition of particulate and polymeric components 
to achieve a composite coating. An additional important advantage of in-situ formation and 
encapsulation of Ag-np is that it does not present possible environmental hazards associated with free 
nanoparticles. 
Addition of silver nitrate to the mixed suspension of chitosan/Bioglass® facilitates formation 
of a chitosan-silver ion complex. Chitosan has been reported as a metal-chelating polymer in the 
literature [226, 331]. The lone pair of electrons on chitosan amine and hydroxyl groups provide 
preferable sites for complexation of electropositive transition metal ions of silver via electrostatic (ion-
dipole) interactions [331], Due to the high deacetylation degree of chitosan used in this work, mainly 
amine and hydroxyl groups are assumed to be involved, but the O of carbonyl groups in the remaining 
acetylated units can also participate in the chelation process. This feature has been exploited to reduce 
chelated silver to silver nanoparticles via different techniques [226, 332, 333]. The mechanism of Ag-
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np formation in the present research has been schematically shown in Figure  6.12. Due to low pH of 
medium in the present system (pH≈3) it can be anticipated that most amine groups are protonated and 
therefore Ag+ has less chance of complexing with them. As the polymer moves toward the negative 
electrode under the EPD voltage, the high local pH leads to deprotonation of amines and formation of 
silver-chitosan complexes. Consequently availability of electrons at the negative electrode, results in 
reduction of silver ions to silver nano-particles. In this context, chitosan acts as a controller of Ag-np 
nucleation and protects them from agglomeration. Indeed TEM images show (Figure  6.6 a and b) that 
Ag-nps were deposited adjacent to the electrode surface. In this context, gelation of chitosan as an 
electrically insulating layer on the Ag-np layer can prevent further formation of Ag-np. 
 
Figure  6.12 - Schematic presentation of mechanism of Ag-np formation in the EPD of CS/Ag 
coating from chitosan/silver nitrate solution. 
In CS/BG/Ag EPD, a similar mechanism is active. Comparisons of FTIR spectra obtained 
from CS/BG/Ag and CS films (Figure  6.9) and the changes in the intensity of peaks can be related to 
two phenomena. One phenomenon is the change in intensities due to formation of hydrogen bonds 
between the oxygen of the glass network and carbonyl and amine groups of chitosan [173]. The other 
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phenomenon is the shift in the amine vibration band in chitosan, in comparison to the same peak in the 
CS spectrum, which can be due to the formation of a bond between N atoms of chitosan molecules and 
silver ions.  
In the CS/BG/Ag system, because a higher voltage (15V) was used, compared to the CS/Ag 
system (10V) a thicker layer of Ag-np was deposited. Also, addition of Bioglass® particles to the 
suspension and their partial dissolution causes an increase in pH of the suspension (from about pH 3 in 
CS/Ag solution to pH 4.2 in CS/BG/Ag suspension). At higher pH, fewer chitosan amine groups are 
protonated and therefore more electron pairs are available to chelate silver ions [334]. This effect in 
turn can lead to formation of more Ag-np nucleation sites and finally smaller-sized Ag-np is deposited. 
The composite coatings developed a HCA surface layer after immersion in SBF, which is an 
indication of bioactivity as frequently discussed in the literature [282]. As this HCA layer is similar to 
the carbonated hydroxyapatite phase in bone, it can facilitate formation of a bond between the coated 
implant and the adjacent bone [10]. In this study, two different morphologies of HCA were observed: 
plate-like on CS/BG/Ag coatings and rod-like on CS/5BG coatings, which may be related to the higher 
wt% of chitosan incorporated in CS/BG/Ag, as determined by TG analyses. It has been reported that at 
the SBF pH (7.40); which is above the isoelectric pH of chitosan (6.4); polymer hydroxyl groups 
acquire negative surface charge [183]: 
CS–OH + OH-→ CS–O-+H2O 
The higher amount of negative surface charge due to the chitosan component in CS/BG/Ag 
coatings results in more Ca2+ absorption on the surface from the SBF solution. Li et.al [335] have 
attributed plate-like apatite formation to a calcium-dominated frontier at the interface between SBF 
and the growing HCA layer. The importance of this aspect is related to the different morphologies of 
HCA found in various biological tissues, e.g. the HCA in bone is plate-like while the one in enamel is 
rod-like [336]. 
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During immersion in SBF, Ag+ ions are released into the medium. The initial burst release in 
the medium can be due to the release of silver ions from the surface layer of the coating. This is 
followed by a second stage which varies linearly with square-root of time which implies that the 
process is controlled by diffusion of silver ions through the coating [337]. Two mechanisms for release 
of silver ion can be anticipated: (a) degradation of chitosan by erosion and subsequent release of non-
reduced silver ions previously complexed with chitosan and (b) diffusion of water in the polymer 
matrix, resulting in matrix swelling and release of Ag+ from nanoparticles. These mechanisms led to 
release of less than 7 wt% of the loaded silver within 28 days of SBF treatment. Comparison between 
the release profiles of monolayer and bilayer silver-containing composites indicates the possibility of 
confining the silver release layer in order to control the release rate. 
6.4. Gentamicin-containing composite coatings 
6.4.1. Results 
6.4.1.1. Microstructural characterization 
As the deposition condition for CS/BG/GS coatings was similar to CS/5BG, except that 
gentamicin sulphate was added to the suspension of the former, its microstuctural features resembled 
that of CS/5BG. The pH of the CS/BG/GS suspension was 4.46 ± 0.02. Low and high magnification 
SEM images of CS/BG/GS (Figure  6.13 a and b) display a rough coating containing chitosan and 
Bioglass® with some cracks in the deposited film. Similar to other composite coatings developed in 
this research project, the EDX spectrum (Figure  6.13 c) contains peaks associated with Si, Na, Ca and 
P atoms which are the constituents of Bioglass® as well as C atoms which can be related to the 
chitosan and gentamicin components of the coating. 
181 
Chapter 6: EPD of Antibacterial Composite Coatings 
 
Figure  6.13 - SEM image of CS/BG/GS coating prepared by EPD at (a) lower and (b) higher 
magnifications and (c) its corresponding EDX spectrum. 
As discussed before (in section  6.3.1.1), the simultaneous thermal analyses (STA) of the 
coatings (Figure  6.14) encompasses subsequent stages of moisture evaporation (below 100 °C) and 
combustion of chitosan (in the range 220-600 °C). Gentamicin is also expected to burn out in these 
stages. Compared to DSC curve of CS, chitosan burning produced less pronounced exothermic peaks 
in the DSC curve of CS/BG/GS due to significantly lower amount of incorporated polymer in the 
antibacterial composite coating. As comparison of different TG curves reveals, the percentage of 
weight loss in both gentamicin-containing and non-containing coatings is notably less than in CS 
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coating due to presence of glass particles. The amount of glass particles in CS/5BG and CS/BG/GS is 
70.1 wt% and 70.9 wt%; respectively, which is indicative of almost similar loading of particles in both 
cases. 
 
Figure  6.14 - TGA and DSC curves comparing CS, CS/5BG and CS/BG/GS EPD coatings, 
showing the weight loss due to water evaporation and burning out of chitosan 
6.4.1.2. Acellular in vitro bioactivity testing 
Incubation of CS/BG/GS coatings in SBF at 37 °C provided evidence of bioactivity of the 
developed gentamicin-loaded coatings. As SEM images and EDX spectrum of a sample after 14 days 
show (Figure  6.15), SBF immersion has lead to formation of some pores in the structure of the coating 
and a nanostructured HAp layer has covered all over the sample. Higher magnification imaging 
confirms fine rod-shaped HAp nanocrystals similar to the ones formed on CS/5BG (reported in section 
 6.3.1.3). As before, the EDX spectrum also demonstrates increase in the peak intensities of P and Ca 
and decrease in Si peak intensity which is associated with deposition of calcium phosphate. 
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 Figure  6.15- SEM images of CS/BG/GS EPD coating at (a) lower and (b) higher magnifications 
and (c) EDX analysis after 14 days treatment in SBF. 
Furthermore, XRD and FTIR results obtained from SBF treated sample, support formation of 
calcium phosphate in as short as 2 days incubation in SBF. The XRD patterns (Figure  6.16) show that 
at day 2 a semi-crystalline phase with main peaks at 32° and 25.8° starts developing. As indicated in 
Figure  6.16, the crystal size and/or degree of crytallinity of the new phase increases in later days and it 
matches the standard pattern of HAp crystals. 
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Figure  6.16.-.XRD patterns of CS/BG/GS EPD coatings before (0d) and after treatment in SBF 
for 2, 5, 7, 14 and 21 days. The standard pattern for HAp (00-001-1008) has been shown for 
comparison. 
The FTIR spectra of the corresponding SBF samples presented in Figure  6.17, display a 
reduction in the peaks of Bioglass® (Si-O-Si at 459 cm-1) and chitosan (amine at 1580 cm-1) with SBF 
immersion time. The spectrum of CS/BG/GS is similar to that of CS/5BG samples. Depicted graphs 
also show formation of new bonds within 2 days, which is consistent with XRD data. Occurrence of 
phosphate (564, 605, 963 and 1030 cm-1) and carbonate (875 and 1420 cm-1) peaks evidences 
formation of carbonated HAp. The vibration at 1640 cm-1 is due to adsorbed water in the structure of 
the new phase. 
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Figure  6.17 - FTIR spectra of CS/BG/GS EPD coatings before (0d) and after treatment in SBF 
for 2, 5, 7, 14 and 21 days. 
6.4.1.3. Gentamicin release study 
The derivatisation and HPLC-UV technique developed in this research facilitated estimation 
of the amount of loaded and released gentamicin. An example of the chromatographs obtained is 
presented in Figure  6.18. Assessment of HPLC peaks in EPD and pipetted samples in comparison to 
the blank and standard, provides evidence for gentamicin quantification. According to the graphs the 
retention times of different gentamicin components are approximately 4.8, 11.1 and 13.3 minutes with 
slight shifting in different samples. Identification of these three gentamicin components however 
would require further investigations such as mass spectroscopy, which was beyond the scope of this 
project. 
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Figure  6.18 - Chromatographs of (a) EPD and (b) pipetted CS/BG/GS coatings in comparison to 
the (c) blank and (standard gentamicin) samples. The retention times for EPD coatings are 
displayed. 
The amounts of gentamicin loaded in 1 cm2 (substrate area) of EPD and pipetted samples were 
144.2 ± 0.8 µg and 218.9 ± 1.1 µg; respectively. As 50 mg of gentamicin sulphate was added to the 
EPD suspension, it can be concluded that 0.3% of the drug in the suspension was deposited by EPD 
sample. 
Gentamicin release profiles from both EPD and pipetted samples are depicted in Figure  6.19. 
While for the EPD sample, nearly 50% of the loaded antibiotic was released within 4 weeks of 
immersion in PBS, similar release percentage was reached in 1 week time for the pipetted sample. 
After the initial burst release, the concentration of the drug in the medium increased slowly up to 8 
weeks and reached up to 57.1% (82.31µg) and 66.7% (146.12 µg) for EPD and pipetted samples, 
respectively. Overall, the release rate of gentamicin form the composite coating was lower for the EPD 
coatings. 
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Figure  6.19 - Cumulative release of gentamicin antibiotic from EPD and pipetted CS/BG/GS 
coatings in PBS. 
6.4.2. Discussion 
As an alternative to electrophoretic deposition of coatings containing Ag-np as antibacterial 
agent (introduced in section  6.3), EPD of gentamicin as an antibiotic agent was investigated in the 
current section. Similar to CS/5BG samples, the high concentration of glass particles (5 mg/ml) results 
in particles’ high deposition rate. On the other hand, the alkaline effect caused by Bioglass® partial 
dissolution, renders lower charge density of chitosan chains and subsequently less deposition rate and 
incorporation of the polymer in the composite film is achieved. These two factors result in formation 
of cracks in the EPD coatings. Furthermore the hydrogen gas produced at the cathode leaves porosities 
in the structure. 
Gentamicin sulphate is a broad spectrum aminoglicosidic antibiotic which is effective against 
many strains of gram-negative (e.g. E. Coli) and some strains of gram-positive (e.g. S. aureus) 
bacteria. The molecule of gentamicin can have several components depending on its functional 
groups. The most common formulae are presented in Figure  6.20. The drug contains different 
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percentages of these components. The gentamicin sulfate used in this study had C1 < 45%, C1a < 35% 
and C2 < 30% according to its product information obtained from Sigma Aldrich [338]. 
 
Figure  6.20 - Molecular structure of gentamicin and its different components, C1: R1=R3=CH3, 
R2=H; C1a: R1=R2=R3=H; C2: R1=R2=H, R3=CH3; C2a: R1=R3=H, R2=CH3. 
Gentamicin has high water solubility. pKas of amino groups of gentamicin are between 5.5 
and 9 and hence at acidic pH it is positively charged [339]. Therefore it was anticipated that cathodic 
deposition of the drug from the composite suspension would be feasible. Moreover its stability over a 
broad pH range (2-10) up to 15 days has been reported [340] which facilitates incorporation of the 
drug in the acidic pH of chitosan solution used in the present EPD experiments. 
One of the complexities associated with gentamicin is its quantification by HPLC. As this 
aminoglicoside is a weak UV chromophore, it needs to be post-column derivatised to be detectable by 
UV absorption. Most derivatisation techniques involve chemical reaction with amino groups of the 
drug [327]. The method developed here utilises o-phthalidialdehyde in the presence of 2-
mercaptoethanol as derivatising agent. It has been shown that this chemical combination can 
significantly improve derivatisation of primary amino groups compared to other chemicals such as 
ninhydrin or fluorescamine and therefore provides higher detection sensitivity [341]. 
Drug release kinetics from a polymer containing matrix depends on various factors such as 
polymer swelling and erosion, drug distribution inside the matrix and matrix porosity [342]. As the 
present coatings are porous and have relatively low wt% of chitosan, the characteristic time of 
diffusion of the solvent is short and consequently drug release can be mainly influenced by drug 
dissolution and diffusion in the liquid which fills the pores. Additionally it has been demonstrated that 
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for a uniform drug distribution the dissolution of the drug at the matrix/release medium interface gives 
rise to a burst effect followed by a slower release rate [342]. As mentioned before, the release profiles 
from both EPD and pipetted samples were found to follow this trend. Because pipetted samples have 
higher total amount of loaded drug as compared to EPD samples; with most of it expected to be 
physically bound to the surface layer; both stages of release occurred faster. Moreover, this feature 
displays efficiency of EPD in incorporation of drug within the coating rather than on the coating 
surface. 
The majority of gentamicin trapped in the present coatings are expected to be physically 
incorporated. In addition, for a small proportion of drug, the presence of amino and hydroxyl groups in 
the gentamicin molecule gives rise to the formation of hydrogen bonds with the hydroxyl moieties of 
Bioglass® [343]. Additional strategies can be implemented to control the drug loading capacity and its 
release profile from the electrophoretically deposited coatings. These approaches can make use of 
functionalized glass particles surface with negatively charged chemical groups which can form strong 
bonds with cationic gentamicin molecules and enhance its loading efficiency. Furthermore, as a 
potential future step it is proposed to have a “sequential drug delivery system” with different release 
profiles through the deposition of different layers of coating. In this system, an outer drug-loaded layer 
can support initial burst release up to the minimum inhibitory concentrations (MIC) and drug-
containing layers below can maintain the MIC for the period of treatment. 
6.5. Biocompatibility studies 
6.5.1. Results 
6.5.1.1. Microbiological Study 
The antibacterial disk susceptibility test indicated that the medium from CS/BG/Ag coatings 
subjected to 10 days immersion in PBS developed a zone of inhibition in the range 15-16 mm (Figure 
 6.21). This result shows in vitro antibacterial activity of the released silver ions against S. aureus over 
the 10 days period. Furthermore, as Figure  6.21 shows, a significant difference was observed between 
190 
Chapter 6: EPD of Antibacterial Composite Coatings 
CS/BG/GS and CS/5BG films only for the first 2 days during which the burst release of gentamicin 
takes place. However after 2 days both CS/5BG and CS/BG/GS were capable to inhibit bacterial 
growth at a significantly lower level (5.4-6 mm). This secondary, low efficiency bacteriostatic effect; 
which can also be observed in CS/5BG samples from day 1; can be related to the local increase in the 
pH during the degradation of Bioglass® [344]. The increase in pH in the immediate environment 
around bioactive glass particles has been reported by other researchers too [312]. The PBS control 
sample, 316SS and CS coatings did not develop any zone of inhibition against S. aureus growth. 
 
Figure  6.21 - Antibacterial disk susceptibility test showing the relative diameters of zones of 
inhibition after different periods of immersion in PBS up to 10 days. The PBS control, 316SS 
and CS samples did not develop any zones of inhibition. The data represent mean ± standard 
deviation of five individual experiments (p < 0.05 at the same time period: * is for CS/BG/Ag vs. 
all other coatings; # is for CS/BG/GS vs. all other coatings). 
6.5.1.2. In vitro cellular study 
The cellular metabolic activity was measured by alamarBlue® assay and based on that the 
percentage of cell number was estimated. As Figure  6.22 shows CS, CS/5BG, CS/BG/GS and controls 
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(316 SS and TCP) supported proliferation of MG-63 cells over the 7-day period study. At each time 
point, all coatings have significantly (p < 0.05) smaller cell number compared to TCP (positive 
control). After 7 days of culture, no significant difference was observed among 316 SS, CS, CS/5BG 
and CS/BG/GS samples. It was observed that the proliferation of cells on all samples increased over 
the period of study. The important aspect to mention is the significantly (p < 0.05) lower percentage of 
cells on CS/BG/Ag samples compared to other coatings throughout the investigation. This behaviour 
might be indicative of incorporation of excessive levels of silver in the composite structure leading to 
cellular toxicity, whereas the gentamicin-loaded coatings proved to be non-toxic to cells. 
 
Figure  6.22 - Osteoblast-like human osteosarcoma cell line (MG-63) response to 316SS substrate, 
CS, CS/5BG, CS/BG/Ag and CS/BG/GS coatings measured by alamarBlue® assay up to 7 days 
culture. Tissue culture plastic (TCP) was used as control. Data represent mean ± standard 
deviation of two individual experiments each performed in quadruplicate. (p < 0.05 at the same 
time period: * is for TCP vs. all other coatings; ¥ is for CS/BG/Ag vs. all other coatings; # is for 
marked bar vs. 316SS; + is for marked bar vs. CS/5BG). 
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Electron microscopy images of samples subjected to cell culture study illustrate evidence of 
MG-63 cells attachment to different samples. As Figure  6.23 shows, cells number and their spreading 
over the samples increases from day 1 culture to day 7 and in 316 SS and CS samples confluent cells 
are observed at day 7 (Figure  6.23 b and d). SEM images of CS/BG/Ag samples did not display any 
cellular attachment probably due to very low number of cells even after 7 days in culture. 
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Figure  6.23 - SEM images showing morphology of MG-63 cells spreading on the surface of (a, b) 
316 SS, (c, d) CS, (e, f) CS/5BG, (g, h) CS/BG/GS and (i, j) CS/BG/Ag at (a, c, e, g, i) day 1 and 
(b, d, f, h, j) day 7 of culture. Black arrows indicate cells. 
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A closer look at CS/5BG samples in Figure  6.24 shows attachment of cell filopodia to a 
Bioglass® particle in the coating. These results confirm that the EPD coatings developed (except for 
Ag-np containing coatings) support growth of osteoblast-like cells. 
 
Figure  6.24 - SEM image showing filopodia (arrows) of a MG-63 cell on a glass particle in 
CS/5BG coating. 
6.5.2. Discussion 
The biocompatibility experiments conducted on the electrophoretically deposited samples 
provides a preliminary tool for comparing the response of different coatings developed in the current 
research, to specific strains of bacteria and to MG-63 cells. 
S. aureus is the pathogen which is responsible for about two thirds of chronic osteomyelitis 
infections [210]. As discussed above, Ag-np-loaded antibacterial coatings exhibited a zone of 
inhibition against S.aureus up to 10 days. In this case, the dissolution data revealed that almost 5 wt% 
of the loaded silver is released within 10 days in SBF. This relatively low concentration of silver ions 
could efficiently provide bacteriostatic effect in vitro and maintain it during the test period. The 
bactericidal property of silver ions has been associated with combination of silver ions with respiratory 
enzyme or the nucleic acid of bacteria and consequent death of the microorganism. Binding to DNA 
and proteins of the bacteria is another mechanism suggested for bactericidal capability of silver ions 
[225]. It should be highlighted that the bacterial study in this research was performed using release 
medium of coatings rather than in direct contact with the Ag-np containing EPD films. Regiel et.al. 
[345] produced solution-cast chitosan films containing in-situ synthesised Ag-np and confirmed its 
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bactericidal effect against a biofilm forming and antibiotic resistant strain of S. aureus. It was shown 
that, complete bactericidal effects were achieved if the bacterial growth would be tested in direct 
contact with the films. Silver in the form of nanoparticles can enhance the antibacterial effect due to its 
larger surface area which provides better contact with and penetration inside the microorganism; and 
also due to greater chemical reactivity which disrupts microorganism metabolic activity [346, 347]. 
The bactericidal property of silver ion at very low concentrations (as low as 35 ppb) has been 
previously observed [221]. Although in this study a very low concentration of silver ion was released, 
a certain cytotoxic effect was observed on MG-63 cells cultured in direct contact with coatings. High 
concentrations of silver have been reported to be cytotoxic due to a concentration and time dependent 
depletion of intracellular adenosine triphosphate (ATP) content [348]. Based on the findings of this 
research, to avoid Ag cytotoxic effects it is suggested that a lower concentration of silver be 
incorporated in the composite structure during electrophoretic deposition. 
Most of the bacteria involved in chronic osteomielitis are susceptible to gentamicin [25]. 
Gentamicin release from CS/BG/GS films could develop a zone of inhibition against S. aureus up to 2 
days. Gentamicin binds to components in bacterial cell and causes production of abnormal proteins 
which are fatal to bacteria [349]. To maintain bactericidal effect for longer periods, the amount of 
loaded gentamicin and its release profile requires to be modified so that after the initial burst release 
more drug would be available for release during the term of treatment. This is achievable through 
techniques referred to in section  6.4.2. Ti rods coated with polyelectrolyte films loaded with 
gentamicin have been reported to release 70% of their drug within 3 days and have delivered a total 
average of 550 µg/cm2 drug within 4 weeks. These films could successfully inhibit S.aureus growth in 
vitro and in vivo. [210]. The corresponding amount of gentamicin loaded in the EPD coatings in this 
study, supported proliferation of osteoblast-like cells in line with chitosan and chitosan/bioactive glass 
films and after 7 days of culture no significant difference was observed between them. This implies 
that the multi-functionalisation process of adding gentamicin antibiotic has not increased the 
cytotoxicity level of the composite coatings. 
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6.6. Summary 
Bioactive and antibacterial composite coatings for potential orthopaedic applications were 
electrophoretically deposited on metallic substrate. Two strategies were implemented for multi-
functionalising of these composite EPD coatings: addition of silver as nanoparticulate and ionic 
antibacterial agent and gentamicin as an antibiotic drug. 
In the first case, a novel approach was utilised for in-situ formation and deposition of silver 
nanoparticles in multifunctional chitosan/bioactive glass coating. The coatings demonstrated uniform 
formation of Ag-np and were bioactive in terms of HCA formation in SBF. The sustained release of 
silver ions from the coatings facilitated bactericidal activity in vitro. In the future work, tuning of the 
release kinetics can be achieved through sequential deposition of different layers as well as 
modification of deposition parameters, all of which is feasible via the EPD technique. Although the 
levels of incorporated silver in the composite coatings under study demonstrated cytotoxic effects on 
osteoblast-like cells, this preliminary investigation paves the way for improvement of such 
multifunctional structures. 
As the second approach, gentamicin which is a broad spectrum antibiotic commonly used in 
treatment of bone infections, was electrophoretically deposited for the first time in the form of a 
composite coating on 316SS substrate. The coating could form bone-like apatite in simulated body 
fluid which is a qualitative assessment of bioactivity. Moreover it released 40% of its gentamicin 
payload within 5 days of burst release followed by a sustained drug delivery over a period of 8 weeks. 
The release kinetics could inhibit bacterial growth for the first 2 days and supported cellular 
proliferation up to 10 days. To further extend the bactericidal behaviour of these coatings chemical 
functionalisation of glass particles and application of a sequential release system were suggested. 
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Chapter 7: Conclusions and Future Work 
7.1. Conclusions 
Novel bioactive orthopaedic coatings in the system chitosan/Bioglass® were fabricated by 
EPD on AISI 316L SS substrates. In the following paragraphs the main results are summarised and 
concluding remarks are included: 
7.1.1. EPD of bioactive coatings 
To achieve this purpose by EPD, three sets of experiments were conducted based on aqueous 
EPD from three types of suspensions; namely chitosan polyelectrolyte solution, Bioglass® particles 
suspension and composite suspension of chitosan/Bioglass®. The Taguchi design of experiment 
technique was applied to optimise the deposition quality in terms of achieving a uniform composite 
coating. 
In the first step, results of EPD of chitosan from dilute solutions (0.1-0.5 mg/ml, 1vol% acetic 
acid) and in the pH range 2.9 to 4.1 showed that the electrophoretic deposition rate depends on the 
linear charge density of the macromolecules, the size of aggregates, and the polymer concentration. 
The EPD rate was shown to vary in the range of 1-5 μg.cm-2.s-1. The mobility of the macromolecules 
was found to be influenced by the pH; which was in turn determined by the concentration of acetic 
acid. Increasing pH resulted in a decrease in the degree of polymer ionization and in lower net charge 
density which led to lower solution conductivity and higher macromolecule mobility. The film growth 
rate was estimated to be in the range 0.02-0.08 µm.s-1 and at growth rates higher than 0.05 µm.s-1, a 
porous film was obtained due to the phenomenon of hydrogen-gas entrapment as a result of water 
electrolysis.  
The EPD of Bioglass® suspensions to fabricate bioactive coatings on metallic implants was 
investigated in the second step. The effect of processing parameters, including the suspension 
concentration, pH and electric field, on the deposition rate was studied. It was shown that the control 
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factors are inter-related and the pH of the suspension has a critical role on determining the deposition 
rate and the stability of the EPD process. A high deposition rate was attained at pH=7 in which the 
combination of particles surface charge and suspension conductivity were desirable for uniform 
deposition. It was also confirmed that a low electric field is more suitable to obtain a stable EPD 
process. The prediction of the Taguchi design of experiment approach was in good quantitative 
agreement with the experimental results. 
Finally, EPD was successfully applied to prepare composite coatings of chitosan/45S5 
Bioglass® (Bioglass® suspension in 0.5 mg/ml chitosan solution, 1vol% acetic acid). It was elucidated 
that the protonated polymer macromolecules and the charged bioactive glass particles in the 
suspension had different electrophoretic deposition mechanisms, which led to dissimilar deposition 
rates during co-deposition. Partial dissolution of the bioactive glass particles in the acidic suspension 
increased the pH and conductivity of the suspension, which resulted in a lower deposition rate of the 
polymer dependent on the bioactive glass concentration. On the other hand, the deposition rate of 
Bioglass® particles increased with increasing the particle concentration according to the Hamaker 
equation [258]. Estimation of the apparent electrophoretic mobility of the composite particles 
confirmed these ionic strength-controlled and concentration-controlled deposition behaviours at 
different Bioglass® concentrations. An optimum condition for controlled co-deposition of chitosan/ 
Bioglass® suspensions was obtained at almost equal concentrations of chitosan and Bioglass® particles. 
7.1.2. Characterisation of EPD coatings 
The microstructure and physical properties of chitosan (CS) and chitosan/Bioglass® (CS/BG) 
coatings prepared by EPD were characterised by SEM/EDX, TGA/DSC, XRD, FTIR and WLI 
techniques. Four different composites of CS/0.4BG, CS/1.6BG, CS/5BG and CS/8BG were compared. 
The coatings had amorphous structure and the amount of incorporated glass particles varied in the 
range 27-71 wt%. It was shown that increase in the amount of BG in the EPD suspension results in 
obtaining thicker coatings with higher glass particle loading, therefore more uniform deposits with 
smoother surface morphology were obtained at lower glass particle loadings. Additionally, it was 
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shown that formation of hydrogen-bonding between carbonyl groups in the chitosan molecules and the 
glass hydroxyl moeties provided electrosteric stabilisation of BG particles in suspension and could aid 
the co-deposition of BG and chitosan components. 
The bioactivity of coatings was evaluated via SBF testing and ionic dissolution measurements 
(measured by ICP-OES). HCA formation on the surface of materials immersed in SBF is regarded as 
the first step in bone-bonding in vivo and represents a well-known marker of bioactive character of 
materials [282]. Results confirmed that incorporation of BG particles provided bioactivity (HCA 
formation) to the otherwise non-bioactive chitosan films. HCA formation was detected on CS/5BG, 
CS/8BG and parts of CS/1.6BG coatings and it was confirmed by SEM/EDX, XRD and FTIR 
analyses. The lack of HCA formation on CS/0.4BG coatings was related to the dissolution of ions 
from the BG in the coatings. It was demonstrated that introduction of Bioglass® particles in the 
aqueous chitosan solution during the EPD suspension preparation results in dissolution of high 
proportions of Na+ and Ca2+ ions from the glass particles. However, this procedure leaves the glass 
with high content of Si-OH groups on the glass surface. Consequently, in spite of loosing high amount 
of glass ions, the surface groups are capable of inducing apatite formation through surface charge 
effects [318]. For CS/0.4BG films the low BG content and the complete coverage of BG particles by 
the chitosan film were assumed to be the reasons of bioactivity suppression. 
Tape testing and micro-hardness evaluations were conducted to mechanically characterise the 
composite EPD coatings. It was observed that in comparison to CS coating, addition of BG particles 
up to intermediate levels (~ 60 wt%) can enhance the adhesion of the EPD film to the substrate. 
Additionally, the hardness of the coatings had a positive correlation with the amount of Bioglass® 
weight percentage in the composite films, as expected. 
200 
Chapter 7: Conclusions and Future Work 
7.1.3. Multifunctionalisation of EPD coatings 
Two strategies were implemented for conferring antibacterial aspect to the composite films via 
in-situ EPD process: (a) addition of silver as nanoparticulate and ionic antibacterial agent; and (b) 
addition of gentamicin, an antibiotic drug. 
In the first case, a novel approach was implemented in which chelation of chitosan and Ag+ 
ions in the EPD suspension was utilised for in-situ formation and deposition of silver nanoparticles in 
the composite chitosan/Bioglass® coating (CS/BG/Ag). An additional important advantage of in-situ 
formation and encapsulation of Ag-np is that it does not present possible environmental hazards 
associated with handling free nanoparticles. TEM examination of the coatings demonstrated uniform 
formation of Ag-np. The Ag-np-containing coatings were bioactive in terms of HCA formation in 
SBF. The in vitro sustained release of silver ions from the coatings facilitated bactericidal activity 
against S. aureus bacterial strain up to 10 days, in comparison to CS and CS/5BG coatings. Although 
the levels of incorporated silver in the composite coatings under study demonstrated cytotoxic effects 
on MG-63 osteoblast-like cells, this preliminary investigation paves the way for improvement of such 
multifunctional structures. 
As the second approach, gentamicin, which is a broad spectrum antibiotic commonly used in 
treatment of bone infections, was electrophoretically deposited for the first time in the form of a 
composite coating (CS/BG/GS). The coatings were bioactive in terms of forming HCA in SBF. 
Moreover the coating released 40% of its gentamicin payload in PBS within 5 days, followed by a 
sustained drug delivery over a period of 8 weeks. Application of EPD could control gentamicin release 
rate due to incorporation of drug within the coating rather than on its surface. The release kinetics 
could inhibit bacterial growth for the first 2 days and supported cellular proliferation up to 10 days. 
AlamarBlue® assay and SEM imaging confirmed that coatings of CS, CS/5BG and CS/BG/GS 
supported MG-63 cells proliferation and attachment up to 7 days in culture. 
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7.2. Future work 
Many exciting and challenging questions have been raised during this study which can be 
potential topics for further investigation. Possible future research avenues are presented below: 
• In order to evaluate the extent of adsorption of chitosan on the Bioglass® particles, the zeta 
potential vs. pH curve should be obtained for the chitosan/Bioglass® suspension (at a 
specific Bioglass® concentration) and be compared with that of the Bioglass® suspension. 
Shifting of the curve toward higher zeta potential values indicates improved stabilisation 
of glass particles with the adsorbed cationic polymer chains. On the other hand the 
saturation amount of adsorbed chitosan on Bioglass® particles can be obtained by studying 
zeta potential vs. chitosan concentration. 
• In the EPD process investigated in this research, a DC electric field has been used. As 
noted before, a major problem of aqueous suspensions is that water electrolysis at high 
voltages required for obtaining thick and good quality coatings, results in formation of 
oxygen and hydrogen bubbles and renders coatings porous. Two strategies can be applied 
to overcome this problem. The first one is application of asymmetric AC or pulsed electric 
fields in aqueous EPD. This innovative approach employs sufficiently high frequency AC 
field in which the rate of decomposition of water becomes too low for gas bubbles to form 
[350]. For CS/BG coatings the AC electric field waveform and frequency need to be 
devised so that formation of hydrogen bubble is avoided without suppressing pH-
dependent deposition of chitosan. The second strategy is application of a 
water/ethanol/acetic acid suspension medium. At a constant electric field, a lower current 
passes through the water/ethanol/acetic acid suspension due to its lower conductivity and 
thus less hydrogen gas evolves at the cathode [191]. For this purpose an optimum ratio of 
water/ethanol should be determined and an in-depth investigation of EPD process 
parameters will be required. 
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• In the current research, micron-sized Bioglass® particles were used which is the 
conventional bioactive glass powder used in many investigations. Utilising nano-sized 
bioactive glass in EPD of chitosan matrix composite should be an interesting topic for 
future novel research due to formation of nano-scale surface topographies. It has already 
been recognized that structural aspects (e.g. surface topography) can have profound 
influence on cell function, fate and tissue formation [351]. In fact, the nano-scale surface 
topography along with high surface area of nano bioactive glass can provide more 
available sites for protein adsorption, thereby it might enhance the cellular/material 
interaction. In addition to the dimensional effects of nanomaterials, possible surface 
chemical changes by nanostructuring can have a significant effect on the cellular response. 
Figure  7.1 shows an SEM image of such a nanocomposite coating prepared by EPD (from 
a preliminary experiment carried out by the author of this thesis). In this coating nano-
particles of Bioglass® seem to be well-embedded in the chitosan matrix.10 This topic 
remains an attractive research area as there is a recent interest in characterisation of nano-
scale bioactive glasses [352]. 
 
Figure  7.1 - SEM image of EPD coating of chitosan/45S5 nano-Bioglass® on 316L SS substrate 
(test condition: 0.5 mg/ml chitosan solution, 0.2 mg/ml nano-Bioglass®, 600 s, 10 V, 1.5 cm inter-
electrode distance). 
10 Flame spray-synthesised 45S5 nano-Bioglass® (35-40 nm) was kindly provided by Prof. W. Stark from ETH, 
Zurich, Switzerland. 
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• Applying the two above-mentioned modifications (reducing porosity and using nano 
bioactive glass) can facilitate deposition of more uniform composite coatings. This 
coating structure fulfils the requirement for evaluating the coating-substrate interfacial 
strength via tensile and lap-shear testing. Additionally, the effect of BG-loading on elastic 
modulus of the composite films can be studied via nanoindentation. 
• In spite of low amount of Ag+ ions released in 28 days (less than 7% of the loaded silver) 
a certain cytotoxic effect was observed on MG-63 cells. To avoid silver cytotoxic effects 
it is suggested that a lower concentration of silver be incorporated in the composite 
structure during EPD. Future work should further explore the suitable range of Ag-np 
loading which provides a minimum inhibitory concentration against bacteria as well as 
supporting osteoblast cellular attachment and proliferation. 
• Additional strategies can be implemented to control the gentamicin loading capacity and 
its release profile from CS/BG/GS coatings; thereby improving their bactericidal 
behaviour. Functionalized BG surface with negatively charged chemical groups can be 
utilised to form strong bonds with cationic gentamicin molecules and to enhance its 
loading efficiency via EPD. As a potential interesting future step, a “sequential drug 
delivery system” with different release profiles can be proposed through the deposition of 
different layers of coating by EPD. In this system, an outer drug-loaded layer can support 
the initial burst release up to the minimum inhibitory concentrations (MIC) while the 
drug-containing layers underneath can maintain the MIC for the period of treatment or 
bone regeneration. 
• Implant coatings should inhibit substrate corrosion and reduce or avoid the release of non-
compatible metal ions at the implantation site. Therefore the corrosion resistance of 
CS/BG coated substrate should be compared with that of bare 316L SS control via 
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electrochemical impedance spectroscopy (EIS) and polarisation tests in SBF at 37  C. This 
aspect of coating characterisation remains for future research. 
• Further cellular tests can extend to alkaline phosphatase assay (ALP) and osteocalcin level 
assay (accompanied by total DNA count) which are early and late markers of osteoblast 
differentiation. LIVE/DEAD assay can also be utilised to measure cell viability on the 
coatings. Clearly, after the comprehensive in vitro assessments, in vivo studies to fully 
characterise the coatings in their functionality will be required. 
• An exciting aspect of EPD is the ability to coat 3D and porous structures compared to 
line-of-site coating methods. This feature is critical in coating porous metallic orthopaedic 
implants or bone tissue scaffolds. As a preliminary experiment, we have 
electrophoretically coated 3D printed Ti-6Al-4V alloy porous scaffolds with 
chitosan/Bioglass® coating. As it is shown in Figure  7.2, both chitosan and Bioglass® have 
infiltrated the pores of the scaffold and have deposited on the inner struts. These results 
highlight the potential of EPD technique for applications in scaffold development by 
coating porous structures with composite bioactive films.11 
11 Ti-6Al-4V scaffolds were kindly provided by Dr. J. Luyten from Ceramic Materials and Powder Metallurgy, 
VITO, Belgium. 
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Figure  7.2 - As-received Ti-6Al-4V porous 3D scaffold (a); Lower (b) and higher (c) 
magnification cross section of coated scaffold with chitosan/Bioglass® composite coating via EPD 
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A.1. EPD of chitosan/Bioglass® composite on Ti substrate 
The EPD of chitosan/Bioglass® composite coating on commercially pure titanium (cp-Ti) was 
investigated. Figure A.1 shows the SEM microstructure of the CS/0.4BG composite coating on Ti 
substrate. It shows uniform distribution of bioactive glass particles in the chitosan matrix similar to the 
CS/0.4BG coating obtained on 316L SS substrate (reported in Chapter 4). Because the thin oxide layer 
on cp-Ti substrate is electrically non-conductive, to improve deposition process, the substrate was 
ground with 800 grit silicon paper prior to the EPD process. 
 
Figure A.1 - (a) High; and (b) low magnification SEM images of CS/0.4BG coating deposited on 
cp-Ti substrate. 
A.2 EPD yield vs. deposition time 
Figure A.2 shows the non-linear increase of deposition yield of composite coating with 
deposition time in constant-voltage EPD. The deviation from linearity (especially at higher deposition 
times) is because of formation of an insulating layer of coating which causes the voltage drop per unit 




Figure A.2 - Non-linear increase in deposition yield with deposition time for constant-voltage 
EPD (EPD condition: CS/0.4BG suspension, 20 V, 1.5 cm inter-electrode distance). 
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